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Abstract
The use of Volumetric Modulated Arc Therapy (VMAT) is expected to increase, 
largely due to development of helical tomotherapy. VMAT minimises the occurrence 
of hotspots and irradiation of critical organs, providing more uniform dose while 
sparing critical organs. Two important characteristics of VMAT are its dynamic 
nature and dosimetric variability in radiation delivery. These present considerable 
challenge for clinical physicists as the implementation of the process contains a 
number of sources of uncertainty and thus require robust QA. This dissertation 
describes an evaluation of the currently achievable accuracy in VMAT delivery. 
Uncertainty in dose determination between primary standards is compared, as well as 
beam calibration of megavoltage photons at reference field sizes and for small field 
dosimetry associated with tomotherapy. Additional steps in the radiotherapy process 
including target volume delineation, evaluation of dose distribution and daily patient 
treatment (patient setup) have also been considered.
The codes of practice currently employed in electron and photon radiotherapy beam 
dosimetry are well developed, in particular those of the International Atomic Energy 
Agency (IAEA TRS-398), the American Association of Physicists in Medicine 
(AAPM TG-51) and the Institute of Physics and Engineering in Medicine (IPEM 
2003). For the photon and electron beams studied, the applied protocols show that all 
measured absorbed doses agree, with differences of less than 2.0%. For the absorbed 
dose calibrations using tomotherapy, beam uncertainty in primary standard calibration 
has been estimated to be 1.05%.
An assessment of uncertainty in target volume delineation has also been considered. 
The combined uncertainty for the head & neck (H&N) study is 1.67%, while for the 
prostate study the combined uncertainty is 5.57%. Regarding actual beam delivery 15 
Delivery QA plans for H&N patients were assessed for a tomotherapy system using 
Kodak X-Omat V film and an AISL Ref F92722 ion chamber versus MapCheck2. 
Gamma matrix distribution was applied to evaluate the difference between measured 
and computed dose distributions. The combined uncertainty from H&N is 1.11%, 
lower than that from the prostate study, which is 1.16%. Generally, the combined 
uncertainties for the whole study in head and neck were found to be 2.35% while for 
prostate cases, the combined uncertainty is 6.29%.
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Chapter 1: Introduction
1.1. Aim of the Thesis
Volumetric Modulated Arc Therapy (VMAT) aims at providing a specified radiation 
dose throughout a given target volume within predetermined levels of accuracy and 
homogeneity whilst ensuring at the same time adequate dose sparing of the 
surrounding normal tissue. Studies based on normal tissue complications (Mijnheer, 
1987) and tumour control (Brahme, 1988) have suggested acceptable tolerance levels 
for accuracy in dose provision in radiotherapy at 3.5% and 3.0% respectively, given 
as one standard deviation. Radiotherapy is a complex process involving several steps; 
the accuracy of each stage has a direct impact on the treatment’s outcome, as 
discussed below.
Radiation therapy treatment-planning and delivery capabilities have changed 
significantly since the 1980s with the introduction of three-dimensional (3-D) 
treatment planning, and continue to change in response to the implementation of new 
technologies. Radiotherapy employs advanced computer technology in systems for 
treatment planning and delivery. Such systems are able to accurately shape the 
distributions of doses by means of computer-controlled multi-leaf collimators, where 
the beam’s fluence optimally ranges in order to accomplish the specified plan. This 
kind of therapy is acknowledged under the name of intensity-modulated radiation 
therapy or IMRT; it generates inhomogeneous distributions of dose allowing concave 
distributions, thus adequately covering the target volume and avoiding certain critical 
normal structures. This has led to high dose gradients, whose control has required 
ever higher precision in dose estimation and provision.
Knowledge of the tissues’ radiation response has also increased, with the biological 
effects strongly corresponding to the absorbed dose in a tissue. It has been noticed 
that in certain cases, this dose dependence is steep, pointing to strictly defined 
accuracy requirements for both the beams geographical delivery location and the 
absolute values of the dose.
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The radiation therapy process is clearly complex and it involves many data transfers 
between the different professional groups responsible for managing the treatment 
applied to the patient. These data include dosimetric and geometric accuracy as 
regards dose delivery, dosimetry, accuracy in calculating the dose for a patient, 
radiological image quality, the actual treatment planning process, patient’s setup 
reproducibility during the treatment, as well as strategies for correcting the patient’s 
positional errors during treatment (Figure 1.1). Comprehensive quality assurance 
procedures are required at each stage in order to provide a safe and accurate delivery 
of the dose prescribed.
~r
Figure 1.1: The radiotherapy treatment process (Radiotherapy) (1)
One of the most important current questions refers to the level of accuracy needed and 
how it may be reached in practice? Additionally, can new methods and new 
techniques, such as Intensity Modulated Radiation Therapy (IMRT) and tomotherapy, 
improve upon the degree of accuracy currently obtained in radiotherapy? The aim of 
this thesis is to investigate this question and to test what achievable accuracy can be 
obtained through best current radiotherapy practice, in order to support evolving 
clinical requirements.
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In the mid 1970s, the ICRU Report 24 (1976) expressed a requirement of ± 5.0% 
accuracy of the absorbed dose delivery, with the caveat that ± 2.0% may be required 
in certain critical situations.
The radiotherapy process has been the focus of a number of analyses attempting to 
derive cumulative uncertainties on delivered dose (Thwaites, 1989, Thwaites, 1993, 
ICRP, 2000, Dutreix, 1984, Mijnheer, 1987, Brahme, 1988, AAPM, 1984). The main 
steps of the process are: absorbed dose to a reference point in water, measurement of 
relative doses and organisation of the treatment planning systems, treatment planning 
for each patient, and treatment delivery to the patient. Every main step has been 
divided into sub-steps and estimates of uncertainty have been allocated at each level 
for every contingent factor. At one standard deviation (SD), the range of the overall 
estimated cumulative uncertainties has been estimated to range from 2.5% to 8.5% 
(VanDyk, 1999). This range results from different interpretations of various authors, 
the number of distinct sub-steps and parameters employed and the type of approach 
adopted -  either optimal or conservative. For these kinds of estimates, a representative 
percentage of 5% (SD) may be appropriate, smaller and larger uncertainties being 
assigned to simple and complex treatments, respectively. The aim of this thesis is to 
provide an updated assessment of achievable accuracy with modem state of the art 
radiotherapy equipment, namely tomotherapy.
Risks can be minimised by checking equipment on a regular basis. Quality assurance 
(QA) is defined as the series of procedures ensuring medical prescription and its 
secure fulfilment according to the consistency of the dose to the target volume, 
minimally required dose to normal tissue, lowest vulnerability of personnel, as well as 
to the appropriate monitoring of the patient, aiming to determine the final outcome of 
the treatment (WHO, 1988). According to ICRU (1976), quality audit is defined as the 
examining of the quality control and quality assurance programs by means of the 
quality control system’s independent review. The independence of the reviewer is 
essential, since an outsider can take a dispassionate view of the processes and avoid 
repeating any flaws or shortcomings that may exist in the day-to-day quality 
processes. This is particularly important during dosimetry audits of absorbed dose 
determinations.
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The first series of investigations in this study involved a comparison of several 
internationally established dosimetry codes of practice (CoP), with a particular 
emphasis on the fact that each of them recommends the use of different ionisation 
chambers and phantoms, while investigating the possible consequences of such 
choices. In this regard, a significant effort is made to identify each protocol’s dose 
delivery impact upon accuracy. Such investigations can be carried out by comparing 
different CoP for high-energy beams (i.e. therapy beams obtained at megavoltage 
potential). The main CoP include those provided by the International Atomic Energy 
Agency (IAEA TRS-398), the American Association of Physicists in Medicine 
(AAPM TG-51) and the Institute of Physical Engineering in Medicine, (IPEM 2003), 
for electron beams, and the Institute of Physical Science in Medicine (IPSM 1990) for 
photon beams. These CoP are a means of defining the way in which the end user may 
achieve high accuracy in beam calibration, being an integral part of the whole process 
of quality assured delivery of radiotherapy treatments.
Tomotherapy is considered both a recent and increasingly popular form of 
radiotherapy, which involves high dose gradients and small fields, and introduces 
challenges that continue to be topical and actively researched. The IMRT treatment is 
delivered while the patient’s support couch is translated in the y-direction (toward the 
gantry) through the gantry bore, quite similar to the way a helical CT study is 
conducted. The International Atomic Energy Agency (IAEA) and the American 
Association of Physicists in Medicine (AAPM) have formed a joint task group to 
analyse the issue of absolute dose in small fields. In this thesis, the recommended 
protocol for clinical reference dosimetry follows the formalism used by the AAPM 
TG-51 protocol (Almond, Biggs et al 1999). The process of linking reference field 
dosimetry to small field dosimetry has also been considered and is described in 
chapter 5.
With regard to the accuracy in dose delivery and target volume delineation, a patient- 
specific treatment delivery check referred to as Delivery Quality Assurance (DQA) is 
used in tomotherapy. Here, a two-dimensional dose profile comparing the measured 
dose and the calculated dose obtained from the treatment planning system (TPS) is 
performed, in order to analyse the dose delivery (Composite dose verification). 
Within this series of investigations, for head and neck and prostate tomotherapy
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treatments, the study of accuracy focuses on the use of two advanced dosimetry 
systems: the Tomophantom (Cheese phantom) and the MapCheck2 detector array 
device.
While the processes of treatment planning have become more efficient and accurate, 
the daily treatment’s delivery itself also acquires accuracy. According to Foreword 
(2007), the imaging occurring in the treatment room has offered clinically significant 
and comprehensive information recording the movement and the anatomic change 
over an individual treatment fraction, over several sessions of therapy and the entire 
treatment course. The ongoing challenge aims at representing, controlling and/or 
incorporating the changes into strategies of managing the uncertainties as far as the 
target set-up and movement is concerned (Foreword, 2007). The major aim is to 
advance automated systems in order to determine and correct such variations in 
treatment, known under the term of adaptive radiation therapy (ART). ART 
incorporates a closed-loop process of radiation treatment through methodical 
evaluations (Hansen, 2006).
Feed-back is provided early or during the treatment’s course in order to enhance the 
treatment plan. Hence, a customized treatment is provided according to daily patient 
target volumes. The effect of dosimetric set-up errors related to cancer radiation 
therapy in the cases mentioned above is also submitted to analysis.
For each of the radiotherapy process steps, an evaluation of the uncertainty is 
undertaken. The outcomes of the assessment potentially allow each step’s 
optimization in the future, enabling overall improvement in accuracy in radiotherapy. 
The determination of currently feasible reproducibility and accuracy in radiotherapy, 
while evaluating the prevailing quality assurance tolerances and recommendations, is 
also provided by the results.
1.2. Structure of the Thesis
The work within this dissertation is organised as follows:
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Chapter 1 provides an introduction to the thesis, outlining the motivation and goals 
of the work while briefly detailing the structure of the thesis.
Chapter 2 presents an overview of achieving accuracy in radiation therapy, which 
includes reference to the relationship between the tumour control probability (TCP) 
and the normal tissue complication probability (NTCP) with absorbed dose. In 
addition, the chapter introduces accuracy with regard to clinical requirements; a beam 
calibration overview; practical aspects regarding the measurements carried out in the 
user beam, including equipment used, consisting of ionization chambers, measuring 
assembly and phantoms.
Chapter 3 provides a literature review of papers considering accuracy in 
radiotherapy.
Chapter 4 compares dosimetry codes of practice referred to in the thesis. Moreover, 
it illustrates the material and methods used, and provides an interpretation and 
analysis of the results of dose measurements by means of the different phantoms used 
for photon and electron beams.
Chapter 5 discusses the meaning of tomotherapy and its features. This chapter 
includes the history of tomotherapy. In addition, a review of beam calibration in 
tomotherapy is presented; also information on how reference field dosimetry links to 
tomotherapy and small field protocols is provided. Furthermore, an experimental 
study of the characteristics of tomotherapy (beam profile and percentage depth dose) 
is presented with a focus on uncertainty in dose delivery.
Chapter 6 provides an assessment of the uncertainty in target volume delineation in 
head and neck and prostate cases. This chapter covers the target volume definition and 
imaging modalities, including a summary of the uncertainties that effect a patient’s 
treatment. Also, it provides illustrated examples of assessment of target volume 
delineation for head and neck and prostate cases.
Chapter 7 provides an experimental investigation of the evaluation of dose 
distribution using two different phantoms in tomotherapy as applied to two clinical 
sites, head and neck cases and prostate cases.
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Chapter 8 provides an evaluation of the accuracy of positioning of patients treated 
for head and neck and prostate cancers.
Chapter 9 provides a summary of the main findings of this thesis.
A list of symbols and a list of abbreviations are presented in Appendix A. Appendix B 
offers details of the QA protocols recommended for daily, monthly and annual testing 
used in tomotherapy. Peer reviewed publications arising from this work are listed in 
Appendix C.
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Chapter 2: Accuracy in Radiotherapy 
2.1. Introduction
The main purpose of improving accuracy is to produce the highest quality treatment 
by ensuring that the treatment is delivered, as closely as possible to the prescription. 
Developments in dosimetry intercomparison for instance constitute one of the 
techniques intended to verify treatment accuracy. What dosimetric accuracy is 
necessary in the management of a patient treated by radiotherapy? This is one of the 
most fundamental -  and fascinating -  questions in modem radiotherapy. The answer 
needs to be searched for in the relationships existing between the probabilities of local 
control and the complications of normal tissue.
2.2. The Relationship between Tumour Control Probability (TCP) and Normal 
Tissue Complication Probability (NTCP) with Absorbed Dose
When both normal human tissues and tumours are considered, the curves of response 
vs. dose show two sigmoid curves. One of these concerns the tumour control 
probability (TCP) -  curve A, while the second concerns the normal tissue 
complication probability (NTCP) -  curve B, both shown in Figure 2.2.1. These curves 
exemplify the demand for accuracy in radiotherapy, which must be underpinned by 
clinical information and dose-response curves (Van Dyk, 1999). The degree of 
steepness characterising a given TCP or NTCP curve illustrates the changes in 
response expected to result from a given dose alteration. In essence, the more 
advanced the NTCP curve is found along the x-axis, beyond the TCP curve, the more 
effective radiotherapy is likely to become. In such cases, one would expect a greater 
therapeutic ratio and a lower probability of a specified response from the normal 
tissue (Podgorsak, 2005). The closer together these curves lie, the greater the 
challenge involved in gauging sufficiently accurate dose delivery. Uncertainties in 
dose manifest either as an increase in the NTCP or a reduction in the TCP, whereas 
the most advantageous choice of radiation dose delivery in the treatment of tumour 
will maximise the TCP, at the same time minimising the NTCP. In a good 
radiotherapy treatment, one might expect to see TCP >0.50 and NTCP <0.05.
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However, there are other parameters that can affect tumour control probability, 
amongst them biological variation resulting from tumour heterogeneity, 
radiosensitivity, and staging/technieal parameters such as dose per fraction.
On this basis, considering the clinical data alongside the dose-effect relationship, 
accuracy of the absorbed dose should be within ± 3.0% at a given point (Brahme et 
al, 1988). The International Commission of Radiological Units and Measurements 
(ICRU) (ICRU, 1976) suggests ± 5.0% accuracy of delivered dose, based on clinical 
context. Minjheer et al (1987) suggested that accuracy in absorbed dose delivery of ± 
3.50% is required.
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Figure 2.2.1: An example situation of (A) Tumour control probability (TCP). (B) Normal tissue 
complication probability (NTCP) (Van Dyk, 1999) (2)
2.3. Accuracy
Very often, the measurement uncertainty in radiotherapy dosimetry is described by 
means of precision and accuracy. Dosimetry measurement accuracy specifies the 
measurement reproducibility in similar contexts, being ascertained using data from 
repeated measurements.
23
High precision leads to small standard deviation in the distribution of measurements. 
The level of accuracy specifies how close the mean value of a measurement comes to 
its true value, which is traceable to a standard value. Measurements cannot be 
absolutely accurate and, therefore, inaccuracy is expressed as part of the uncertainty. 
Uncertainty can be evaluated in three ways, namely:
• Standard uncertainty -  the uncertainty of a result expressed in terms of 
standard deviation.
• Type A standard uncertainty -  the evaluation of a series of observations, using 
statistical analysis (random error).
• Type B standard uncertainty -  the assessment by means different than 
statistical analysis (systematic error).
Overall uncertainties are established by combined uncertainties, estimated as a square 
root of the quadrature sum of all components in both categories of uncertainty, as a 
one-standard deviation value.
2.4 Beam calibration
The output produced from external beam radiotherapy machines producing electron 
and photon beams must be calibrated before clinical use and periodically thereafter. 
This is required in order to ensure accurate dose delivery.
For a radiotherapy machine, the basic output is stated as the dose absorbed at a 
reference depth, Zref, in a water phantom, either by means of a fixed source to surface 
(SSD) or a fixed source to axis distanee (SAD) (as indicated in Figure 2.4), for a 
reference field size such as 10 x 10 cm .^ Output is expressed in Gy/MU 
(Gray/Monitor Unit) (Khan, 2003). The measurement is carried out with special 
dosimetry techniques and radiation dosimeters.
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Figure 2.4: Geometry set-up of the SSD (source to surface distance) and the SAD (source axis
distance) (Podgorsak, 2005) (3)
The radiation dosimetry process determines the absorbed dose to water (IAEA, 2000). 
The radiation dosimeter is a device that measures or provides a dose (or other related 
quantity) reading in the sensitive volume of the dosimeter, by means of ionizing 
radiation. In a water phantom, reference dosimetry is referred to as the direct dose or 
dose rate measurement calibrating a clinical radiation beam’s output under specific 
reference conditions. The most common form of dosimeter used in clinical photon 
and electron beam calibration are ionisation chamber dosimeters as described in 
section 2.5.1 (Podgorsak, 2005; Halperin et al, 2008).
2.5. Equipment
Below are described the equipment used in this dissertation.
2.5.1 Ionization Chambers
Reference clinical beam dosimetry uses two main types of ionization chamber. These 
are cylindrical chambers and parallel plate chambers. Figure 2.5.1.1 shows the main 
components of the ionisation chambers
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The features and components that comprise ionization chambers, include three 
electrodes that determine the air volume (which is referred to as the chamber sensitive 
volume and is generally 0.10 to 1.00 cm^\ namely:
• Polarizing electrode connected directly to the power supply.
• Measuring electrode which is connected to the ground via an electrometer.
• Guard electrode, directly grounded.
Sensitive
volume
Polarizing
(biasing)
electrode
Guard /  
electrode
Measuring
(collecting)
electrode
Figure 2.5.1.1: The circuit o f an ionization chamber system (Podgorsak, 2005) (4)
In figure 2.5.1.1, V represents the power supply, the electrometer. The ionization 
chamber is generally linked to the electrometer using a shielded reduced noise tri­
axial cable. The signals from the measuring electrode to the electrometer are carried 
via the central wire, while the first shield connects the guard electrode to the ground, 
and the polarizing electrode outer shield connects the power supply (Podgorsak, 
2005).
The two chambers used in the experiment are illustrated in Figure 2.5.1.2.
Figure 2.5.1.2(A) The Farmcr-typc chamber NE 2571 graphite walled ionization chambers. (B) The 
plane-parallel chamber PTW Markus chamber (Tawam Hospital, UAE) (5)
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2.5.2. Electrometer
A  current charge measurement requires an electrometer and power supply for the 
ionization chamber polarizing voltage. It is performed using the measuring assembly. 
It is essential that the electrometer has a digital display and offers a four-digit 
resolution. For long-term stability, variation in response should not be higher than ± 
0.50% (IAEA, 2000).
F A R r V lE R  D O S E I V 1 E T E R  2 5 ÿ ' 0 F A R M s n  a r 4
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Figure 2.5.2; Example of the Electrometer named Farmer dosimeter 2570 (Royal Surrey County
Hospital) (6)
2.5.3 Phantoms
Various codes of practice recommend water as the reference medium when measuring 
absorbed dose for electron and photon beams. To ensure scatter equilibrium at the 
measuring position the phantom should extend beyond the field size, on all sides by a 
minimum of 5.00 cm. It should also offer a minimum margin of 5.00 cm  ^beyond the 
maximum measurement depth (IAEA, 2000).
At the reference depth, measurements in other phantom materials should be referred 
to the absorbed dose to water in a homogenous water phantom. The phantom material 
should offer the same absorption and scatter characteristics as water. Water- 
equivalent plastics include the proprietary media: plastic water™, virtual water™ and 
solid water™. Other materials which are not exactly water equivalent, such as 
polystyrene or PMMA, may also be used. Additionally, for non-water phantoms, the 
material may be in slab form to enable measurements at varying depths and to
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decrease charge storage. These are sometimes used for low-energy electron beam 
dosimetry.
Given their tendency to generate the highest discrepancies in determining absorbed 
dose, plastic phantoms should not be employed in reference measurements. This is 
applicable for most types of beam, usually because of the variations in the density of 
different batches (IAEA, 2000). However, plastic phantoms can be used for routine 
measurements of quality assurance, after having established the connection between 
water and plastic readings for the user beam at the time of calibration (IAEA, 2000).
Figure 2.5.3: (A) water phantom QADOS mini phantom. (Royal Surrey County Hospital). (B) Brown 
solid phantom™  (Virtual W ater™ ) (Tawam hospital, UAE) (7)
2.6. Practical Considerations on User Beam Measurements
Some issues must be considered before beginning the measurements:
• A check source must be employed to ensure the stability of the dosimeter 
system.
• The integrity of the waterproofing sleeve should be checked.
• The dosimeter must be given sufficient time to reach thermal equilibrium.
• It is good practice to pre-irradiate the ion chamber by using 2-5 Gy in order to 
arrive at charge equilibrium determination.
• When polarising voltages are modified, sufficient time must be allowed for the 
ion chamber reading to reach equilibrium.
• The measuring system generating the leakage current when radiation is absent 
must be measured both before and after irradiation (IPSM, 1992; AAPM, 
1991).
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This chapter describes general requirements in terms of equipment (NPL, 2006). It 
must be established from the outset that before any measurement begins, the phantom 
and chambers must be placed in the treatment room and allowed to reach thermal 
equilibrium with their environment. This will usually take several hours.
The radiotherapy beam calibration dosimetry system comprises:
• One or several ionization chambers
• Electrometer
• One or several phantoms
The dosimetry system should also comprise at least one. if not several, devices for 
stability check (IAEA, 2000).
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Chapter 3: Literature Review of Papers Addressing 
Accuracy in Radiotherapy
3.1 Accuracy in conformai radiation
Accuracy requirements for radiotherapy should be established based not only on the 
radiobiological behaviour of tumour cells and normal tissues, but also on clinical 
evidence reflecting such behaviour. However, uncertainties in delivered and reported 
dose, as well as variations in tumour cell characteristics, have had a negative impact 
on the reliability of the clinical evidence acquired. A number of authors have 
reviewed the results of clinical trials in order to demonstrate the need for accuracy 
(Pettersen, 2008, FitzGerald, 2012a, Cui Y, 2013, Followill, 2012).
Due to their valuable importance for the implementation of the most efficient 
practices aiming to ensure the safe and accurate delivery of radiation therapy, national 
clinical trials play a significant part in facilitating the diffusion of such practices 
nationwide. Furthermore, information about general applicability and usefulness can 
be derived from detailed small studies (Jones, 2002).
Pettersen et al. (2008) have stated that suitable dosimetry QA minimises the risk of 
under-powering clinical trials, therefore enabling a reduction in the number of patients 
needed in such studies. This therefore demonstrates that dosimetry QA in clinical 
studies is cost effective (Pettersen, 2008).
Moreover, Followill et al. conducted a study and concluded that the credentialing of 
centre for clinical trials has four objectives: (1) to ensure that the institution’s 
employees are well-informed about the requirements for treating the specific protocol 
patient; (2) to confirm the institution’s capacity to carry out the required radiotherapy 
treatment accurately; (3) to provide the institution with comments and observations 
related to the necessary approach to correct errors or improve their radiotherapy 
treatment technique; and (4) to reduce the proportion of patients ranked as deviations. 
Making decisions about the adequacy of both credentialing and data review is an 
essential component of clinical trial development. In some clinical trials, chart review 
encapsulates only data capture, whereas certain protocols, such as CNS leukaemia, 
lack an ascribed credentialing or radiation therapy (RT) object review goal. This
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ensures that the resources for the clinical trial effort are distributed properly 
(Followill, 2012).
Radiation oncology process improvements in clinical trials were examined by 
FitzGerald (2012), with particular focus on the extent to which the quality for the next 
generation of trials has been enhanced by these improvements. Important progress has 
been made recently from time-restricted data collection to real-time monitoring of 
clinical trials quality. The essential elements, such as staging, eligibility, response, 
and outcome for all trial investigators, can thus be immediately made available. 
Future adaptive clinical trials rely on efficiently designed contemporary informatics 
platforms. The requirements for the informatics structure of both existing and fiiture 
clinical trials has been reviewed by FitzGerald (2012b).
Given the above, in the future, requirements should be more stringent in order to 
address this issue. While investigating variations in tumour cell characteristics, Webb 
and Nahum (Das, 2008) noted that, if such variations were taken into consideration, a 
steeper dose-effect curve and, implicitly, a higher dose accuracy demand would be 
obtained. A series of accuracy requirements could be derived from the broad variety 
of tumour sensitivities and normal tissue tolerances observed in practice. Due to the 
fact that such a situation is unwanted in practice, it is believed that requirements 
should be formulated on the basis of the most critical cases that oncologists come 
across in regular radiotherapy practice.
The clinical evidence underpinning the significance of radiotherapy accuracy was 
reviewed in ICRU report 24 (Brahme, 1988), indicating that, in the case of tumours, a 
difference of 10% in absorbed dose can be observed clinically, while in the case of 
normal tissue reactions, a difference of between 5% and 7% in absorbed dose is 
occasionally clinically noticeable (IPEM, 2008). Brahme et al (cited in Palta, 2011) 
comprehensively reviewed dose-response data, observing that this concerned cell and 
population averages and drawing the conclusion that, in order to maintain sufficient 
control of the treatment outcome (with a 5% action level), the standard deviation in 
the average dose should not exceed 3% (1 S.D.). A similar conclusion was reached by 
Mijnheer et al (Moran, 2011) in their review of dose-response steepness data related 
to normal tissue complications. To transfer these data between institutes, the authors
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established that the dose must be known at the specification point within 7% 
accuracy, which they correlated with 2 S.D., arguing that a correlation to 3 S.D. 
would not be presently feasible (1987). Based on inferences of their data of highest 
sensitivity, disregarding practical feasibility would lead to an even more stringent 
requirement (e.g. 2% taken as 1 S.D.), which in the ICRU Report 24 (Li, 2010), has 
been considered as the most vital requirement (no standard deviation defined). 
Likewise, a Nordic report (Alfonso, 2008) proposed a dose accuracy of only 1 Gy (1 
S.D.) for steep responding tumours, equivalent to approximately 1.5% for regular 
dose prescriptions.
In the case of less stringent dose requirements in different points of the target, aspects 
related to heterogeneity in dose and tumour cell characteristics over the target volume 
have been employed as an argument, resulting in a 5% value(l S.D.) across the whole 
target volume (Brahme, 1988). However, as it has been demonstrated that even large 
variations in tumour cell density allow only limited dose variations (Das, 2008, 
Aspradakis, 2010), a possible spread in tumour cell densities would not admit a 
significant spread in dose.
Ahnesjo (ICRU, 2010, Jin, 2010) approached the problem fi"om a different angle. He 
established a practical limit so that an additional rise in dose calculation accuracy 
would not result in a rise in the overall treatment accuracy, bearing in mind 
documented uncertainties in calibration and delivery technique. The author concluded 
that there is currently no need for dose calculation accuracy better than 2%, which 
could eventually be confined to 1%. In similar fashion, it was argued by Mackie et al. 
(Jin, 2008) that it is not necessary for dose calculation accuracy to be as accurate as 
absolute dose calibration, but that the calculated dose should, relatively speaking, 
correspond to the prescribed dose. The authors proposed that dose calculation 
accuracy should be in the range of 2% to 5%.
Given the ambiguity of the conclusions drawn by tumour control studies, a criterion 
of 4 mm (1 S.D.) has been established on the position of beam edges (Brahme, 1988). 
All geometric and movement factors are incorporated in this criterion. Standard 
deviation of about 1 mm have been allocated in a recent review (Aguirre, 2011) not 
only to organ motion, but also to set-up-error for certain treatment areas and motion
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directions. To ensure that treatment planning is not the flaw in the chain, a criterion of 
2 mm (1 S.D.) or less should be applied in the case of treatment planning alone. In 
this context, the established total criterion of 4 mm may be perceived as insufficiently 
stringent. Certain requirements, like leaf position in some dynamic IMRT fields, are 
required to be stricter, for example, 1 mm (Korreman, 2013). In conclusion, it is 
adequate to apply accuracy criteria of 2% (1 S.D.) in calculated dose and 2 mm (1 
S.D.) in field edge position, while in certain cases 1% or 1 mm may be necessary.
It is well recognised that quantifying the dose delivery uncertainty values is intimately 
related to the determination of the accuracy of a dose calculation (Johansson 1982, 
Mijnheer et al, 1987, Brahme et a l, 1988, Ahnesjo, 1991, Ahnesjo and Aspradakis 
1999, AAPM, 2004). With regard to radiotherapy patients, each researcher suggests 
an overall tolerance upon the value of dose uncertainty. For instance, Brahme et al
(1998) suggested that ± 3.0% (standard deviation, S.D.) controls the treatment 
outcome with a 5% tolerance level. This confirms the suggestions provided by 
Mijnheer et al (1987) from the review of dose response curves steepness analysed for 
normal tissue complications, as well as other clinical observations; Mijnheer et al 
(1987) suggested ± 3.5% (1 S.D.), and the ICRU (1976) suggested ± 5.0%, which 
may also be interpreted as 95% Confidence Interval (Van Dyk, 1999; Van Dyk and 
Kron, 2007; IAEA Technical reports series No. 398, 2000). Furthermore, the IAEA 
supports the claim by ICRU, stating that ± 5.0% (1 S.D.) would be a suitable accuracy 
value for the TRS-398 (Knoll, 2000). A range of uncertainty of 2.6 to 4.8% (1 S.D.) is 
still present for the remaining treatment process, taking into account the treatment 
planning and delivery process and other steps following beam calibration. (IAEA 
Technical reports series No. 398, 2000).
In 1976, the ICRU Report No. 24 stated that ± 5% accuracy was necessary for the 
delivery of the absorbed dose to the target volume. However, it was also accepted that 
± 2% could be advantageous in certain (critical) situations. Whether these values were 
intended to be understood to be 1 or 1.5 S.D. or as comprehensive absolutes, was not 
stated. Mijinheer et al (1987) studied data on dose results relating to problems 
occurring in normal tissue. For the relative gradients of the steeper graphs, 7% was 
used as a representative value.
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In 1988, Brahme et al. conducted a study which examined the results related to a 
variety of malignancies. Using this data, they analysed the expression of correlation 
between the tumour control probability (TCP) and dose. In cases in which the 
tolerance threshold of 5% (1 SD) is based on the uncertainty in the TCP, then the 
steepness of the specific dose-response graph determines the dosimetric accuracy 
necessary to achieve this.
An absorbed dose delivery accuracy of 3% (1 S.D.) can be attained when the steeper 
tumour response graphs are used. It should be realised that a variety of influences 
mean that it is not uncommon for clinically monitored dose result graphs to 
demonstrate steepness that is less than the expected response. These influences 
include clinical, physical and technical elements. For example, the biological factors 
which may affect the results are the radiosensivity of different categories of patients, 
dissimilar tumour cell density within the target volume, heterogeneity of different 
cells and their location throughout the cell cycle.
Therefore, by considering the data on TCP and NTCP (Normal Tissue Complication 
Probability), it is possible to appoint a 3% value as the recommended accuracy 
requirement on dose. This figure is taken as one relative standard deviation in relation 
to the dose delivered to the patient at the dose specification point.
Table 3.1: Empirical assessment o f total uncertainty arising from main stages o f radiotherapy process
         .
Cause o f uncertainty Published Uncertainty 
Values (% )
Reference
Calculation o f dose 3 .0 -3 .5 • Mijnheer e/ûf/.,
1987
• Brahme ef a/.,
1988
Target volume and 
delineation
5.0 • ICRU, 1976
Delivery o f dose 3 .0 -5 .0 • Mijnheer e ra/.,
1987
• Brahme a/.,
1988
• ICRU, 1976
Beam monitor stability 1.0 • IAEA, 2000
Absolute calibration 1.5 • Kron e /a /., 2007
Beam characterisation 1.5 • Kron e? Of/., 2007
Setup patient 
Imaging aspect (image
2.0 • Kron era/., 2007
0.8 • Hanley era/., 1995
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registration)
Total uncertainty 
value
7.1-8.5 n/a
Table 3.1 above provides a comparison between published uncertainties of different 
processes in radiotherapy. In addition, it is to be noted that the largest contribution in 
published uncertainties accrues from the uncertainty in the delivery of dose and target 
volume delineation.
The recommended accuracy is of ± 5.0% on absorbed dose, delivered at the 
specification point. This is a requirement for one standard deviation level, and it is 
applied to the final patient dose, incorporating all contributing uncertainties up to and 
including treatment delivery. To meet this, comprehensive quality assurance and 
quality control programmes are important. The accuracy achieved in practice can be 
estimated by analysing the uncertainties at various stages in radiotherapy and by 
measurement based studies, including dose inter-comparisons, which can be carried 
out at various levels of the technical radiotherapy process to define errors and 
uncertainties at each of those stages.
3.2. Accuracy in tomotherapy
Many of the elements within the radiotherapy process may generate uncertainty. For 
example, there exist a number of factors affecting the way the dose is deposited 
within the target tumour: patient positioning, machine output fluctuations, imaging 
modality, organ movement, delineation of various targets, and assumptions about the 
treatment planning algorithm. There may be debate about the most suitable dose for a 
patient; this may be due to the variation between patients, or to specific conditions or 
sensitivities within the individual. Much uncertainty surrounds the topic of how dose- 
volume changes with regards to treating normal tissue.
In the paragraphs below, a review of various literature surrounding this topic and its 
limitations within the tomotherapy process will be provided.
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The concept of 3D imaging techniques facilities accurate treatment planning and 
target volume delineation. These techniques adopt various imaging modalities 
including computerised tomography (CT), positron emission tomography (PET) and 
Magnetic Resonance Imaging (MRI) methods amongst others, which help to plan the 
initial stages of radiotherapy treatment. In order to ensure that the patient is positioned 
correctly, megavoltage CT (MVCT) techniques and images are obtained during 
tomotherapy treatment and applied to verify correct patient set up by comparison with 
planning images . There is a general uncertainty value of 3.8% with this technique, 
according to the AAPM TG-148, as well as to other sources. Such uncertainty may 
arise from the limitations in the image quality (such as contrast and resolution), 
MVCT dosimetry, and image registration aspects (AAPM, 2010; Meeks et al, 2005).
Once the 3D imaging data has been collected and refined, a radiation oncologist will 
confirm the target volume and the organs at risk (OAR) in order to avoid error. Any 
possible errors can affect the treatment delivery accuracy. Errors could stem from 
measurements of the clinical tumour volume (CTV) or the planning target volume 
(PTV). Additionally, they maybe concern with regard to the set-up, organ motion or 
target delineation processes. Empirical research has found that a 5% tolerance is 
suitable for these kinds of treatments, especially concerning the OAR and the PTV 
volumes. Moreover, MVCT imaging data is uploaded onto a tomotherapy treatment 
planning computer for further analysis. Delivery optimisation is then undertaken, 
which helps in isolating other key points of information, such as patient 
immobilisation and optimal treatment set-up. However, it is important to acknowledge 
the risk of uncertainty that may arise from these processes.
Much research has been conducted regarding the accuracy levels surrounding photon 
beam dose calculations within the tomotherapy treatment planning systems 
(Venselaar and Mijnheer, 2001). A maximum overall accuracy level of ± 3.5% (1 
S.D.) is deemed to be suitable for establishing the delivered dose value to the ICRU 
specification point (Minjheer et al, 1987). With regards to dose calculation, tolerance 
values should be of 2%, or 2 mm along an isodose line in order to ensure the highest 
level of accuracy (Jack et al, 2011).
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The various different stages within the tomotherapy process can result in error or 
uncertainty. Therefore, in order to reduce overall uncertainty of the entire process, 
researchers need to isolate these individual errors and minimise them. A 
multidisciplinary approach is often taken, whereby the various stakeholders 
(radiographers, physicists, radiation oncologists, engineers etc.) collaborate to reduce 
uncertainty and risk. Table 3.2 provides published review estimated uncertainty 
values relevant to tomotherapy.
Table 3.2: Uncertainty estimated from published review values o f tomotherapy treatment (2)
Cause o f uncertaintv Published Uneertaintv Values Reference
Target volume and delineation • ICRU, 1976
Delivery o f dose 3.0-5.0% • ICRU, 1976
• Mijnheer e? a/., 
1987
• Brahme ef a/., 1988
• Wambersie, 2001
Planning treatment 3 J % • Mijnheer e? a/., 
1987
DQA 3T^& • Westerly D. a/., 
2009
Imaging aspect o f the 
tomotherapy
L8% • AAPM TG-148
Output o f calibration 1.4% • Bailat e /a /., 2009
Total uncertain ty  value (% ) 8.4% n/a
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Chapter 4: Experimental Comparison of Dosimetry Codes of 
Practice for Reference Beam calibration
4.1. Dosimetry Protocols
The existence of a number of internationally recognised radiation dosimetry codes of 
practice containing detailed instructions regarding the procedures to be used for 
calibrating clinical radiation beams (photon and electrons) is acknowledged. These 
include codes published by national organisations, such as the UK Institute of Physics 
and Engineering in Medicine and Biology (IPEM) and the American Association of 
Physicists in Medicine (AAPM). In addition, there are also codes published by the 
International Atomic Energy Agency (IAEA). Adherence to these published 
procedures help to achieve general consistency in dose measurements between 
different radiotherapy departments, both at national and international levels (IPEM, 
2003). Individual radiation therapy departments are generally free to choose their 
preferred protocol, although all UK centres follow the IPEM recommendations.
Among the most recent codes for the calibration of clinical radiotherapy electron and 
photon beams are those of the International Atomic Energy Agency (IAEA TRS-398) 
(2000) and the American Association of Physicists in Medicine (AAPM TG-51)
(1999). The Institute of Physical Engineering in Medicine, (IPEM, 2003) has 
published a code exclusively for electron beams, while for photon beams there is the 
code issued by the Institute of Physical Science in Medicine (IPSM, 2006). In recent 
years, calibration has evolved from air kerma-based calibration to calibration of 
absorbed dose to water. The absorbed dose to water reflects the biological effects, 
being of utmost importance in radiation therapy. Standards relating to absorbed dose 
to water decrease the level of uncertainty in the dosimetry of radiation beams, 
providing a stronger system of primary standards, compared to standards based on air 
kerma. Huq et al (2001) suggest that the IAEA TRS-393 provides a general and 
highly flexible calibration protocol based on theoretical or experimental beam quality 
conversion factors, namely, the absorbed dose to water calibration of an ionization
j^rCo-60
chamber at ^^Co, .
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Using basic experimental beam quality conversion factors, strictly determined in a 
standard laboratory (such as the UK National Physical Laboratory (NPL), 
Teddington), is recommended within the IAEA TRS-398. AAPM TG-51 relies on the 
use of ion chambers, with calibration coefficients of absorbed dose to water for ^^ Co 
quality Qo, and beam quality conversion factors.
It is only strictly possible to compare the IPSM and the TRS-398 and TG-51 codes of 
practice in terms of chamber calibrations Nd,w in a ^^Co beam (where the subscripts 
refer to dose measurements, D, in water, w) and theoretically determined kq factors. 
IAEA TRS-398 states that, for chambers used in a beam of quality Q, differing from 
the one used in their calibration Qo, the absorbed dose to water at reference depth Zref 
in water is:
^ ^Q^D,w,Qo^Q,Q^ ......... 4^^
where Mq represents the chamber charge or current, corrected for the influence 
factors and determined at beam quality Q. There are differences between the reference 
beam quality Qo and the effective user quality Q; hence, the beam quality factor
is used to correct it. Employing theses standards, users can obtain various
D^,w,Qo calibration types.
The formula for absorbed dose to water provided in TG-51 resembles the one 
provided in the IAEA TRS-398 CoP. The ^^Co gamma-rays absorbed dose to water at 
the reference depth -  the recommended calibration of the chamber in water in a 
quality Q beam, is expressed as (ICRU, 1976):
................. (4 .1 ),
j y  Co-60
where the absorbed dose to water calibration factor for ^^Co beams is
converted by for a quality Q arbitrary beam.
For electron energies, is expressed as the product of three factors (ICRU, 1976):
U  _  p Q y  Ir  
Q gr R$o (4.2),
pG
where the gradient correction factor ^  is comprised of kq in an electron beam 
depending on the ionization gradient at the point of measurement, the quality
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conversion factor of the electron, which depends on the electron beam quality 
provided by R50 and , the photon-electron conversion factor.
4.2. Current CoP Beam Quality Specifiers
For the measurement of photons beams, the IPEM (1990) and IAEA TRS-398 
protocols recommend the use of the tissue-phantom ratio (TPR20, 10) as a beam quality 
determiner (IAEA, 2000, Lilicrap et al 1990). TPR2 0 ,10 represents the dose ratio on 
the central axis of the beam at 20 and 10-cm depth in water, obtained by means of a 
10 X 10 cm  ^field size and a constant 100-cm source to detector distance. This quality 
index permits choosing the beam quality conversion factors (calibration coefficients). 
AAPM TG-51 (1999) recommends establishing the quality specifier as the percent 
depth dose obtained at 10 cm depth, %DD (10) x, excluding electron contamination by 
means of a 1.00 mm lead foil (a 1-mm lead foil was provided at the University of 
Surrey for the experimental measurements).
In the case of electron beam measurements, the protocols IAEA TRS-398, IPEM 2003 
and AAPM TG-51 (1999) discuss beam quality depending on the water depth at 
which the absorbed dose falls to 50.0% of the maximum (R50). According to the 
IAEA TRS-398 and the AAPM TG-51 protocols, the electron beam reference 
dosimetry measurements used a plane-parallel PTW Markus chamber. Also, the 
measurements carried out in agreement with the IPEM 2003 CoP utilised a NACP 
chamber.
As stated by all the protocols, the electron energy determination set-up is carried out 
by means of a 10 x 10 cm  ^field size at 100 cm SSD, with the gantry and collimator at 
0 . The absorbed doses to water, by means of IAEA TRS-398 and AAPM TG-51, are 
determined using the most appropriate type of ionization chamber. For the photon 
beams use was made of a cylindrical ionization chamber, while in the case of the 
electron beams, a plane-parallel ionization chamber was employed, with direct
j y  Co-60
calibration in a ^^Co gamma-ray beam.
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4.3. Methods and materials
For nominal 6 and 18 MV photon energies and 6, 9, 12, 16 and 20MeV electron 
energies, measurements were carried out by means of a 0.6 cm  ^ Farmer ionization 
chamber and a plane-parallel ionization chamber. The Farmer chambers used in this 
study are NE 2571 ionization chambers with graphite walls (s/n 237 and 2433), cross­
calibrated against an NE 2611 Secondary Standard, the latter calibrated at the NPL. 
The IPEM protocol was used for photon energies only, while the readout was 
obtained by means of two different electrometers: a Keithley (Cardinal Health 
Therapy Dosimeter, USA, s/n 64106) and a Dosemaster (NE Technology LTD, UK, 
lONEX Dosemaster 2590, s/n 416).
The reference standard employed the NPL NE 2611 primary standard in graphite (NE 
Technology Ltd, Reading, UK). A plane-parallel PTW Markus chamber was used for 
electron beams. The absolute dose, achieved in the reference setting, was measured by 
means of all three protocols, the beam quality indices were also determined as part of 
this procedure. It should be pointed out that protocol recommendations were closely 
observed.
Measurements were performed by means of a brown solid phantom (Virtual Water™, 
Density BWP = 1.03 g/m^; water equivalent materials, Med-Cal, USA) and a water 
tank phantom (Scanditronix Medical AB, Sweden, RFA water tank). As regards the 
calibration set-up, the choice of quality index and ionization chamber calibration 
standards, the protocols have both differences and similarities.
The determinations were performed on two Varian linear accelerators (types 21 CGC 
and 600C) in Tawam Hospital in the UAE, using the IAEA TRS-398 and the AAPM 
TG-51 for both the photon and the electron beams. On the other hand, the photon 
measurements using the IPEM protocol were also carried out in Tawam Hospital, but 
the electron beams measurements were carried out in the Royal Surrey County 
Hospital in the UK. Determinations were performed by means of a computer- 
controlled scanner (Scanditronix Medical AB, Sweden, RFA) used in a large water 
tank and brown solid water phantom.
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The measurements for the photons beams were made at 100 cm source-surface 
distance (SSD), 10.00-cm depth and a  1 0  x 10-cm^ field size at the phantom surface. 
The measurements for electron beams were performed by means of two different 
electron applicators, being a function of the electron energy, by using the IAEA TRS- 
398 and the AAPM TG-51 protocol. For example, a  1 0  x 10-cm  ^applicator was used 
at 6 , 9, and 12MeV, while a  2 0  x 20-cm^ applicator was employed for the 16 and 
20MeV electron energies. Electron beam determinations by means of the IPEM 2003 
protocols were carried out employing one electron applicator for all the electron 
beams, i.e. a  1 0  x 10-cm^ applicator. Both applicators used an SSD of 100 cm. The 
ionization chamber position was also directly checked.
Both protocols, the IAEA TRS-398 and the AAPM TG-51, used for photon beams, 
suggest a 10.00-cm reference depth in a water phantom. The IPSM reference depth 
for E < 10 MV is 5.00 cm, and for E > 11 MV, 7.00 cm. In addition, for electron 
beams (in low energies), both protocols suggest the reference point Zref for all 
measurements obtained by means of plane-parallel chambers to be near the maximum 
Zmax of the dose depth. Measurements are carried out from the inner surface of the 
entrance window at the centre of the window. The IPEM-based reference depth is at 
0 . 6  R50 -  0 .1  g/cm^, which is actually the dose maximum depth for beams with 
energies below 10 MeV; it is deeper than the dose maximum depth for higher-energy 
beams (IAEA, 2000, IPEM, 2003, AAPM, 1999).
4.4. Results and discussion
4,4.1. Photon energies
The three protocols have been compared in terms of their dose and beam quality 
measurement: %DD (10) % and TPR20, 10, as shown in the Tables given below. Table
4.4.1.1 shows the estimated values of absorbed dose, determined in Virtual Water ™ 
by means of the three protocols. Table 4.4.1.2 details the measured values for TPR2o,io 
for the protocols IAEA TRS-398 and IPEM 1990, for 6 MV from two linear 
accelerators (600C, 2100C). The TPR2 0 ,10 measurements for the 600C and the 2100C 
accelerators agree within the evaluated measurement uncertainties. The three sets of 
tabulated determinations were obtained by means of a Farmer ion chamber
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NE2571/237 and a Dosemaster electrometer. Tabulations also include the absorbed 
dose to water, Dw, and the beam quality factors, kq. The beam quality is given by the 
quality index; in the IPEM CoP, it is represented by the tissue-phantom ratio (TPR) 
of a radiation beam.
Table 4.4.1.1: The absorbed dose for photon beams achieved in the solid water phantom together with 
the beam quality for the three CoP o f interest herein, for a given 100 cGy delivered (3)
IAEA TRS-398 IPEM 1990 AAPM TG-51
Dose (cGy) Dose (cGy) Dose (cGy)
6 MV/600C Not performed 100.64 ±0.04 99.58 ± 0 .20
6M V/2100C 99.60 ±0.19 99.27 ±0.12 100.00 ±0.13
18MV/2100C 100.06 ±0.19 99.00 ±0.05 100.70 ±0.11
Table 4.4.1.2: TPR20, 10, results o f the two protocols: IAEA TRS-398 and NPL (4)
IAEA TRS-398 IPEM 1990
TPR2 0 ,10 TPR2 0 ,10
6 MV/600C 0.66 ±0.15 0.66 ±0.15
6M V/2100C 0.68 ±0.15 0.67 ±0.15
Table 4.4.1.3: Measured and tabulated %DD (10) values for photon beams o f nominal energies 
comprised within the range 6 - 1 8  MV by means o f TG-51. (The% error = (A-B)/A*100) (5)
%DD (10)
Value
(from planning system)
Measured Value
6 MV/600C 66.36 66.08 ± 0.42
6 MV/2100C 67.20 66.97 ± 0. 34
18MV/2100C 78.90 77.93 ± 1.23
Determinations on the 6 MV/600C linear accelerator were carried out by means of the 
protocols of the IPEM and AAPM, as illustrated in Table 4.4.1.1. Determinations of 
the absorbed dose at 6 MV, achieved by means of the 2100C linear accelerator, using 
the TRS-398, IPEM 1990 and TG-51 protocols, reveal maximum uncertainties of 
0.19%, 0.12%, and 0.13%, respectively. The uncertainty evaluation in this thesis is
43
based on the approach described in the IAEA TRS-398. The uncertainties are equal to 
the square root of the summed uncertainty factors squared that are involved in the 
absorbed dose measurements.
The percentage difference between the measurements for the above two protocols in 
absorbed dose for the photon beam 6 MV/600C in the solid water phantom was 
established at 1.1%.
For the determinations obtained in the 6 MV/2100c solid water phantom, and 
following the IPEM protocol, the absorbed dose difference from the AAPM protocol 
is of - 0.73%, a greater difference than that obtained using the IAEA protocol of - 
0.40% compared with the AAPM CoP.
By applying the IAEA TRS-398 and the IPSM 1990, the comparison quality index 
TPR20, 10 values shown in Table 4.4.1.2, are in conformity throughout the photon 
energies within the assessed uncertainties. The factors likely to influence the 
measured values are the measurement depth Zref and the chamber reference point’s 
position between the three protocols, also using the solid water phantom. In addition, 
it can be seen in Table 4.4.1.3, obtained by means of the TG-51 protocol, that 
measured and tabulated %DD (10) values for photon beams (where the %DD 
tabulated values are taken from the planning software) are in close agreement to 0.3% 
for the 6 MV beam and 1.23% at 18 MV, as shown in Table 4.4.1.3. As previously 
mentioned, %DD (10) for 18 MV was obtained through equation 4.4 in TG-51 
(Figure 4.4.1.1 shows the set-up of the high energy photon beam measurement using 
TG-51 protocol). The result obtained, 77.93%, does not differ greatly from the 
tabulated value, differing by 1.23%. Moreover, the %DD using the 1-mm lead foil, 
that is, %DD (lO)pb, was established at 74%, with the beam quality kq = 0.985. The 
absorbed dose ratios obtained are in the range of 0.994 to 1.004.
=[0.8116 + 0.00264%Z)D(10)pi,]%-Da(10)pj...................... (4.4)
[Foil at 30 cm, %DD (10) ?b > 71%].
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1 mm 1;ad foil
Chamber location
Lead filter placed at 30 cm from 
the surface of the solid water 
phantom
Figure 4.4.1.1: Set-up of the high energy photon beam measurement using the TG -51 protocol (8) 
Table 4.4.1.4 Illustrates the outputs of photon beams and the standard deviation over 12 months (6)
Energy Mean (output) cGy Standard deviation
6 MV-600c 99.059 ±0.780
6MV-2100C 99.569 ± 0.700
18MV-2100C 99.546 ± 1.120
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Table 4.4.1.5 Comparison between present experimental data and IAEA TECDOC-1455 (7)
Energy TRS-398- TPR2 0 ,10 
Exp.: Experiment 
diff.: different
TG-51-% DD(10)x D^(7%5'-398)
D^(TG-51)
TECDOC-
1455
Exp.
% ; 
d iff ;
TECDOC-
1455
Exp.
%
diff.
TECDOC-
1455
Exp.
6 0.680 0.680 : 0.00 67.40 66.97 0.43 1.001 0.996
18 0.778 0.778 0.00 80.10 77.93 : 2.00 1.000 0.994
Table 4.4.1.4 shows the absorbed dose for 6 and 18 MV photon beams obtained over 
a period of 12 months. The outputs are in the range of 99.059 to 100.66, with standard 
deviations between 0.4% and 1.0%.
Comparisons of beams qualities between present findings and published values can be 
carried out, as is the case for instance of Antonio et al. (2003), obtained at 6 MV. The 
maximum deviation from TRS-398 and TG-51 was determined to be 0.006% and 
0.01%, respectively. At 18 MV, the maximum difference was reported to be 0.97%, 
using the same set-up as herein, with a layer of Pb foil of 1-mm thickness placed at 30 
cm from the exit level of the collimator to the surface of the foil, as provided in the 
TG51 protocol. Perfect agreement was found (0.00 difference) with Huq et al. (2001) 
for TPR20, 10, using the TRS-398 protocol for 6-MV photons.
Complete agreement was found between the values reported in the lAEA-TECDOC- 
1455 for TPR2 0 ,10 using the TRS-398 protocol for 6 MV, as shown in Table 4.4.1.5. 
Conversely, a difference of 2% was identified between the present values and the 
published values using TG-51. Moreover, figure 4.4.1.2 provides an analysis of IAEA 
TRS-398 and TG-51, between %DD (10) and TPR20, lo-
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Figure 4.4.1.2: Comparison made by employing the 6-MV photon beam in two different protocols, 
namely TG-51 and TRS-398. (5% error bars) (9)
In Figure 4.4.1.2, two protocols, namely the AAPM TG-51 and the IAEA TRS-398, 
are compared using 6-MV photons. With a difference of much less than 1.00%, the 
use of %DD generally produces the highest values and the difference of Sw, air is 
accounted for by the kind of method used for the calculations. Both the TRS-398 and 
the IPSM take Sw, air values from Ding et al (1995), who made use of Monte Carlo 
simulations; within the IPSM, basic input data from ICRU 37 (ICRU 1984) was used. 
In the AAPM TG-51, calculations were made by using the Monte Carlo method, 
computed according to Nahum (1978) and ICRU (1984)
4.4.2. Electron energies
Electron beam comparisons using the three CoP: IAEA TRS-398 and AAPM TG-51 
were carried out in the Tawam Hospital in the United Arab Emirates, while the IPEM 
2003 measurements were carried out at the Royal Surrey County Hospital in the UK. 
These cannot be used as a direct comparison between CoP but enable assessment of 
the protocol from a practical basis. The IAEA TRS-398 and the AAPM TG-51 
protocols can be shown in terms of fluence ratios of the absorbed dose measured in a
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water phantom (Scanditronix Medical AB, Sweden, RFA water tank), as well as the 
absorbed dose determined in a brown solid phantom TM (Virtual Water TM, Density 
BWP = 1.03 g/m :^ water equivalent materials, Med-Cal, USA) found by means of a 
Markus chamber. The ratio between the measurements carried out in the water 
phantom and the solid water equivalent phantom of the three CoP fluence results was 
close to 1.0 for all the electron beams.
Specifically, the IAEA fluence values found were 1.008, 0.995, 0.997, 0.998 and 
0.993 for the respective nominal electron beam energies 6MeV, 9MeV, 12MeV, 
16MeV and 20MeV; the corresponding AAPM TG-51 values were found to be 1.002, 
0.996, 1.007, 0.974 and 0.998, respectively. The IPEM 2003 values were 1.002, 
0.999, 0.992, 0.994 and 1.021, respectively; these determinations were performed at 
the Royal Surrey County Hospital using the NACP chamber (Nordic Association of 
Clinical Physics) -  Scanditronix NACP PP chamber. As stated the IPEM 2003 
measurements cannot be compared directly with measurements from other linear 
accelerators but enable water to solid water comparison. The measurements were 
performed by means of two phantoms: a water phantom (QADOS, UK) and a brown 
solid phantom (Virtual Water TM, Density BWP = 1.03 g/m^: water equivalent 
materials, Med-Cal, USA), employing a 10 x 10-cm^ electron applicator for all 
electron energies. Figure 4.4.2.1 shows the set-up of the measurements employed with 
the IPEM 2003 protocol.
48
Phantoms
W ater
(QADOS,
UK)
10 X 10
electron
applicat
Brown solid 
phantom™  (Virtual 
W ater™ , USA)
NACP PP 
chamber
Figure 4.4.2.1 (A) The water phantom set-up, with obvious impurities in the water. (B) The set-up using solid 
water phantom. In both set-ups, the 10x10 em^ electron applicators and the NACP chamber were used (10)
The output measurements were carried out using two phantoms: Solid water TM 
(Virtual Water™, Density BWP = 1.03 g/m :^ water equivalent materials, Med-Cal, 
USA) and a water tank (Scanditronix Medical AB, Sweden, RFA water tank). The 
determinations were realised with a plane-parallel PTW Markus chamber; a Varian 
2100C linear accelerator gave the five clinical electron beams. The depth ionization 
curves were computed by means of a source to surface distance (SSD) of 100 cm and 
a  10 X 10-cm  ^ electron applicator for electron energies 6, 9 and 12MeV; for the 16 
and 20MeV electrons, a 20 x 20-em^ electron applicator was used. Figure 4.4.2.2 
illustrates the set-up for electron measurements for high energy 16 and 20MeV using 
a  20 X 20-cm^ electron applicator, applying protocols IAEA TRS-398 and AAPM 
TG-51.
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Plane-parallel PTW 
Markus chamber
20 X 20-cm 
electron applicator
A brown solid 
phantom™ (Virtual 
Water ™.USAt
Figure 4.4.2.2 The set-up o f electron measurements for high energy 16 and 20MeV20MeV 
using 20 X 20 electron applicator by means o f IAEA TRS-398 and AAPM TG-51 protocols in
the Tawam Hospital, UAE (11)
The ionization chamber readings were corrected for standard atmospheric pressure 
and for polarity and recombination effects. Within the plane-parallel chamber, the 
reference point was set at the centre of the window, on the inside of the window. The 
differences between the absorbed doses measured in solid water phantom for electron 
energies were lower by 0.1%, compared to those obtained in the water tank. From 
Table 4.4.2.1, it can be seen that the measurements achieved by means of the IAEA 
TRS-398 protocol with the solid water phantom give an average absorbed dose of 
99.67 cGy with 0.20 cGy standard deviation, being closer by 1% to the expected dose 
compared to the measurements obtained using the water tank. Conversely, the 
absorbed dose measurements obtained using the AAPM TG-51 protocol and carried 
out using a water tank are closer to the reference value of 100 cGy, compared to the 
measurements performed by means of a solid phantom, with a standard deviation of 
0.5 cGy and 0.9% difference, respectively. There are differences in the outputs, which 
are due to the differences in the calibration factors used for each code. They are also 
due to the differences in the fluence factor recommended by each code, in the case 
where solid water is used. Furthermore, the N d ,w ,q  used for the IAEA TRS-398 and 
the AAPM TG-51 are calculated by using kg factors given by each code, in addition 
to the N c o - 60d,w  provided by NFL. Moreover, this difference can be due to the 
difference in the perturbation correction factors given by each code (pceii, Pwaii, pdis, 
pcav)- Figure 4.4.2.3 shows a plot of the three protocols checking the cavity
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perturbation correction factor and it outlines that the three protocols are close to each. 
The equation used is below.
PMa,h„.R,„ = 1 -  0.037 • exp(-0.27 .
Perturbation ca\1tv factor vs. R50
1.2
1
0.8 — L4EA
TRS-398 
—* -A A P M
TG-51 
—i — IPEM
2003
0.6
0.4
0.2
0
2.255 3.49 4.8"9
R 5 0 a n
6.526 8.069
Figure 4.4.2.3: Plot o f the cavity perturbation values using the three protocols (12)
For the IAEA TRS-398 and the AAPM TG-51 codes of practice, R$o and Zref for all 
electrons energies are essentially in agreement without significant differences. 
However, differences occur between R50 and Zref in EPEM 2003 compared with the 
above mentioned protocols. The table clearly shows that the percentage difference on 
absorbed dose measured from IAEA TRS-398 is lower than AAPM TG-51, by 0.52%, 
on average.
Table 4.4.2.1: Absorbed dose, beam quality, R50 and Zref for the following protocols: IAEA TRS-398 
and AAPM TG-51 (8)
6MeV lAEA-Tawam TG-51-Tawam IPEM 2003-RSH
Solid Water phantom
Rso=  2.255 cm R so=  2.255 cm P-50“  Kq =2.5
Z,-ef= 1.25 cm Z,-ef= 1.25 cm Zref “ 1.4
= 0.923 f^ q.RSO — 0.939
Dose(cGy)=99.60 ±0.15 Dose(cGy)=l00.38 ± 0.21 Dose (cGy)= 
99.77 ± 0.23
Water Tank
R so=  2.3 cm Rso=  2.255 cm R50= Kq —2.5
Z,.g/-= 1.28 cm Zref= 1.253 cm Zref = 1.4
7 ,^ = 0.923 Kq,R5o ~  0.939
Dose(cGy)= 100.41 ± 0.2 Dose(cGy)=l00.58 ± 0.21 Dose(cGy) =100.00 
± 0 .0
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Ratio= Dosew/DosCeq.w 1.008 1.002 1.002
9MeV IAEA TG-51................................. IPEM 2003-RSH
i?5o= 3.490 cm i?5o= 3.490 cm RsO~ =3.67
Solid W ater phantom Zref= 1.99 cm
Z^e/-=1.99cm Zref =2.1
^  = 0.925 q^.RSO ~  0.930
Dose(cGy)=99.83 ±0.13 Dose(cGy)=l 00.29 ± 0.19 Dose(cGy) =99.04 ± 
0.96
3.49 cm R so=  3.34 cm A 50 = Kq =3.71
Water Tank
Zref= 1.99 cm Zref= 1.90 cm Zref =2.1
A:, = 0.95^ q^.RSO ~  0.930
Dose(cGy) = 99.35 ± Dose (cGy)= 99.92 ± 0.20 Dose(cGy) =99.00 ±
0 J 6 1.15
Ratio= DosCw/Doseeq.w 0.995 0.996 0.999
12MeV IAEA TG-51................... ............... . IPEM 2003-RSH
i?50= 4.879 cm 7?5o=  4.879 cm R so~ Kq =5 .25
Solid Water phantom
Z^e/-=2.83cm Zref= 2.83 cm Zref =3
A:, = 0.906________ Kq,R50 — 0.920
Dose(cGy)=99.39 ± 0.12 Dose(cGy)=99.33 ±0.19 Dose(cGy) =100.85
± 2.4
Rso=4.98cm i?5o= 4.88 cm R so~ K q  =5 .25
Water Tank
Zref= 2.89 cm Zref= 2.83 cm Zref =3
Kq =  0.906 ^g,R50 — 0.920
Dose(cGy)= 99.07 ±0.12 Dose(cGy)=100.04 ± 0 .19 Dose(cGy) =100.00 
± 1 .3
Ratio= DosCw/Doseeq.w 0.997 1.007 0.992
16MeV IAEA TG-51 IPEM 2003-RSH
i?5o= 6.526 cm i?5o= 6.526 cm Ajo= ATg =6.797
Solid Water phantom Zref= 3.82 cm Zref= 3.82 cm
Zref=3.9
J ^  = 0.897______ = 0.910
Dose(cGy)=99.87 ±0.11 Dose(cGy) = 98.88 ±0.19 Dose(cGy) =100.61
± 2.3
R so=  6.53 cm R so=  6.63 cm 7^50=A^ =6.797
Water Tank
3.82 cm Z;-e/-= 3.88 cm Zref=3.9
A:,=q.897 f^ g,R50 — 0.910
Dose(cGy)=99.63 ± 0.12 Dose(cGy)=99.18 ±0.19 Dose(cGy) =100.00
± 1.23
Ratio= DosCw/Doseeq.w 0.998 1.003 0.994
20MeV IAEA TG-51.............. IPEM 2003-RSH
i?5o= 8.069 cm i?5o= 8.069 cm Rso=Kq=?>.54
Solid W ater phantom
Z;-e/-= 4.74 cm Zref= 4 .74  cm Zref =4.9
A:q = 0.889 Kq,R50 =  0.901
Dose(cGy)=99.68 ± 0.11 Dose(cGy)= 100.01 ±0.19 Dose(cGy) =100 ± 
2.11
i?5o= 8.069 cm R so=  8.172 cm -^50= ATç =8.54
Water Tank Zref= 4.74 cm Zref= 4.80 cm Zref =4.9
AT, = 0.889 “  0.901
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Dose (cGy)= 99.03 ± 
0,12
Dose (cGy)= 99.82 ±0.19 Dose(cGy) =100.00 
±1 .5
Ratio= Dosew/DosCeq.w 0.993 0.998 1.021
4,4,2.1. Percentage depth dose (Solid water and water phantoms and entrance dose)
The clinical electron beam depth dose of a linear accelerator gives an initial surface 
dose, which grows progressively to its peak value, there is a small plateau region and 
then it falls sharply. The beam is normalised to its maximum dose and it is graphically 
depicted in Figures 4.4.2.1.1, presented for two types of phantom: solid water and 
water tank measurements for five clinical electrons beams. It should be noted that 
measurements using the solid water phantom were obtained to a maximum depth of 
81 mm while the maximum depth at which measurements were obtained in the water 
tank was 132 mm. Differences are noticeable for the entrance doses obtained using 
the water tank and solid water phantom (see circled area on Figure 4.4.2.1.2, shown 
below), perhaps because of the use of the chamber sleeve in the water phantom. 
Additionally, probably due to the use of different chambers, there is difference in the 
build-up region, as the beam passes from one media (air) to another (water) and to 
surface tension. On the other hand, at depths greater than 25 cm, the difference refers 
to the change in chamber efficiency, related to the electronic equilibrium that affects 
the stability of this region.
In Figure 4.4.2.1.2 is shown a curve of percentage depth dose obtained from a 6 MeV 
beam by using two different phantoms. Systematic error was found in the depth 
interval 1.8 to 3.5 cm, beyond the build-up region. At the other energies, 6 , 9, 12, 16 
and 20MeV, the normalisation output from the two phantoms is perfectly 
superimposed, as illustrated in Figures 4.4.2.1.1. In addition. Table 4.4.2.1.1 shows 
the absorbed dose outputs for the electrons beams over a period of 12 months. The 
results show that the outputs are within the acceptance range of ± 2 %, the range of 
the outputs shown in Table 4.4.2.1.1 being 98.00 to 100.5 cGy, with a standard 
deviation range of 0.36 to 0.92 cGy. Compared to previous results recorded by Huq et 
al. (2 0 0 1 ), present findings are in good agreement in regard to R50, z^f, and Dw at 
approximately 1%. As shown in Figure 4.4.2.1.3 below, the three protocols agree in
S\v,air values.
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Table 4.4.2.1.1: Outputs of electrons beams and the standard deviation over 12 months (9)
Energy Mean (output) cGy Standard deviation
6MeV 98.550 ±0.921
9MeV 98.000 ± 0.780
12MeV 98.000 ± 0.800
16MeV 99.000 ±0.360
20MeV 100.530 ±0.630
The measurement of depth dose in equivalent solid water phantom (eq-W) and water tank (w) for 
electron beams 6,9,12,16 and 20
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6MeV (eq-W) 
6MeV (w) 
9MeV(eq-W) 
9MeV(w) 
12MeV(eq-W)
■ 12MeV (w) 
16MeV(eq-W) 
16MeV(w) 
20MeV (eq-W) 
20MeV(w)
Depth (cm)
Figure 4.4.2.1.1: Comparison of depth dose between equivalent water phantom and water phantom for
electron beams. (5% error bars) (13)
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♦ Water eq. 
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Depth (mm)
Figure 4.4.2.1.2: Measurement of depth dose in equivalent solid water phantom and water tank for 
electron beam 6MeV. (5% error bars) we plot at dmax- (14)
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Figure 4.4.2.1.3: The values o f Sw,airfor electron beams o f high energy given by TRS-398 and TG-51 
by means of two phantom. (5% error bars) The eiTor included is very small. (15)
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4.4.2.2. Comparison between Three Protocols in the Beam Quality Correction 
Factors kg Values
To validate the eomputed values of kggo for high energy photon and electron beams, a 
comparison with experimental values derived in clinical beams was carried out. All 
the kg beam quality correction factors derive from the use of ^^Co as the reference 
beam quality Qo.
When applying the IAEA -  TRS-398 and AAPM TG-51 Co? for the electron beams, 
± 1.0% agreement was found. This difference is due to the electron quality conversion 
factor k rso. The (k R50) value is obtained by the estimations on the figure in the AAPM 
TG-51 protocol (Figure 6 , page 1859) which is calculated at dref as a function of R50 
for plane-parallel chambers. Moreover, k rso accounts for the Nd.w variation between 
the Qecai and the R50; additionally, kg which is independent of Pgr stands for the 
gradient at the point of measurement. An important number of uncertainties are 
included when calculating the beam quality (AAPM, 1999). Figure 4.4.2.2.1 shows 
the comparison between the protocols TG-51 and IAEA-398, using solid and water 
phantoms.
Comparison bePi een TG-51 & IAEA 1RS 
using solid and w ater phantoms
v = -0.0081iFBm
R^ = 0.9981
§  0.90 
?  0.89
solid-phantom-TG-51
water-phantom TG-51
solid phantom-IAEA 
TRS-398
water-phantom IAEA 
TRS-398
Linear (water-phantom- 
lAEA TRS-398)
2.50 3.Î 5.10
R(50)
6.80 5.60
Figure 4.4.2.2.1: Comparison between protocols TG-51 and IAEA-398, employing solid and water
phantoms. (16)
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4.5. Estimated uncertainty from the experiment
The protocol describes in great detail the measurements’ range of variation under 
reference conditions, which alter depending on the beam quality and the type of the 
radiation applied.
For the purposes of the current study, we employed two beam methods falling into 
common radiotherapy energy ranges: 1) a first method referring to photons with 6- 
MV to 18-MV nominal energies, produced by linear accelerators Varian (600C, 
2100C), and 2) a second method referring to electrons produced by linear accelerators 
Varian (2100C), with 6, 9, 12, 16, and 20MeV nominal energies. The following 
paragraphs will discuss the estimation of the uncertainties coming from this 
experiment.
A number of sources of uncertainty appear during this experiment; to start with, the 
value of the leakage must be mentioned, which can be determined by measuring the 
collected charge in the absence of radiation before and after the irradiation. With 
regard to the uncertainties of charge reading, a number of factors were involved for its 
measurement. Additionally, reproducibility, which is a standard Type A uncertainty, 
may be assessed in relation to a series of repeated measurements. For both ionization 
chambers used in this experiment, cylindrical and plane-parallel chambers an 
electrometer were employed.
One standard deviation is applied to each uncertainty value. Random uncertainties, 
hereby referred to as Type A, are estimated by means of the following methodology. 
Dosimeter responses (linearity and stability), which can be calculated from Strontium 
(^ ^Sr) check source measurements and were found to have a standard deviation of ±
0.1%, measuring the charge at various times. Phantom material is typically placed in a 
treatment room for three hours before any measurement is taken. This allows enough 
time for the phantom to reach equilibrium, thus ensuring an accurate temperature 
measurement.
The level of uncertainty recorded by the barometer was of ± 0.01%; it is necessary to 
be checked from a practical point of view. Readings were performed at every depth
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within each ionization chamber, in order to reduce the level of possible uncertainty. 
These ionization chambers are responsible for determining the absorbed dose within 
the study.
The same sets of equipments were used in the beam calibration process, in spite of the 
applied CoP. Therefore, the experimental uncertainties (such as the barometer’s 
accuracy, the thermometer’s accuracy, the chamber’s position, the field size set-up, 
the machine’s output etc.) remain the same. In order to establish the uncertainties 
while measuring the absorbed dose in reference conditions, both the TRS-398 and the 
IPEM CoP provide detailed information, unlike the TG-51 and the IPSM CoP.
The estimations of the various energies used in radiotherapy have been made 
according to their uncertainty values. From the tables below, the photon energy has an 
uncertainty range between ± 1.6% and ± 0.8%, while the electron energy’s 
uncertainty range is between ± 1.6% and ± 0.8%, using the IAEA TRS-398 protocol 
adopted precisely for these estimates. The largest level of uncertainty was found in the 
AAPM TG-51; it had a range of ± 2.4% to ± 2.0% in the electron energies. The 
majority of uncertainties calculated for the absorbed dose fell within the accepted 
range. Moreover, the electrons doses determined by using the AAPM TG-51 code 
fi*om measurements in the water phantom reveal a 0.5% standard deviation higher 
than the doses determined based on the IAEA TRS-398. Additionally, when using the 
AAPM TG-51 code, the beam quality of the TPR2o,io rises up to 1.0%, while the 
IAEA TRS-398 protocol provides a good agreement between the theoretical and the 
experimental values.
According to high energy electron beams, TRS-398 was used to estimate the 
combined standard uncertainty measurements. The value for the kq was found to be 
around ± 1.0%, when tested with a plane-parallel calibrated Markus chamber against a 
^^Co beam. The standard deviation measurements found for the solid water phantom 
were of ± 0.2%, while those for the water phantom were of ± 0.5%. The same 
measurements for the Dw were around ± 1.5%, when considering a plane-parallel 
chamber calibrated against a ^°Co beam.
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The solid water phantom (± 0.9%) and the water phantom (± 0.5%) standard deviation 
provide the basis of the uncertainties associated with high energy electron beams. 
Abiding by a 95% confidence level, the uncertainty in Nd,w for the NPL was 
estimated at ± 1.5%. This estimation was calculated using the IPEM code. 
Furthermore, the combined uncertainty may be calculated at around ± 2.0%, 
according to the dose of absorbed water and the reference depth. Additionally, the 
uncertainty about the non-water phantom use can be estimated by means of the IPEM 
code, calculated around ± 1.5%.
The systematic uncertainties, hereby referred to as Type B, derive fi*om the ionization 
ehamber calibration process, as well as from the thermometer and the barometer 
accuracies. The experiment adopts multiple phantoms with certain consequences on 
the uneertainties; the phantoms may increase the uneertainties as a result of fluence- 
scaling factors, yet they may also deerease the positional uncertainties due to the 
subsequent effects. The selected values of the hm usually have standard uncertainties 
between 0.2-0.5%. However, when considering various sets, they may have higher 
values compared to the combined uncertainties (Fenwick et al, 2013).
The uncertainty values of the current study are displayed in Tables 4.5.1, 4.5.2 and 
4.5.3. By ealculating the square root of all the squares of the relative component 
standard uncertainties, the combined uneertainty for the data set can be established. 
The information relevant for the TRS-398 can be used to make comparisons against 
the set-up uncertainties used for this experiment. Consequently, the aforementioned 
uncertainty estimates provide a realistic perception of the combined standard 
uncertainty for the Dw, if the appropriate protocols are used. When measuring photon 
qualities, the experimental uncertainty in %DD (10)x for a 6 MV beam was 0.3%, 
while for an 18 MV beam it was 1.23%. Additionally, when considering the TPR2o,io, 
the value for a 6 MV beam was 0.4%, and 2.0% for an 18 MV beam.
Table 4.5.1: Uncertainty values o f the absorbed dose o f photon beams, for both the IAEA TRS-398
and the AAPM TG-51 (10)
Photon uncertainty values
IAEA TRS-398 AAPM TG-51
Energy 6M V  18 MV 6M V  18 MV
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1. Electrometer reading
• Reproducibility 0.03 0.03 0.03 0.03
• Linearity 0.1 0.1 0.1 0.1
• Stability 0.6 0.6 0.6 0.6
2. Corrected reading 0.02 0.02 0.02 0.02
• Pressure 0.07 0.07 0.07 0.07
• Temperature 0.046 0.047 0.045 0.04
• Humidity (40%) 0.1 0.1 0.1 0.1
• Electrometer calibration 0.02 0.02 0.02 0.02
• Polarity 0.01 0.01 0.01 0.01
• Recombination 0.01 0.01 0.01 0.01
3. Calibration factor 0.022 0.022 0.10 0.04
4. Dose 1.5 0.5 1.4 1.4
5. Total uncertainty value 1.626 0.806 1.540 1.538
Table 4.5.2: Uncertainty values o f the absorbed dose o f electron beams for IAEA TRS-398 (11)
Uncertainty values for IAEA- TRS-398 (%)
Electron Energy 6MeV 9MeV 12MeV 16MeV 20MeV
1. Electrometer reading 
• Reproducibility 0.03 0.03 0.03 0.03 0.03
• Linearity 0.1 0.1 0.1 0.1 0.1
• Stability 0.6 0.6 0.6 0.6 0.6
2. Corrected reading 0.05 0.053 0.052 0.054 0.056
• Pressure 0.01 0.01 0.01 0.01 0.01
• Temperature 0.037 0.038 0.038 0.041 0.04
• Humidity 0.1 0.1 0.1 0.1 0.1
• Electrometer calibration 0.02 0.02 0.02 0.02 0.02
• Polarity 0.01 0.01 0.01 0.01 0.01
• Recombination 0.01 0.01 0.01 0.01 0.01
3. Calibration factor 0.00182 0.00182 0.00182 0.00182 0.00182
4. Beam quality correction 0.51 0.44 0.44 0.37 0.39
5. Dose 0.4 0.3 0.9 0.13 1.4
6. Total uncertainty value 0.898 0.818 1.179 0.735 1.581
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Table 4.5.3: Uncertainty values of the absorbed dose of electron beams for the AAPM TG-51 (12)
Uncertainty values for the AAPM TG-51 (%)
Electron Energy 6MeV 9MeV 12MeV 16MeV 20MeV
1. Electrometer reading 
•  Reproducibility 0.03 0.03 0.03 0.03 0.03
• Linearity 0.1 0.1 0.1 0.1 0.1
• Stability 0.6 0.6 0.6 0.6 0.6
2. Corrected reading 0.052 0.053 0.053 0.054 0.056
• Pressure 0.01 0.01 0.01 0.01 0.01
• Temperature 0.05 0.04 0.04 0.04 0.04
• Humidity 0.1 0.1 0.1 0.1 0.1
• Electrometer calibration 0.02 0.02 0.02 0.02 0.02
• Polarity 0.01 0.01 0.01 0.01 0.01
• Recombination 0.01 0.01 0.01 0.01 0.01
3. Calibration factor 0.00182 0.00182 0.00182 0.00182 0.00182
4. Beam quality correction 2.26 2.37 1.99 1.81 1.73
5. Dose 0.6 0.2 0.9 0.83 1.4
6. Total uncertainty value 2.420 2.458 2.271 2.086 2.311
The above analysis provides an updated assessment of differences between current 
dosimetry codes of practice. Previously Nisbet et al. (1998) evaluated the electron 
codes of practice published prior to 1998, the IAEA (1997), the IPEMB (1996) and 
the AAPM (1994). The authors acknowledge that a previous analysis of the protocols 
on dosimetry showed that the measurements of the absorbed dose to water obtained 
by various protocols was expected to be within ± 1.0%, when the measurements were 
carried out by means of a graphite-walled cylindrical ionization chamber. It was 
concluded that the use of the 1996 IPEMB electron dosimetry code of practice in the 
UK would contribute to an increase in the measured dose by approximately 0.5% to 
1.6% at the maximum dose depth, increasing with energy in the range from 5 to 17 
MeV. There is good agreement between the measurements of electron beam in this 
dissertation, using different protocols in order to obtain the absorbed dose, and the 
results of Nisbet et al. In the IPEM 2003, it was concluded that the electron dosimetry 
code improves consistency with the similar UK approach to megavoltage photon
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dosimetry, in use since 1990. It provides redueed uneertainties, approaching a 1%- 
standard uncertainty in optimal conditions, and a simpler formalism than previous air 
kerma calibration based reeommendations for electron dosimetry (IPEM, 2003). 
Comparing the measurement uneertainty using the IPEM 2003 report, Nisbet et al 
found that they have a combined uncertainty equal to ± 0.75%, while the estimates 
within this dissertation show the combined uneertainty of ± 0.8%.
Additionally, the research conducted by Huq et al (2001) was used to eompare their 
results with the results in this dissertation. By using the TRS-398 protocol for photon 
beams, the estimated combined standard uncertainty for resulted in 1.5%, as 
eompared to the result in the current thesis, which estimated a value of 1.6%.
Banjade et al (2001) pointed out in their paper that the protocols developed for high- 
energy dosimetry for photons and electrons (IAEA, 1997, AAPM, 1983, IPEMB, 
1996 and HP A, 1983) continually improved the precision in dose measurements and 
radiotherapy procedures optimization. Banjade et al (2001) concluded that the 
measurements obtained by observing individual protocols also agree with previous 
comparisons.
Sathiyan and Ravikumar (2008), in their paper on the use of International Atomie 
Energy Agency (IAEA), Technical Reports Series (TRS) TRS 277, TRS 381 and TRS 
398 dosimetry protocols, compare the evaluation of absolute dose measurements 
performed in high-energy electron beams, by means of parallel plate and cylindrical 
ion chambers. The outcome from the measurements showed eonsistent divergences 
between the TRS 398 and the TRS 381 of about 0.24% to 1.3%, depending upon the 
energy; the maximum difference between the TRS 398 and the TRS 277 was 1.2%. 
This overall result shows good agreement with the findings from this dissertation.
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Chapter 5: Comparison of Dosimetry Codes of Practice for 
tomotherapy units
5.1. History of Tomotherapy
Helical tomotherapy was developed to find a solution for three overarching problems 
in radiation therapy: (1) to ensure that the patient is correctly positioned, by ehecking 
the correct beam shape and position, (2) restrictions to the target delivered in the 
presenee of sensitive structures, (3) potential collisions between the patient and the 
treatment unit in courses of dynamic therapy, restricting the safety of such therapy 
(Khan, 2003; Mackie et a l, 1993).
In 1959, a multi-leaf collimator was used to treat a patient for the first time, in a 
technique known as “step-and-shot IMRT” (Gseheidlen, 1959). The concept of serial 
tomotherapy originated with Carol Yu (Yu, 1995), who used a narrow rotating 
radiation beam, modulated by two sets of binary collimators allowing the 
simultaneous irradiation of twin slices. The delivery unit was of a design that eould be 
attached to a conventional linae gantry.
Mackie, along with Paul Reckwerdt and Tim Holmes, determined the fundamental 
properties of the collimator motion, the geometrical configuration of the delivery 
system, the dose calculation and the optimisation system. It beeame apparent to 
Holmes that a CT ring gantry would be perfect to use in tomotherapy, if it were to 
include a detector system, leading to a unit able to generate patient CT scans (Mackie, 
2006). However, multiple rotationally-delivered slit fields demand high levels of 
translation precision in order to avoid the development of hot or cold spots along the 
field’s junction. Over time, advances in spiral CT (or helical) delivery reduced hot 
and cold junction artefacts (Kalenderand Polacin, 1991).
Mackie et al (1993b) described in detail mueh of the modem helical tomotherapy.
The first paper on tomotherapy introduced various important ideas (Figure 5.1). The 
paper stated that a ring gantry is optimal for getting a CT image set prior to the 
treatment, in order to make sure that the patient set-up was correet. The paper 
described the placement of a separate kilovoltage (kV) CT seanner at right angles to
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the treatment beam line. It even raised the possibility to CT scan the patient during the 
treatment (Maekie, 2006).
In fact, a team from the University of Wisconsin produced a 3D stereotactic planning 
system, which was marketed by Philips Medical as Pinnacle'^^ (Mackie, 2006). 
Mackie (1993) described a tomotherapy unit that eould control delivery, isolating or 
separating particularly sensitive structures from the target volume. He also claimed 
that dose verification, using tomographic reconstruction techniques, was feasible. An 
expectation arose that information concerning the relationship between the organ and 
the target volume treated and the dose distribution delivered would be available in 
previously unheard of quality and quantity. This data would be the key to 
establishing, much more accurately than before, the relationships between the dose 
delivered and the dose response of both tumours and normal tissue. This information, 
in its turn, would be used to improve the basis for the treatment prescription.
Tomotherapy is an extremely efficient daily image-guided radiotherapy (adaptive 
radiotherapy) technique which allows for correcting position, and for the delivery of 
treatment plans by means of high-quality intensity-modulated radiotherapy.
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Figure 5.1: CT ring gantry could be best suited for Tomotherapy given the modulated slit beam using 
the bank of fast moving collimators. Spiral delivery should improve the hot-spot or cold spot problem
at the junction (Mackie et a l ,  1993) (17)
5.2. Features of helical tomotherapy unit
A helical tomotherapy system employs a unique geometry, yet comparable to the one 
found in a helical CT scanner. In the helical tomotherapy system, a beam is generated 
by a slip ring gantry, in which is mounted a 6 MV linear accelerator. This energy is 
reduced to 3.5 MeV in the imaging modality. The beam travels through a primary 
collimator, where it is further collimated by an adjustable jaw into a fan beam shape. 
Further collimation is conducted by a binary multi-leaf collimator (MLC). 
Throughout the treatment, the ring gantry continuously rotates and the patient passes 
through the rotating beam plane. The linac is 180° away from a detector’s arc. This 
arc is used to obtain a megavoltage CT (MVCT) scan of the patient (Figure 5.2.1). 
The MVCT is carried out before treatment, in order to localise the treatment area and 
allow the patient’s repositioning, if needed. The detectors are also active while the 
patient is treated, producing a data sinogram from the patient’s treatment (Figure 
5.2.2).
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Figure 4.2.1: Linac is mounted on a slip ring that allows continuous rotation 
around the patient. (Fenwick, 2006) (18)
\
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Figure 5.2.2: Tomotherapy HD: During imaging or irradiation, 6 MV linear 
accelerator gantry rotates around the patient as the couch simultaneously moves 
through (Schwarzand Krull, 2008) (19)
Helical tomotherapy occurs when the gantry rotates around the patient while the 
couch moves into the treatment unit. In the patient’s view, the source of radiation 
appears to spiral around them in a helical path. The couch moves into the unit through 
an 85 cm diameter bore. The distance from the source to the rotation centre is 85 cm 
and is 145 cm to the detector (Mackie et al, 1993).
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The field width of the radiation beam comes from the lateral (x) direction towards the 
isoeentre and the fan beam extends for 40 cm. A binary 64-leaf collimator is used to 
divide the fan beam in this direction. The leaves are 95% tungsten and 10-cm thick. 
The multi-leaf collimator (MLC) is focused on the lateral direction only. A beamlet is 
the part of the treatment beam that is covered by one MLC leaf. The tomotherapy 
MLC system is binary, so that each leaf position is either open (i.e. not in the path of 
the beam) or closed (i.e. blocking the beam). A leaf is open for various amounts of 
time, in order to create non-uniform beam intensities -  depending on the gantry angle 
and couch position -  for intensity-modulated radiation therapy (IMRT) (Lyle, 2013). 
Figure 5.2.3 illustrates the MLC, revealing both open and closed states.
TMnponüN Uodu 
MuRHm I Conmator
Xfty BMdi
Closed
Figure 5.2.3: The binary multi-leaf collimator leaves used in Tomotherapy’s (Mackie
eta l, 1993) (20)
The beam is collimated by an adjustable jaw in the (y) direction; the beam can be 
collimated to any size equal to or below 5 cm. However, as a rule, only three 
treatment slice widths are commissioned for clinical use in the treatment planning 
system. At the isocentre in the y-direction, these fields extend 1.00, 2.50 and 5.00 cm. 
It is characteristic of tomotherapy units that they do not have a field-flattening filter. 
Each beamlet’s y-dimension at the isocentre depends upon the y-jaw setting. The size 
of each beamlet in the x-direction is 0.625 cm (that is, 40 cm divided by 64 leaves) at 
the isocentre.
67
The aim of the tomotherapy treatment system is to optimise the MLC leaf open times 
(i.e. beam weight) for 51 gantry angles or projections in each rotation. A projection 
consists of a radiation beam, directed towards the patient from a particular angle 
(gantry angle and couch position). During the treatment process, the couch proceeds 
into the bore at the rate dictated by the gantry rotational period, the width of the jaw 
and the pitch. The pitch is defined as the ratio between the distance crossed by the 
couch in each rotation, and the width of the jaw at the rotation axis. Typically, pitch 
values for a treatment delivery are within the range of 0.2 to 0.5 (Mackie et al, 1993).
The tomotherapy treatment room has two laser systems, in an arrangement dissimilar 
to the one usually found in a treatment room. A virtual isocentre lying outside the 
bore is defined for patient set-up purposes. The treatment plane is located within the 
bore. The distance between the virtual and the treatment plane isocentre, in the y- 
direction, is of 70 cm.
A moveable red laser, resembling the laser marking system commonly found in a CT 
simulator suite, is installed. There are a total of five red laser units in the room, of 
which two are axial, two are coronal and one is sagittal. The red lasers are mounted on 
tracks, together with which they move and are projected onto the virtual isocentre. 
The red laser can be used to project lines onto the patient setup marks, within the 
treatment plaiming system. A fixed green laser system projects lines onto the virtual 
isocentre, and can be used for physics tests (AAPM, 2010).
5.3. Beam Calibration
In intensity modulated radiation therapy (IMRT), the dosimetry of very small 
radiation fields has proved to be a major challenge. To date this challenge has not 
been comprehensively tackled, but is of great clinical importance for the further 
development of radiotherapy. Tomotherapy dosimetry exemplifies this necessity, as 
shown by the investigations in this thesis.
The International Atomic Energy Agency (IAEA) and the American Association of 
Physicists in Medicine (AAPM) have formed a joint task group to analyse the issue of
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absolute dose in small fields. This will generate an international protocol for beam 
quality specification in small fields, detector-specific correction and perturbation 
factors. The group also aims at publishing an extended code of practice, providing 
recommendations on reference conditions and reference dosimetry procedures for 
small and composite fields (Dasa et al. 2007; Alfonso et al 2001).
5.3.1. Defining a small field
A  field is considered “small” if its size is smaller than that of the lateral range of 
charged particles. Sometimes, the size of the penumbra approximates that of the field: 
this generally occurs due to non-standard fields (which can be made up of small 
fields) or may arise in conditions where equilibrium is lacking. Figure 5.3.1.1 gives a 
visual example and shows how the problem increases as the size of the field reduces. 
When the size of the field is large enough to yield charged particle equilibrium (CPE) 
and fully-viewed sources, then the full width at half maximum (FWHM) of dose 
profiles will give correctly-determined field sizes, the field borders being 
approximately at the level of 50.0% of the dose level of CPE, as shown in panel (a) of 
Figure 5.3.1.1 (Dasa et al, 2007).
Penumbra dose profiles at CPE 
Field dose profiles
Actual fie ld size setting 
FWHM of resulting dose profiles< >
Figure 5.3.1.1: Dose profiles for different field sizes, and penumbra dose profiles at charged particle
equilibrium (CPE) (Dasa et al.,2007) (21)
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At the heart of this formalism lie two related methods through which is determined 
the absorbed dose to water in external beam radiotherapy, by means of ionization 
chambers, in contexts other than conventional reference conditions applied by 
dosimetry codes of practice. They are often required in special or complicated 
treatment deliveries. Both these methods demand that the concept of a reference field 
be extended and include small and non-standard fields, as well as modified reference 
conditions, such as the shape and the material of the phantom.
The two methods are:
1. Small, static-field dosimetry, traceable to a broad-beam calibration, which 
introduces an intermediate step through a machine-specific-reference field 
(msr) for treatment machines that fail to establish a conventional reference 
field. A machine-specific reference field, fmsr, is used; the formalisms of the 
absorbed dose and the beam quality index occurring in this method appear in 
the equation below:
 (6)
' - S .................................
where the beam quality of machine-specific reference field. The other
symbols used here have already been described in the first part of this thesis in 
chapter 3, section 3.1.
2. Composite-field dosimetry, traceable to a broad-beam calibration, in which an 
intermediate machine-specific reference field can be included, if required, as can a 
so-called plan-class specific reference field {pcsr). The use of a plan-class specific 
reference field, fpcsr, as well as the formalism of the absorbed dose and the beam 
quality index occurring with this method, are displayed below:
 (6.2)
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where the beam quality of plan-class machine specific reference field.
5.3.2. TG-51 equivalent calibration o f a helical tomotherapy unit
The beam quality presents an issue in the tomotherapy unit, since high-energy x-ray 
dosimetry in TG-51 and TRS-398 was mainly developed as a result of the experience 
with photon beams. They contain flattening filters and therefore have a harder energy 
spectrum. However, some argue that in the energy region of beams with nominal 
energies of around 6 MV, the variation of beam quality correction factors with 
beam quality Q, is small (Jeraj et al., 2005; Thomas et ah, 2005).
Key uncertainties enter the process, first with the calibration of the measuring 
instrument for a standard radiation beam, and in the absorbed dose measurement in 
the user’s radiotherapy beam. National and international protocols and codes of 
practice (IAEA TRS-398 and the AAPM TG-51) are employed worldwide in order to 
increase the accuracy and consistency of values at these two crucial points. Most of 
the current dosimetry protocols provide a basic formalism for the absorbed dose 
measurement, such as:
D^=M *kQ*  .................... (6.4)
Where:
Dw is the absorbed dose to water at the ion chamber point of measurement and M is 
the fully corrected electrometer reading. Moreover, Nd.w is the ^^Co absorbed dose to 
water calibration factor and kq represents the quality conversion factor. The kq values 
(e.g., in the AAPM TG-51) were tabulated in the AAPM TG-51 code of practice 
depending on the percentage depth dose [ %DD(10)] at 100 cm SSD for a reference 
field size of 10 x 10 cm .^ These tabulated values are not adequate for helical 
tomotherapy units because they were obtained under very specific reference 
conditions, which cannot be achieved with helical tomotherapy (AAPM, 2010).
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D ^ = M » k Q  ........................ (6.5)
Bailat et al. (2009) used accepted procedures, described in the IAEA TRS-398 Code 
of Practice and the AAPM TG-51 protocol in order to calibrate a conventional 
accelerator’s absorbed dose output. The documents differ in their definitions of 
radiation beam quality: the IAEA TRS-393 uses a beam quality of TPR20.10, while the 
AAPM TG-51 uses %DD (10)% beam quality (Bailat et a l, 2009; AAPM, 2010) (see 
chapter 4, section 4.4.1).
The following equation derives fi*om the TG-51 calibration protocol and illustrates the 
absorbed dose to water estimation:
A & , = KZ • • *aa '  ..........
Where:
Q is the beam quality (%dd(10)x) of the conventional field 10 x 1 0  cm  ^at
100 cm SSD;
Qmsr is the beam quality (%dd(1 0 )x) of the machine-specific reference field
fmsr (10 X 5  cm  ^field at 85 cm SSD);
is the corrected reading of the dosimeter in the field fmsr;
is the absorbed dose to water calibration factor for ^^Co determined by
the standard laboratory;
is the beam quality correction factor for beam quality Q of the 
conventional reference field frefi 
jçfmsrJr^  Is the coiTection factor for the differences between the conditions of
^msr,Q
field size, geometry, phantom material and beam quality of the 
convention reference field fief and the machine-specific reference field 
fmsr- Jeraj et al (2005) determined this value as being equal to 0.997 
for most ion chambers commonly used.
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In the equation above, kq represents the beam quality correction factor for beam 
quality Q of the conventional reference field fief (10 x 10-cm^ at 100 cm SSD). As it 
has already been stated, it is impossible to generate a 10 x-10 cm  ^field size at 100 cm 
SSD, using helical tomotherapy. Thomas et al (2005) established a relationship 
between the Qmsr, measured on a helical tomotherapy unit, for a 10 x 5-cm^ field size 
at 85 cm SSD and the equivalent Q measured for 10 x 10-cm  ^field size at 100 cm 
SSD as required by TG-51 (Thomas et a l, 2005). He obtained the following equation 
which is taken directly from AAPM (Bailat et al, 2009):
6  = 1.35805 .  G L  -  244.493 .  g L  +14672.98 .  -  293479.4.......(6.7)
The highest error to be generated by the equation above is of 0.30% (AAPM, 2010). 
Thomas et al (2005) also claimed that an accurate method is needed for determining 
the absorbed dose under reference conditions for a helical tomotherapy (HT) facility. 
There are limitations in determining the kq in HT by using the value of %DD (10)%. 
This cannot be used unless the HT design complies with the TG-51 reference 
conditions, which cannot occur as a result of (i) the absence of the flattening filter, 
leading to beam quality changes, (ii) the field size and (iii) the practical SSD required 
by TG-51. The stopping power ratio is not influenced, as a result of its direct 
relationship to %DD(10)x. Thomas et al (2005) derived a relationship for the Exradin 
AISL ion chamber under HT reference conditions (SSD = 85 cm and a 5 x 10-cm^[ 
%DD(10)x[HTRef]] field size) to determine the dosimetric equivalent value under TG- 
51 reference conditions [ % D D ( 1 0 ) x [ h t t g - 51]] for HT.
%T^T)(10) [^;^g_g q = 1.35805 • — 244.493» (%DD(io);c[/m-ef])^ _____
+14672.98 .  -  293479.4
Jeraj et al (2005) conducted a similar study and observed a decrease of approximately 
4% for the %DD(10). They also found a 2.5% decrease in the TPR20.10 (Robert et a l, 
2005).
Bailat et al (2009) determined a value of 0.629 for the TPR2o,io beam quality index, 
close to that of a 4-MV conventional accelerator. However, they noted that 
tomotherapy accelerators typically use 6-MV accelerating potentials owing to the
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absence of flattening filters (Bailat et a l, 2009). Overall, Bailat and his team found 
that the measurements in dynamic helical mode were compatible, with the different 
dosimeters, to within 1.4% (Bailat et al., 2009).
The decrease in the number of errors and uncertainties in dose calculation is crucial, if 
the clinician is to ensure the effectiveness and accuracy of the delivered dose to the 
patient. From the investigations above, it is obvious that guidelines and 
recommendations are needed for beam quality, suitable detectors, correction factors 
and reference field criteria. This thesis will consider those matters and provide 
relative measurements using two different dosimeters.
5.3.3. Longitudinal Beam Profiles
The longitudinal profiles constancy is important for helical tomotherapy. The dose to 
the patient is the combination of the longitudinal profile shape with couch motion. If 
the longitudinal profiles change, the delivered dose will change. The longitudinal 
beam profile constancy test is primarily a slice width test and the beam width at half 
maximum is recommended for monitoring (AAPM, 2010).
The resulting beam profile scans demonstrates the variation in flatness and symmetry 
of the field size as a function of the specified depths in both x and y directions 
(longitudinal and transverse axis).
The helical tomotherapy system differs from other radiotherapy systems. The most 
important difference are: the absence of a flattening filter, a beam hardener, an 
electron stopper, and a thin target, all together causing the radiation field to be 
significantly different from that of other treatment units.
74
The absence of a flattening filter results in a higher dose rate, which reduces treatment 
duration, the beam fluence profile presenting as cone-shaped (the intensity in the 
centre is twice as large as on the sides) (Claude, 2011) (See figure 5.3.3.1.3 below).
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Figure 5.3.3.1: Longitudinal beam profile FW; 50 mm (22)
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Figure 5.3.3.2: Longitudinal beam profile FW: 25 mm (23)
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Figure S.3.3.3: Longitudinal beam profile FW: 10 mm (24)
5.3.4 Cone (Transverse) Beam Profiles
Tomotherapy units do not use a flattening filter and the transverse beam profiles are 
cone-shaped. In the Transverse beam profiles, the intensity at the beam edge falls to 
approximately 50% of the central axis value. The figures below illustrate the cone- 
beam profiles with different FW.
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Figure 5.3.4.1: Transverse beam profiles FW=50 mm (25)
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Figure S.3.4.2: Transverse beam profiles FW: 25 mm (26)
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Figure S.3.4.3: Transverse beam profiles FW: 10 mm (27)
5.3.5. Percentage Depth Dose
In comparison to a typical 6-MV beam, %DD at a depth of 10 cm is reduced due to 
the shorter SSD in the standard tomotherapy. In addition, due to the lack of a 
flattening filter in the tomotherapy units, the natural energy is lowered. Figure 5.3.5 
illustrates the %DD of 6 MV in tomotherapy at a 10-cm depth.
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Figure 5.3.5: % DD 6 MV in tomotherapy (28)
S.3.6 Output Calibration
Typical dose rate of tomotherapy machines is 850 cGy/min = 8.5 Gy/min at 85 SSD 
(source to phantom surface distance), 1.5 cm depth for the 5 x 40 cm  ^field. The dose 
received by the patient will be lower than the reference output of the machine, due to 
the use of the multi-leaf collimator to block the radiation. The dose can be measured 
using ion chambers, film, diodes, etc. Table 5.3.6 shows the output measured using 
the tomotherapy machine.
The calibration protocol for setting the helical tomotherapy unit follows the same 
principles as the procedures for the TG-51 protocol.
1. The ionization chamber has to be placed in a water phantom so that for a 5 x 
10-cm  ^ field, the central electrode is positioned at a depth of 10 cm at 85 cm 
SSD or SAD. The temperature of the phantom should be the same as the room 
temperature and the ionization chamber should be allowed to reach 
equilibrium with that as well.
2. The temp erature/pres sure correction T*tp must then be determined by recording 
the temperature and pressure readings.
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3. In order to obtain Mraw readings, ionization readings per unit time at full bias 
must be taken.
4. In order to get the Mraw  ^ readings for determining the ion recombination 
factor Pion per TG-51, ionization readings for every unit time at half bias must 
be taken.
5. In order to get the Maw + readings for determining the polarity correction Ppd 
per TG-51, ionization readings for each unit time at the opposite polarity of 
the full bias reading must be taken.
6. The corrected ionization chamber reading should be calculated as for TG-51 :
Mgrnsr^^*^ =  M raw ' P t P * P io n  " P p o l ' P elec-
7. At a depth of 10 cm, the dose to water per unit needs to be calculated as 
follows:
'Dwû., = • *e.a '
8. Using the clinical %DD (10) for the set-up of SSD or the clinical TMR (10) 
for the SAD set-up, the dose to water per unit time at cLax is then calculated.
Table 5.3.6: The output measured Cheese phantom (13)
output check using solid Cheese phantom 
T °C= 20.6 °C, P=985.9 mmHg, 
Ct,p~ 1.023
Depth Reading(nC) : Dose Difference
1.5 cm (mean) 14.94 : 858.241 0.97
10 cm(mean) 9.25 518.775
20 cm (mean) 4.84 2.714
Energy
(D20/D10)
0.523243 (nC) expected energy 0.525076 (nC)
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5.4. Recommended tests and tolerance limits
Several factors affect the delivery of a patient’s absorbed dose. Such factors may be: 
radiological images’ quality, delivery dose, geometric and dosimetric accuracy, 
dosimetry’s quality, proper calculation of patient’s dose, process of treatment 
planning, patient set-up reproducibility all along the treatment and, lastly, the strategy 
of correction in case of positional errors through a patient’s treatment. In a hospital 
physicist’s perspective, the procedures of quality control (QC) focus on all these 
factors, starting from the selection of high-quality equipment and the proper software 
to perform accurate procedures and measurement. Moreover, in order to achieve the 
required accuracy in radiotherapy, QA programmes have an obviously important role 
in reducing uncertainties and improving accuracy, which is the goal of this thesis.
Recommendations for HT QA procedures have been published by several groups of 
researchers (Mahan et al., 2004, Fenwick et ah, 2004, Balog et al., 2006), following 
the testing structure originally proposed in the AAPM (TG-40) report. In 2008, the 
AAPM commissioned a task group (TG-148) to develop a comprehensive QA 
methodology for HT (AAPM, 2010). With consideration to the challenges regarding 
QA of an HT unit, the tables provide in appendix B recommended QA protocols for 
daily, monthly and annual testing.
In summary, a comprehensive QA program for an HT unit is the key element of the 
overall success of radiation therapy department. Tolerance thresholds for the proposed 
test stem from the necessity to minimize deviation between calculated and delivered 
doses to the patient. Eventually, careful and timely QA testing of the HT unit ensures 
that the system is functioning according to the specifications, and treatment is 
delivered accurately and precisely. The next section in this thesis will evaluate the 
uncertainty occurring during the whole process involving the HT unit.
5.5. Conclusion
TG-51 requires a beam quality to be defined at SSD= 100 cm, FS (Field Size) 10 x 
10-cm  ^ and depth of 10 cm. On the other hand, a tomotherapy unit has physical
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limitations/differences: different energy spectrum, maximum field size of 5 x 40 cm , 
the SAD = 85 cm and an un-fiattened beam.
The uncertainty values determined in this study are displayed in Tables 5.5. By 
calculating the square root of all the squares of the relative component standard 
uncertainties, the combined uncertainty for the data set can be established. The total 
uncertainty found was 1.05%.
Rajesh et al (2009) investigated the dosimetric parameters (output and energy) 
following major repair. The tomotherapy system maintained its calibration to within 
+/- 2.0% and energy to within +/- 1.5% over the initial twelve-month period. 
Comparing our result with those obtained by Rajesh et al (2009) referenced in this 
study, it was found that the energy uncertainty is +/- 1.82 over the twelve-month 
period and the percentage difference is +/- 0.7%.
Table 5.5: Uncertainty values o f the absorbed dose o f 6-MV beams for the AAPM TG-51, using
tomotherapy machine (14)
Parameters Uncertainty
1. Electrometer reading
• Reproducibility 0.02
• Linearity 0.1
• Stability 0.3
2. Corrected reading
• Pressure 0.06
• Temperature 0.08
• Humidity 0.1
• Polarity 0.02
• Recombination 0.01
3. Calibration factor 0.014 from the certificate
4. Dose 0.99
5. Total uncertain ty  value 1.05
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Table 5.6: Output measurements for a period o f 12 month at 85 SSD, 1,5 cm depth for the 5 x 40-
field (15)
cm
M onths 2012-2013 O utpu t cGy/min
November 849.84
December _____ 8 ^ .6 2 _________
January 854.66
February 852.59
March 855.63
A pnl ______________ 850^1
May 849.01
June 841.77
July 8M.60
August ____844.67 ____ j
September ^ . 7 7
October 85A02^
STDV 6.30
uncertain ty L82 _
From the %DD, the expeeted energy equal to the ratio between the doses at depth 20 
cm to the dose at depth of 10 cm can be obtained.
Using a cylindrieal solid water phantom (Cheese phantom, Gammex RMI, Middelton, 
WI), AISL chambers (Exradin, Model AISL, S/N XW102094, Standard Imaging, 
Middleton, WI) are inserted in the holes of the phantom at different depths (1.5, 10, 
20 cm) in order to verify the dose delivered at these points.
The practical considerations on user beam measurements, as stated in the previous 
chapter, were followed prior to measurements. Table 5.3.6 shows data and 
measurements. From the data illustrated in the table, the energy (actual energy) can be 
compared to the expected energy. The percentage depth dose at two different depths 
of 20 and 10 cm, respectively, is measured and compared to that expeeted.
We can summarize the main points in this investigation in three lines:
1. In the procedure of on-site aceeptance testing, abbreviated ATP, are tested the 
percentage depth dose, both longitudinal and transverse beam profiles, and also 
the beam energy and output. A field service engineer will perform all the 
adjustments required. Likewise, they will be verified by a medieal physicist.
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2. Also assessed is the agreement between the beam quality modeled within the 
systems for planning and the beam quality measured. The purpose is to set the 
machine’s output, energy, etc. so that it matches the modeled beam employed for 
planning. A comparison between the modeled and measured FDD is shown in the 
figure 5.5 below.
3. The daily output and energy are measured in a cylindrical Virtual Water™ 
phantom so that the differences quoted in Table 5.3.6 are between two completely 
different phantoms. The initial output and energy measured in the water tank were 
8.50 Gy/min and 0.525076, respectively. The initial output and energy measured 
in the Cheese phantom were 8.582 Gy/min and 0.523243, respectively. The 
quoted D20/D10 ratio of the modeled beam is 0.523243.
SINJ418 -  May 28*’’ 2013 - FDD 50 mm - PASS
Figure 5.5: FDD curve of 5 x 40 cm field measured in water tank ( - )  and the modeled FDD (— ) at
an SSD of 85 cm (29)
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CHAPTER 6: Assessment of the uncertainty in target 
volume delineation
6.1. Target volume definition
There is a continuing need to gain better tumour control and improve the outcome of 
radiotherapy, with ample evidence of the on-going efforts directly impacting on 
improved accuracy and precision of dose delivered to the tumour. At the very 
essential level, normal healthy tissues surrounding the tumour limit the extent to 
which a high radiation dose can be prescribed; the aim is to optimise the best dose and 
the homogeneity of dose distribution across the tumour against possible risks to 
surrounding healthy tissues and organs at risk (OAR). Furthermore, the process of 
tumour localisation is characterised by various uncertainties. The report drawn by the 
International Commission on Radiation Units and Measurements (ICRU), ICRU 50 
and its updated version ICRU 62 (4) provide definitions of the volumes of tissue to be 
treated, together with the corresponding prescriptive methodology.
In terms of designing a strategy for radiotherapy treatment, imaging is the first 
necessary step, accurate imaging of the gross tumour being critical in defining the 
Clinical Target Volume (CTV). Against a backdrop of a range of challenges, good 
quality imaging determines the volumes and is vital in assessing the location of the 
gross tumour. Thus, the new advances in technological capabilities brought about 
further developments in the tumour imaging process, pointing to significant 
improvements in similar efforts in the years to come.
Burnet (2004) has outlined a number of elements that should be taken into account 
when determining the essential Planning Target Volume (PTV) margin. These 
elements include: 1) imaging standards; 2) co-registration effectiveness for the 
various imaging modalities; 3) electronic transfer protocols; and 4) scanning 
equipment faults. In the case of the Gross Tumour Volume (GTV), Jane (2003) 
provided explanation of the GTV as the volume containing the tumour, as shown by 
clinical assessments.
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Clinical Target Volume (CTV) refers to the expanded volume that potentially 
contains microscopic malignant issues. Planning Target Volume (PTV) refers to an 
expanded volume that makes up the actual location of the CTV, since the motion can 
move in varying ways each time the tumour is administered treatment. Therefore, the 
expanded margins allow for the movement of the CTV. According to ICRU 62, the 
margins can be categorized as Internal Margins (IM) and Setup Margins (SM). The 
setup inaccuracies can be considered a SM, while organ movement could be 
considered to be an IM. This is known collectively under the term of Planning Target 
Volume (PTV). Putting the ideas together, formulations can be produced. For 
example, in order to obtain the Internal Target Volume, the formula CTV+IM is used. 
To obtain the Planning Target Volume, the formula ITV+SM is used. Figure 6.1.2 
shows SM and IM. Table 6.1 shows the summary of ICRU volumes from 1970 to 
present; in addition, figure 6.1.1 shows the ICRU volumes, extracted from ICRU 29 
to ICRU 62. To understand how to calculate these margins and uncertainties related to 
these margins, there are various papers describing how to calculate margins, which 
will be studied in the next section (6.2).
Table 6.1. Summary o f the ICRU volumes (1970 to present) (Purdy, 2004) (16)
ICRU Report 29: 
1970-1993
ICRU Report 50: 
1993-1999(present)
ICRU Report 62: 
1999-present
Target volume GTV GTV
CTV CTV
PTV Internal target volume
PTV
Treated volume Treated volume Treated volume
Irradiated volume Irradiated volume Irradiated volume
Organ at risk Organ at risk Organ at risk
Planning risk volume
Hot spot (area outside 
target that received dose 
larger that 100% of 
specified PTV dose )( at 
least 2 cm^ in a section
Hot spot (volume outside PTV 
that received dose larger that 
100% o f specified PTV dose) 
(>15 mm diameter )
Hot spot (volume 
outside PTV that 
received dose larger 
that 100% o f specified 
PTV dose) (>15 mm 
diameter )
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Dose heterogeneity (no Dose heterogeneity (+7 to 5% Dose heterogeneity (+7
value given) of prescribed dose) to 5% of prescribed
dose)
f Irradiated \  olimic  ^ f '  Inadtated %'olimie 
Treated Volume Treated N'olumc \
large*
I Volume
\
V .
PIV
CT\'
\ ( ' GTV ! \I 
\
Irradiated \  olumc 
Treated \'olumc
I CTV ;
\)IC R i:29  IB) ICRU 50 (C) ICRl 62
Figure 6.1.1 ICRU 29 to ICRU 62 (Purdy, 2004) (30)
Figure 6.1.2 ICRU 62 volumes planning target volumes: IM (Internal Margin) and SM (Setup Margin)
(ICRU, 1999) (31)
6.2. Margin calculations: Van Herk method (equation and related uncertainties)
The total error derived from adding the systematic setup error, phantom transfer error, 
doctor delineation error and motion error is known as the systematic Gaussian error 
( Z ) -  The total error derived from adding up the beam penumbra, motion error, and the 
random setup error is known as the random Gaussian/ treatment execution error (o). 
In order to find the CTV-PTV margin, the following equation is used; CTV-PTV
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margin= 2.5 X ^ + b + p (a-Op). In this case, ^  = systematic error, a = treatment 
execution error, a = linear treatment planning beam algorithm error, b = linear 
breathing error (i.e. target location uncertainty in terms of the patient’s respiration 
cycle), p = planning parameter (which considers the varying treatment beam 
configurations), and Op = beam penumbra width (is the standard deviation of the dose 
penumbra) (BIR, 2003). Gordon et al (2008) note the same which is that S and o 
denote the standard deviations (SDs) of systematic and random errors that are 
assumed occur with all axes.
With this condition, the margin can be given as M=  2.5Z+0.7a, according to the Van 
Herk Margin Formula (VHMF). The full version of the Van Herk margin formula is
M=  2.5Z + 1.64(a'-ap), where a ' = + (tI  . Applying the formula, it can be seen
that 90% of patients have a CTV minimum dose that is greater or at least equal to the 
minimum planned PTV dose. In linear form, this equation can be expressed, with an 
assumed value of op = 3.2 mm, as: M =  2.5E + 0.7a (Van Herk, 2000; Mika, 2013; 
Carmen, 2013)
When delineating the target, the severity of the uncertainty is linked to the imaging 
method, along with the physician’s skill regarding the analysis of the image, and in 
outlining the target. The ‘gold standard’ imaging modality was MRI alongside CT 
(BIR, 2003). In terms of prostate radiotherapy treatments, all of this suggests that the 
physician can use a delineation error of 2mm.
To explore geometric uncertainties, a further model, less complex than the BIR 
method, was adopted by researchers such as Enmark (2006), Schallenkamp (2005) 
and Nichol (2007). However, in terms of similarities, the Van Herk method 
incorporates both the treatment execution error and the combined systematic error. 
However, the Van Herk method does specifically use algorithm error, plarming 
parameter, motion, breathing or penumbra.
In order to find the CTV-PTV margin, the follow formula is given: CTV-PTV 
margin= 2.5%]+0.7a. This means that a EUD (Equivalent Uniform Dose) of 98% is 
found in all but 10% of patients. Van Herk (1995) and Rasch (1999) explained the SI,
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AP and lateral prostate movement errors, as well as the delineation; in addition, Bel
(1996) gave the figures for the setup uncertainties.
Systematic setup errors were shown to have a greater effect than random setup errors 
on boost-IMRT head and neck treatment plans (i.e. when carried out at the same 
time). Specifically, 10% of the plan having more than 3% dose error (in simulated 
systematic setup errors of ^=1.5mm). On the other hand, over 50% of the plans 
having more than 3% dose error, and 28% of the plans having more than 5% dose 
error (in simulated systematic setup areas of ^ =3.0mm). Finally, 50% of plans having 
more than 3% dose error and 38% of plans having more than 5% dose error (in 
combined, random and systematic dose errors of a =Yr 3.0 mm). Seibers (2005) 
revealed that (in the case of 3mm PTV), the dose deviations were reduced by a factor 
greater than 5% in the a =%]=3.0mm simulations, for 5.4% of the plans.
Table 6.2 shows published margin recipes which differentiate between systematic and 
random errors. Also, they can often be written as linear combinations of the SD of the 
systematic and random errors.
Table 6.2 Summary o f Published Margin Recipes for Target (17)
A uthor Application Recipe Assumptions
McKenzie et al, 
2000(McKenzie
AL, 2000)
Target 2.5X+P(o-Op) Extension o f van Herk et al 
for fringe dose due to 
limited number o f beams
Parker et al,
2002 (Parker BC,
2002)
Target E + V + S " ) 95% minimum dose and 
100% dose for 95% o f 
volume. Probability levels 
not specified
Van Herk et al, 
2002(van Herk M,
2002)
Target 2.5X+0.7a-3 mm Monte Carlo test o f 1% TCP 
loss due to geometrical 
errors for prostate 
patients
Van Herk et al, 
2003 (van Herk M,
2003)
Target M-2 mm 
M- 5 mm
Correction for non uniform 
cell density
Abbreviations: SD o f systematic errors; a , SD o f random errors; M , margin before adjustment for
described effect.
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6.3. Imaging modalities
The assessments of CTV and GTV are the most inaccurate, and it is thus essential and 
evidently sensible that the most efficient diagnosing imaging equipment be used. 
Under these circumstances, there may be a large proportion of irradiation on the 
normal tissue surrounding the PTV when the tumour is found, and those tissues often 
limit the dose prescription, due to the concerns raised by the negative additional 
consequences of the treatment.
Dose escalation (i.e. the condition of extra doses) can be achieved through the 
implementation of ITV (Internal Target Volume) onto the PTV through Intensity 
Modulated Radiotherapy (IMRT). Irradiation of the normal tissue can be narrowed 
with 3D Conformai Radiotherapy (CRT); which reduces the ITV on the PTV to the 
best possible extent.
Since the uncertainties regarding the location of the tumour can be minimised through 
imaging, the reduction of margins that increase the PTV from the CTV could be 
achieved using Image Guided Radiotherapy (IGRT), since it is able to image the body 
in every treatment fraction.
In regard to head and neck tumours, Lattanzi (1997) pointed out that intra-cranial 
structure displacements do not affect CT-MRI co-registration. In addition, the 
information gathered from CT images can be used in conjunction with the information 
from both MRI and PET scans (i.e. from functional imaging techniques). At the extra- 
cranial location, Beavis (2004) discussed solutions to issues regarding the distortion 
of MR images and the internal organ shift, also showing that functional imaging can 
provide details comparable to those of MRI scans. Information can be found about 
possible tumours using the technique of functional imaging; this can prove useful in 
dose escalation and save parts of the normal tissue. By means of the MRI scans, the 
GTV and the areas around it can be described with excellent anatomical efficiency, a 
method successfully used in brain tumour radiotherapy planning.
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Figure 6.3.1 The CT simulator was able to accurately locate and record the different densities of 
tissues, organs and bones in the human body, i.e., these can be accounted for in radiotherapy planning 
(MyRadiotherpy.com: http://www.mYradiotherapv.com) (32)
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Figure 6.3.2 MRI machine scans showing the functional imaging which can provide details 
(MyRadiotherpy.com: http://www.myradiotherapv.com) (33)
In recent years, molecular imaging using positron emission tomography (PET) has 
been proved to have a great medical effect on malignancy staging and diagnosis. As 
Thorwarth (2010) points out, this means that radiotherapy planning should absolutely 
integrate PET results. The evolution of modem imaging strategies will help to 
understand the placement and extent of tumours. This can also be achieved with 
improvements of biological strategies that utilize practical imaging and malignancy 
molecular markers.
Positron emission tomography-computed tomography (or PET-CT) equipment (i.e. 
the dual usage of a PET scanner which also includes a CT scanner) increases the 
efficiency of the PET data. The PET information is also enhanced by registration to 
anatomical CT images.
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Bujenovic (2004) explains that the results of PET scans affect the planning process of 
30-40% of the radiation treatment plans in cancer patients. In addition, the most often 
changes point to the evolution of the disease and the discovery of métastasés. In the 
case of high tracer uptake tumours, the PET scan accurately determines and stages the 
disease. Nevertheless, tracer uptake absence does not eliminate the possibility of 
residual latent disease. After the radiation therapy, it is advisable to delay the PET 
scan for a period of minimum 6 weeks or up to 3 - 4 months, in order to allow the 
dissipation of the inflammation within the radiation field. Although PET caused 
modifications in the volume of the gross tumour volume, this process is still a 
subjective one (Bujenovic, 2004).
Apisamthanarax (2005) also shows that, since PET-CT involves sequential imaging, it 
allows reductions in the target volumes. This contributes to diminishing the 
uncertainty of the clinical target volume, which constitutes a major goal of oncologic 
imaging, aimed to reduce the internal and setup margins.
Multiple observations should be made to delineate the tumour volumes and these have 
to be cross-checked with their mean data, as recommended by Buijsen et al. (2012). 
They also must be cross-checked against the mean value of the volume, which is 
calculated by the automatic delineation software. This will reduce the risk of 
variations being recorded by different observers. Buijsen et al. recommend the above 
procedures to minimise inaccuracies, ensuring accurate tumour volume delineation. 
This may spare healthy tissue and optimise best tumour control probability.
Four-dimensional (4D) Adaptive Radiotherapy is able to consider an extra factor of 
tumour volume compared to 3D treatment. It is also highly probably that IMRT be 
used together with 4D adaptive radiotherapy. IGRT could contribute to reducing 
uncertainties in terms of tumour geometry evolution. Dose delivery and treatment set­
up can be allowed through the use of adaptive therapy, as required.
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Figure 6.3.3 An integrated PET-CT scan combines the images from a positron emission tomography 
(PET) scan and a computed tomography (CT) scan, performed at the same time on the same machine
(GEISINGER, 2013) (34)
There are a number of studies showing how different clinicians outline targets and 
normal organs and show the effects of the imaging modalities in target delineations.
For example, Nyholm et al. (2013) carried out a study using results from the MRI 
trials on a sample size of 25 patients (with 5 patients taken from 5 different healthcare 
establishments, assessed by 2 doctors of each establishment). Each pair of doctors 
delineated the seminal vesicles and the prostrate of the MRI results and examined the 
delineation in terms of the general intra-physician and inter-physician difference, 
along with the way that the variability and origin of the MR images impacted each 
other. The seminal vesicles and the prostrate were shown in the MRI results (Fig. 
6.3.4 exhibits MRI picture quality).
In terms of intra-physician variability, the results showed that the differences fell from 
1.3-1.9 mm for the prostate and 3-4 mm for the seminal vesicles, with a standard 
deviation of 1; 0.7-1.7 mm for inter-physician variability; the results are about the 
same for seminal vesicles and the prostate. Marked differences were noted for each 
participant. This was also the case for the imaging sequences from each 
establishment. On the other hand, when the field power increased, there was no sign 
of difference lessening. This means that the total delineation variability is smaller for 
the prostate than for the seminal vesicles. This could be explained by the fact that 
there is more variability in volume delineation by an individual physician than 
between them. T2-weighted spin-echo based sequences were used by each of the 5
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establishments, and it was shown that the level of difference was greatly impacted by 
the imagining sequence, even in this case (see Fig. 6.3.5 for the seminal vesicles and 
prostate delineations of the various establishments).
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 ^ Center A
&
Center B
Center D
Figure 6.3.4 Examples o f the image quality of the images from the different centres (prostate and
seminal vesicles) (Nyholm, 2013) (35)
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Center A
Center B
Center C
Center D
Center E
Figure 6.3.5 Examples of the delineations (prostate and seminal vesicles)(Nyholm T. ,2013) (36)
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6.4. Uncertainty factors in target volume delineation
6.4.1. Systematic error: X
The target delineation error reflects the variance between the ideal CTV and the 
observed CTV, which can incur if the CTV is delineated. The uncertainties in the 
systematic treatment planning, for example the delineation of the tumour by the 
clinician, the transmission uncertainties, and the displacement caused by predictable 
physiological evolutions and uncertainties in the treatment planning algorithm, are 
included in the PTV. The phantom transfer error incorporates differences in the 
alignment of the laser (i.e. between the gantry and collimator angle accuracy, the 
isocentre location, the field edge and multi-leaf collimator leaf position, the margin 
growing algorithm, the CT couch longitudinal position indication image resolution 
and the CT and linear accelerator) (BIR, 2003).
The patient setup error is a single potential element of the total systematic setup error, 
and it is measured in terms of the shift in the location of the isocentre, when the image 
is contrasted to its corresponding reference; additionally, it reflects the deviation from 
the expected position to the actual position. This type of error is also representative of 
every reason behind treatment setup errors that cannot be explained through phantom 
transfer error (above). This type of error can appear as a result of hair loss, weight 
change, or other shifts in the patient’s size, shape or position. Furthermore, it can 
reflect the treatment carried out on different couches, and target displacement in terms 
of skin setup marks, as a result of the CT scan. Finally, the number of types of 
systematic error involved in the measured setup error is shaped by the selected model 
of treatment verification (BIR, 2003).
6.4.2. Random error: a
Random error is known as the ‘treatment execution error’, since it appears at the point 
of treatment delivery. The various types of random errors include:
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1. Patient setup error, due to shifts in the setup methodology, treatment 
equipment or patient’s position from one delivered fraction to another. Patient 
setup errors can somewhat differ, and they are unpredictable.
2. The target position and shape error is similar to systematic errors, apart from 
the fact that it incorporates inter-fraction motion instead of delineation to 
treatment motion. Target position refers to the shift in the shape and position 
of the target.
3. Intra-fraction errors happen at the delivery stage of a fraction (i.e. when the 
patient is breathing), and they reflect shifts in the patient’s internal anatomy 
and position.
Finally, in terms of random errors, department protocols, patient compliance and 
immobilisation methods can have an impact on the overall result. For example, a 
random error may change if the immobilisation technology used during treatment is 
innovated. An online modification strategy can be implemented in order to manage 
random errors, since offline modification strategies are not able to forecast random 
errors in friture fractions (i.e. in this case, the variations should be incorporated when 
formulating the treatment margins) (BIR, 2003).
6.5. Uncertainties in target volume delineation from literature review
Setup variations, gross tumour volume (GTV) errors in terms of tumour delineation, 
variation of the location of the patient’s organs, and lack of knowledge about the 
severity of the microscopic tumour, are key reasons behind delineation uncertainty. 
Studies such as those conducted by Nowak (1997) and Valley (1993) have illustrated 
that the reliability of delineated structures can be largely affected by the use of 
inconsistent directions on target volume delineation. Throughout the treatment 
planning process, every treatment fraction will be impacted the same way, since 
delineation uncertainty is due solely to systematic error (Valley JF., 1993, Nowak P, 
1997).
Various studies, such as those conducted by Stroom (1999), Dawson (1998), Melian
(1997) and Roeske (1995) have used series of CT scans when investigating organ
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movement in radiotherapy. Furthermore, Van Herk (1995) showed that the combined 
motion of prostate and seminal vesicles could be illustrated through primarily-left- 
right-axis rotation and anterior-posterior direction movement (van Herk M, 1995). 
Similarly, Aaltonen (1997) stated that the ‘internal margin’, referring to organ motion, 
and the ‘setup margin’, referring to positioning uncertainty, are two types of margins 
suggested by the Nordic Association of Clinical Physics, and argues that a linear 
movement of organs (away from each other) is possible (internal errors) and setup 
errors can happen (Aaltonen P, 1997b).
A study conducted by Austin-Seymour (1995) with physicians used a cylindrical 
expansion of CTV in order to suggest an anisotropic margin for setup and organ 
position errors. It was discovered that the PTV margins had a probability of 75%. In 
terms of margin for random errors. Hunt (1993) illustrated that the criteria would rely 
on the field design and the treatment technique (Hunt MA, 1993). Furthermore, in 
order to maintain a 95% dose coverage, Bel (1996) used a simulation study to show 
that a margin for random deviations of 0.7 times the standard deviation is needed (Bel 
A, 1996). McKenzie (2000) showed that the particular beam arrangement dictates 
where the figure of 0.7 appears, while Aaltonen (1997) used biological modelling to 
suggest that the margin for random errors is 0.5 to 0.7 times the standard deviation 
(McKenzie AL, 2000, Aaltonen P, 1997a).
In addition, MacKay (1999) revealed that random errors are far less significant than 
systematic errors; this was achieved by testing systematic errors through computing 
DYHs for a few possible shifts (MacKay RI, 1999).
Killoran (1997) carried out many mathematical simulations of prostate radiotherapy, 
and proposed the idea of prescription dose probability as per each specific organ. In 
order to provide the dose to a particular fraction of the patient population, the beam 
margin was repeated (Killoran JH, 1997). In addition, Fontenla (1996) explained 
position uncertainties in the target and organs at-risk via a consideration of the target 
shape during a measurable optimization process that was used to examine treatment 
margins (Fontenla E, 1996).
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Van Herk and Stroom (2000) proposed margin guidelines, which outlined this 
variance (Van Herk M, 2000). For example, patients will experience a medium level 
of impact from a slightly lowered dose on the peripheral high dose region, resulting 
from the blurring effect of random errors; while patients will be severely impacted 
when the dose is shifted due to systematic errors, such as the CTV moving outside the 
high-dose region. The margin for random errors is 0.7a, which is low, when 
permitting a lower repeated dose (for example, up to 95%).
The BIR (2003) guidelines, together with various studies such as those by Hoogeman 
(2005), Nederveen (2003), Wu (2001) and Langen (2001), explored prostate motion 
error with Langen and Jones (2001) illustrating a degree of difference from each piece 
of research to the next. However, Langen and Jones (2001) discovered that across all 
examples of research, the prostate motion remained at a severity of -0.2±3.2mm for 
superior-inferior (SI) motion; -0.4±3.9mm for anterior -posterior (AP) motion; and
0.6±0.7mm for lateral motion. Finally, motion error employed the findings from the 
BIR (2003) guidelines.
6.6. Conclusion
In this part of the study, the focus will be on target volume delineation at Tawam 
Hospital using 2 sites, head and neck, and prostate.
Delineation is currently performed in most centres by the radiation oncologists, who 
may have a limited background and experience in radiology, making it difficult to 
precisely identify the detailed anatomical structures on computed tomography images 
(CT). On the other hand, the radiologist, more skilled in radiological anatomy, does 
not always have a detailed understanding of the natural history of the disease. 
Differences in delineation may therefore be observed between physicians due to 
imprecise CT data or divergent assessments. At the Tawam radiotherapy department, 
a team of Radiation Oncologists, Dosimetrists and RT Technologists worked together 
to establish protocols from sources such as RTOG atlas which are implemented. 
These protocols give clear directions on the type of imaging to be used, how to
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interpret the imaging, target volume delineation and how to deal with uncertainties of 
imaging and prescription.
Uncertainty value is another name for PTV margin. In any department we need to 
employ a PTV margin because of:
1. Patient setup errors, e.g. bladder and rectal filling
2. Geometric uncertainty e.g. linac geometric accuracy
If we do not have good immobilization devices, then it is necessary to have bigger 
PTV so that we do not miss the target volume etc.; however, the down side of this is 
in the fact that the bigger the PTV, the more toxicity the patient will experience.
In the Tawam department, the PTV given for prostate is 5mm isotropic (except 
posterior); where only a 0.5em margin is applied. This is explained by the rectal dose. 
In prostate it is important to control the bladder and rectal filling, so as it doesn’t 
affect the PTV margin. For prostate the bladder must be comfortably full and the 
rectum must be empty. (Patients are given instructions on how to do this).
For nasopharynx, the PTV to the tumour site, the margin is lem. Also, to the nodal 
site, the margin is 7mm. From our study we obtained combined uncertainties of 1.68 
mm in head & neck cases, due to the immobilization used it has been possible to 
minimize the uncertainty. On the other hand, in the prostate eases, combined 
uncertainties of 6 mm were observed, due to the internal motion. Table 6.6 shows the 
estimated measurements of the uncertainties for head & neck and prostate eases which 
include the delineation, transfer and patient setup errors. The combined uncertainty 
for the head & neck study is 1.67%, while for the prostate study the combined 
uncertainty is 5.57%.
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Table 6.6 Uncertainties estimated for head & neck and prostate cases (18)
Systematic errors (mm) Head & neck Prostate
^ d elin eation Systematic error; 1.23mm 
Random error: 0.36mm 
Margin in total = 1.59 mm
Systematic error: 4.11mm 
Random error: 1.15 mm 
Margin in total= 5.26 mm
^ tran sfer Couch Long.: 0.04 
Couch Vert.: 0.03
Couch Long.: 0.63 
Couch Vert.: 0.21
Epatient-set-up X Shift (Lat):0.34 
Y Shift (Long):0.27 
Z Shift (Vert.): 0.27
X Shift (Lat):1.46 
Y Shift(Long):0.47 
Z Shift (Vert.):0.59
E to ta l 1.67% 5 ^ 7 %
Table 6.7 below provides information about imaging modalities, target volume 
delineation and sources of uncertainties in prostate and head & neck patients
Table 6.7 Information on imaging modalities, target volume delineation in the Tawam Hospital (19)
Head and neck Prostate
Imaging modalities 1-Diagnostic CT-scan head and neck
2-MRl head and neck with and 
without contrast with gadolinium Pre 
and post chemo MR
(if possible treatment immobilisation 
device should be used for the MRl 
scan)
3-Bone scan, PET CT
4-Nutritional evaluation prior to RT 
for prophylactic gastrostomy 
Consider “PEG” tube
5-Dental evaluation. Tooth 
extractions should take place prior to 
shell /  planning CT (simulation 
preferably 2 weeks after major 
extraction)
(For simple extraction e.g. 1 tooth 
extracted simulation date 
preferably earlier)
6-Evaluate beard length and thickness 
(for physician discretion)
CT/MRl:
The bladder should be
reasonably full for simulation, 
keeping in mind that patients 
may not be able to maintain as 
ftill a bladder during 
radiotherapy. Having a
somewhat full bladder at
simulation ensures that the CTV 
will be o f maximal dimensions. 
The seminal vesicles or
remnants thereof, i f  identified 
on CT or M Rl as being present, 
will receive the full dose.
An overly distended rectum can 
introduce a systematic
positioning error that may 
increase the probability o f 
missing the CTV. An enema 
before the plarming CT scan 
and/or use o f a hollow catheter
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to evacuate flatus will empty the 
rectum. Immobilization o f the 
hips and feet using a cradle 
should be considered (RTOG 
Atlas).
Target Volumes
1- GTV70= Gross tumour and gro:
APPLY TO pres: PTVT 76 or 
PTVT 70
nodes (if gross node in the low nec 95% o f volume to receives
gross node can receive 63 Gy 100% o f prescribe dose
No variation :
(ideally gross node should No more than 3% o f PTV more
receive 70 Gy) than 107% o f prescribe Dose
2- CTV70= GTV70+10mm
Minor Deviation
3- PTV70=CTV+3-5mm 3% o f PTV >107 to <110% of
Prescribed Dose
Mai or Deviation
3% o f PTV more than 110% of
prescribes Dose.
CTV= PROSTATE
PTV =CTV +10m m
isotropically except posterior
5mm.
Source of Change in the size o f tumour, loss o f Target movement, seminal
uncertainties weight vesicle and internal movement
(Bladder, rectum ).
104
CHAPTER 7: Evaluation of Dose Distributions Using Two 
Different Phantoms for Tomotherapy Treatments (Validation 
of treatment plan and delivery QA DQA study)
7.1. Introduction
IMRT treatment consists of steep dose gradient throughout the treatment volume and 
any small mis-registrations of these gradients can lead to cold and hot spots in the 
composite dose. This may lead to target region geometrical miss. Treatments may be 
verified prior to treatment by the integration of spatial dosimeters (e.g. film and ion 
chamber arrays employed in dose measurement and analysed by means of DTA 
(spatial distribution of distance -to- agreement) and gamma index (y)) or by means of 
metrics such as comparisons of dose profiles. The second methodology includes 
absolute dose variation (AD) at the points of choice between the calculated and 
measured doses. Low et al. developed a technique to simultaneously incorporate both 
(AD) and DTA values into the quality index called gamma (Pelagade et al., 2009; 
Low et al 1998). The gamma index presents disagreement in the regions that fail the 
acceptance criteria and indicates quality in the regions that pass. Otherwise, the 
gamma index shows the difference between the calculated and the measured doses of 
the acceptance tolerances. The acceptance criteria for the dosimeters used in this work 
belong to VanDyk et al. (1993) and they are of 3%/3 mm (3% dose difference/ 3mm 
distance difference).
The current standard of practice for the HT requires dosimetric verification for each 
patient by examining patient-specific delivery quality assurance (DQA) for treatment 
delivery. The aim is then to use the original patient plan from the tomotherapy 
Treatment Planning System (TPS) and transfer it to the DQA planning system. The 
plan is then recalculated using the same fluence pattern applied to the original plan. 
When the DQA plan is ready and approved by the physicist, it can then be used on the 
tomotherapy unit using the same setup applied to the plan based on the appropriate 
phantom in the DQA plan.
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This work focuses on the patient-specific QA component and includes a DQA 
verification analysis of 15 cases for head and neck patients and 13 cases for prostate 
using two different phantoms: MapCheck2 and Cheese phantom system.
7.2. Methods and materials
The primary points of the DQA comparison were as follows:
• Comparison of the dose profile between the measured dose using the Cheese 
and MapCheck2 phantoms and the calculated dose from the treatment 
planning system (TPS). The Cheese phantom is a cylindrical solid water 
phantom assembled as two hemispheres, each with cavities for ion chambers 
and plugs for CT scans;
• Gamma factor comparison between the two phantoms;
• Point dose comparison between the calculated and measured doses.
7.2.1. Cheese Phantom
A cylindrical solid water phantom called a “Cheese phantom” was used with film and 
ion chamber, the phantom has multiple holes to insert AISL chambers in order to 
verify the dose delivered at these points. The Cheese phantom can be divided into 2 
hemi cylindrical parts to fix Kodak XV film inside. When not filled with an ion 
chamber, these holes are plugged with solid water. The advantage of using this 
Cheese phantom is that the radiation beam is always perpendicular to the film. Kodak 
X-Omat V film is placed on the surface of the phantom’s film plane (central coronal 
slice) and taped to avoid any movement.
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Figure 7.2.1.1: A: Cheese phantom with the film placed in the centre of the phantom and 
the ion chamber; B: The setup using the CHEESE phantom (Gammex RMI, Middelton,
WI) and the ion chamber (Exradin, Model AISL, S/N X W 102094, Standard Imaging,
Middleton, WI) (Tawam hospital, UAE) (37)
The Cheese phantom was aligned using the DQA module of the Tomotherapy 
planning station software using the patient-positioning red lasers. A patient-specific 
DQA plan was created for each case and delivered to the DQA Cheese phantom. 
Point doses were sampled from the plan at the location at which the ion chamber 
measurements were acquired. An AISL Ref F92722 ion chamber was placed in the 
appropriate hole, with setup as shown in Figure 7.2.1.1 above. The electrometer was 
then turned on, warmed-up and then turned to zero. The voltage used for the chamber 
was +300V. A treatment was administered, and the detector response was recorded. 
The percentage dose difference between the calculated dose, Dc, and the measured 
dose, Dm, at a specific depth is given by (Ardu et al 2011);
%AD = ” * 100%...................(7)
The film was left to stabilize after irradiation for the same period of time as for its 
corresponding calibration film before processing. The film was processed using a 
Kodak RP X-OMAT processor and then scanned and digitized so that finally the
optical density is converted to dose. The film dose distribution is compared to the
calculated dose distribution using the DQA analysis tools provided on the
tomotherapy planner work station (Pelagade SM, 2009). A VEDAR VXR-16
Dosimetry Pro scanner (VIDAR Systems Corporation, Herndon, VA) was used to 
scan the treatment film (see Figure 7.2.1.2 below). All films were taken from the same 
film batch and were processed under the same conditions.
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Figure 7.2.1.2: A VIDAR VXR-16 Dosimetry Pro scanner (VIDAR Systems 
Corporation, Hemdon,VA) (Tawam Hospital, UAE) (38)
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The film dose distribution was compared to the calculated dose distribution using the 
DQA Analysis Tools provided on the Tomotherapy Planning workstation (DQA 
Planning). The DQA Analysis Tool allows the film data to be registered to the 
calculated dose using the reference points selected during the measurements and then 
extract measured dose profiles, as well as to compare the calculated dose distributions 
using isodose lines and gamma distribution (Pelagade 2009).
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When a Cheese phantom is used, the radiographic film and/or the ion chambers are 
placed into the phantom, and then the phantom is irradiated (the setup shown in 
Figure 7.2.1.1 above), the measured data using both film and chambers are then 
collected and evaluated using the DQA software. Evaluation tools include a 
comparison of the calculated and measured isodose curves, plots of the dosage 
comparisons along an arbitrary direction, gamma plots and gamma histograms and a 
comparison of the point-calculated dose versus the ion-chamber measurement 
(Mackie2006). The figures above show the evaluation windows.
7.2.2. MapCheck2 phantom
With its excellent spatial resolution, film dosimetry has been widely adopted for the 
purpose discussed above. However, the procedures are time-consuming and require 
great care when used for absolute dosimetry. Detector arrays with excellent 
reproducibility and independence in the dose-rate response are now replacing films 
for routine QA, simplifying the verification procedures.
The Model 1177 MapCheck2, manufactured by Sun Nuclear Corporation, is a two- 
dimensional radiotherapy dosimetry system for quality assurance. 2D diode array 
measurements were taken using the MapCheck2 with MapPHAN combination (Sun 
Nuclear, Melbourne, FL). The MapCheck2 detector provides high quality assurance 
tests of the ability of the linear accelerator to successfully deliver a planned quality 
assurance dose map (called delivery QA or DQA) in a phantom. The DQA plan is not 
a measurement of the planned dose map to be delivered during the treatment of the 
patient, but a recalculation (on a phantom) of the dose defined by the treatment 
planning system, TPS, which must be delivered by the linear accelerator.
The MapCheck2 detector consists of 1527 diode detectors with uniform detector 
spacing throughout the array of 7.07 mm, equalling a total octagonal detector array 
size of 32 x 26 cm. The sampling frequency of the MapCheck2 detector is 50 ms and 
each diode in the array has an active detector area of 0.64 mm^ and an active detector 
volume of 0.000019 cm  ^(Sun Nuclear Corporation, 2009).
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The MapCheck! detector offers a quality assurance test assessing the linear 
accelerator ability to successfully provide a planned QA dose map by means of a 
phantom. However, the DQA plan is not a measurement unit of the planned dose map 
to be delivered throughout a patient’s treatment. It is rather a phantom recalculation of 
the dose (defined by the TPS) to be delivered by means of the linear accelerator.
Figure 7.2.2.3: MapCheck! setup in Tomotherapy machine. (Tawam Hospital, UAE). MapCheck! 
device and MapPHAN phantom. The MapCheck! slides into the MapPHAN for rotational delivery
measurements (43)
7.3. Results and discussion
The measurements are presented as the point dose measured using the cylindrical 
phantom and the DQA point dose calculated using the tomotherapy planning 
software. The calculated and measured point doses were in good agreement with each 
other (data provided in the Tables below). The average percentage dose difference 
and standard deviation for the set of cases evaluated for each body site were: 3.5% 
±2.54 for head and neck cases using the Cheese phantom; 0.7% ±0.32 for head and 
neck cases using MapCheck!; 2.7%±1.33 for prostate cases using Cheese phantom; 
and 1.3% ±0.60 for prostate cases using MapCheck!. These differences may be 
attributed to the varying degree of target complexity and to the critical structure shape 
and proximity, which require sharper dose gradients to be planned and delivered in 
head and neck versus prostate cases. Figure 7.3.1 illustrates a comparison between
11!
gamma % for head and neck patients using different phantoms (MapCheck! and 
Cheese phantom), with a gamma percentage ranging from 100 to 98%. Figure 7.3.! 
illustrates a comparison between gamma % for prostate patients using different 
phantoms (MapCheck! and Cheese phantom).
The difference was calculated using the gamma equation of Low et al. (1998; 
Pelagade et al, !009), and the plans were normalised to a global dose value according 
to equation (1):
D = ^ « *100%------- (7.1),
D m
where Dc is the dose value at a point in the calculated or planned dose matrix and Dm 
is the dose value at the corresponding point in the measured dose matrix (Myers et al 
! 01!).
Furthermore, the standard deviation was calculated using the following equation:
.......................
V n — \
The isodose distribution accuracy, i.e. the agreement of the measured and calculated 
relative doses is evaluated by gamma percent (y %) values between head and neck and 
prostate cases conducted in the tables below. On one hand, the average reported for (y 
%) prostate was (97.33%±1.57) when using the MapCheck! and (97.44%± 3.35) 
when using the Cheese phantom. On the other hand, the average (y %) for head and 
neck cases was (96.79%±!.4!) when using MapCheck! and (98.65%±!.5!) when 
using the Cheese phantom. In addition, the average percentage dose difference and 
standard deviation in head and neck using the Cheese phantom was 3.5±!.5%, while 
the percentage using MaphCheck! was 0.7± !.4 %; for prostate cases, when using 
Cheese phantom this value was found to be !.7±3.35% and 1.3±1.57% when using 
MapCheck!. The Cheese phantom-based study conducted by Pelagade and Paliwal 
(!01!) revealed an average percentage dose difference and standard deviation for 
head & neck of 1.19 ± 0.79% and for prostate 1.91±1.39%. This lower result obtained
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by Pelagade and Paliwal’s may be due to the dose gradient at that point. IMRT 
treatment result in a steep dose gradient all through the treatment volume which leads 
to hot and cold spots in the composite dose (small misregistrations). Moreover, 
Westerly et al (2009) found averages of ±4.47% in head & neck cases and ±0.48% in 
prostate cases using the Cheese phantom. This result is higher by 0.97% than the 
result obtained in the present study and by 3.3% than the result obtained by Pelagade 
and Paliwal as far as the head & neck cases are concerned. As for the prostate cases, 
my result is different from the one reported by Westerly et al by 2.2% and by 0.91% 
from Pelagade and Paliwal’s.
As excellent agreement between measured and calculated dose distribution was found 
in homogeneous media. The graphs below show the same appearance of the curves as 
could be seen in Figures 7.3.1 and 7.3.2. The results are showed in Tables 7.3.1.1-2 
and 7.3.2.1-2.
7.5.7. Evaluation o f Head and Neck cases using two types ofphantoms
Table 7.3.1.1 Cheese phantom measurements compared to the DQA calculated for the 15 head and
neck cases (20)
Patients Map check2 DQA-C
Measured Calculated
Point dose (Gy) Point dose 
(Gy)
Difference (%) (7) %
1 1.6 1.7 3.1 99.5
2 1.5 1.6 2.0 100.0
3 1.4 1.4 2.1 99.9
4 1.4 1.5 5.0 99.9
5 2.2 2.2 1.9 99.7
6 1.6 1.7 2.4 100.0
7 1.3 1.3 2.4 94.5
8 1.7 1.7 3.0 99.7
9 1.5 1.5 0.7 99.4
10 1.2 1.3 1.6 99.6
11 1.5 1.6 2.6 91.0
12 1.9 2.1 11.1 99.6
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13 1.5 1.6 3.3 99.5
14 1.7 1.8 5.2 98.2
15 1.4 1.5 5.8 99.2
Average difference= 3.5
STDV 2.53 2.52
Uncertainty 0.65 0.65
Table 7.3.1.2 MapCheck! phantom measurements compared with the DQA calculated for the 15 head
and neck cases (21)
DQA-CMap check2-M
Patient Measured Calculated
Point dose (Gy) Point dose (Gy) Difference (%) (Y)%
2.0 2.0 0.5 98.3
1.9 1.9 0.9 92.1
0.61.8 96.31.7
2.0 0.9 97.02.0
2.6 2.6 0.4 99.5
0.62.0 99.62.0
1.4 98.21.8 1.7
2.1 0.2 98.92.1
0.7 96.41.9 1.9
1.0 93.01.6 1.5
1.8 1.2 98.81.8
0.52.5 96.82.5
0.81.9 97.31.9
0.92.0 97.0
0.31.8 1.8 92.7
Average difference= 0.7
0.33 2.41STDV
0.08 0.62Uncertainty
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7.3.2, Evaluation o f Prostate cases using two types ofphantoms
Table 7.3.2.1 Cheese phantom measurements compared with the DQA calculated for the prostate cases
(22)
Patients Map check2 DQA-C
Measured Calculated
Point dose (Gy) Point dose (Gy) Difference(%) (Y)%
1 2.9 2.8 0.7 92.4
2 2.2 2.2 1.2 99.1
3 1.9 2.0 2.4 99.5
4 2.2 2.3 3.1 93.8
5 2.2 2.3 3.5 92.6
6 2.0 2.0 2.9 91.9
7 2.0 2.1 2.4 99.6
8 1.9 2.0 4.3 100.0
9 2.0 2.0 1.8 98.7
10 2.0 2.0 1.0 100.0
11 2.0 2.1 5.1 100.0
12 2.0 2.1 3.0 99.7
Average difference= 2.7
STDV 1.34 3.44
Uncertainty 0.38 0.99
3.2.2 MapCheck! phantom measurements compared
cases (23)
with the DQA calculated for the p
Patients Map check2-M DQA-C
Measured Calculated
Point dose (Gy) Point dose 
(Gy)
Difference(%) (Y)%
1 3.6 3.5 0.7 97.7
: 2 2.8 2.8 1.7 98.1
3 2.5 2.6 0.8 98.4
4 2.0 2.0 1.1 99.0
5 2.7 2.7 0.9 96.7
6 2.5 2.5 1.6 99.0
7 2.6 2.5 0.9 96.2
8 2.6 2.5 1.2 94.7
9 2.4 2.3 1.3 95.0
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10 2.5 2.5 1.2 99.5
11 2.6 2.5 2.9 96.4
12 2.5 2.5 0.9 97.3
Average difference^ 1.3
STDV 0.59 1.56
Uncertainty 0.17 0.45
Comparison between gamma % for head and neck patients using different phantoms (MapCheck2 and
Cheese phantom)
150 1
140 -
130 -
120 -
MapCheck-H&N
Chesse-H&N
110 -
100  -
Patients
Figure 7.3.1: Comparison between gamma % for head and neck patients using different phantoms
(MapCheck2 and Cheese phantom) (44)
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Comparison between gamma % for prostate patients using different phantoms (MapCheck! and Cheese
phantom)
150 1
140 -
130 -
120 -
MapCheck-prostate
Chesse-prostate
100  -
Patients
Figure 7.3.2: Comparison between gamma % for prostate patients using different phantoms 
(MapCheck! and Cheese phantom) (45)
7.4. Conclusion
DQA (Delivery Quality Assurance) is essential for quality patient eare in radiation 
therapy achievable via phantom measurements. Using phantom measurements, 
absolute and relative dose evaluations are routinely performed for patient 
Tomotherapy QA. Film and ion chamber in phantoms have been traditionally 
employed to “validate” the tomotherapy plans, to ensure that the tomotherapy plans 
are accurately delivered to the patients by proving agreement between the measured 
and calculated doses.
The results of this study indicate that the Cheese phantom technique provides a 
superior gamma factor relative to that of the MapCheck! technique because of the 
improved resolution of the film. However, the MapCheck! system has other benefits, 
such as ease and speed of use and less consumable costs than the Kodak X-Mat film. 
The differences between the planned and measured doses can be attributed to three 
different sources of error: the dosimeter employed, the delivery system and the dose 
calculation system. The combined uncertainty from head & neck is 1.11%, lower than 
the combined uncertainty from the prostate study which is 1.16%. Table 7.4 shows the 
estimated uncertainties in this investigation.
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Table 7.4 DQA estimated uncertainties for head & neck and prostate sites.
Source of uncertainties Head & neck DQA Unc.% Prostate DQA Une. %
Cheese phantom 0.65 0.38
MapCheck! 0.09 0.17
Gamma index 0.89 1.08
Combined uncertainties 1.11 1.16
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CHAPTER 8: Assessment of uncertainty in daily patient 
treatment - including patient treatment preparation (patient 
setup) and treatment recording.
8.1. Introduction
The radiotherapy vérification procedure allows us to be confident that we are treating 
the tumour volume as planned. Geometric and dosimetric verifications are the two 
measurements required to ensure that the right radiation dose is directed to the correct 
area.
When using geometric verification, the goal is to guarantee that the geometric 
accuracy of the radiotherapy delivered is within the limits set by the uncertainty 
margin permitted by the treatment plan. This is achieved by matching delivery data 
with the planned data. Verification is just one factor of the treatment process. 
However, accurate and reproducible planning processes, together with the acquisition 
of reference images of reasonable quality, are vital for achieving a successful 
verification.
Throughout the whole treatment course, the radiotherapy treatments require accurate 
and reproducible patient positioning. Local failure could arise in case of improper 
patient positioning, causing geographical tumour misses. The immobilization devices 
reduce setup uncertainties during the treatments. Several parameters, such as the type 
of immobilization device, table couch, and linae laser beam for setup alignment may 
affect the overall uncertainty. In addition, radiation therapists are likely to influence 
the overall accuracy and reproducibility of patient positioning. It is essential that 
patient immobilization is factored into the equation. It is also highly important to 
develop strategies for daily reproducible set-up (i.e. patient positioning). Studies 
(Nakata et al, 2013) have looked at reproducibility and uncertainty in patient set up, 
revealing the occurrence of translational errors that are likely to impact upon the 
patients’ treatment and should necessarily be considered in establishing the treatment 
plan. Moreover, setup accuracy has been explored by many researches, including 
Hurkmans (2001), Tinger (1998) and Ekberg (1998). Specifically, Hanley (1997),
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Creutzberg (1996), Yan (1997) and Bel (2000) found that solid setup protocols and 
well-considered immobilization could lead to a 2mm standard deviation for the axis’ 
setup accuracy regarding prostate irradiation. Furthermore, Weltens (1995) found that 
rigid immobilization could assist in incurring lower setup errors when treating the 
neck or head. Patient setup reproducibility on the CT scanner can be hindered by the 
effect of the skin’s motion on the internal anatomy of the patient, which leads to 
systematic setup errors.
The ‘Van Herk’ method (2000) outlines that 90% of patients are given an equivalent 
uniform dose of 98% or more, according to the margins laid out in the method. The 
‘BIR’ method (British Institute of Radiology) revealed the source of many geometric 
uncertainties and formed margins to ensure that CTV is included in 90% of scenarios. 
Van (2004) showed that various strategies for forming the necessary geometric 
uncertainty margins have been examined and re-evaluated over recent years.
ICRU (1993; 1999) showed that the PTV is a geometrical phenomenon, which 
incorporates the net effect of the total potential geometric variations into formulating 
the prescribed dose and ensuring that it is delivered to the CTV. Furthermore, the BIR 
method of formulating the CTV-PTV margin determines the difference in those errors 
that are brought in via treatment preparation. In this scenario, during the course of 
treatment, errors are broadcasted systematically. The BIR method differentiates this 
from the errors found in carrying out the treatment, which arises as a consequence of 
normal uncertainties in terms of motion, organ shape and setup. Furthermore, the BIR 
method incorporates the impact of various treatment beam setups.
8.2. Material and Methods
In this respect, an evaluation of the positioning accuracy in patients treated for head 
and neck and prostate cancers was undertaken. 15 head & neck and 12 prostate 
patients were selected and treated using a 6 MV photon beam delivered by 
“Tomotherapy HD”. The unique technological feature of tomotherapy consists in the 
fact that it is both a CT scanner and a treatment delivery unit, thus allowing imaging 
and treatment in one seamless procedure. This facilitates daily imaging prior to 
treatment.
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Skin marks, tattoos and shells are used to mark and record the daily set up details. 
Patients are positioned in the supine position at the CT Simulation procedure using 
appropriate immobilisation devices as per the departmental protocol. This set up is 
reproduced on the treatment unit and an MVCT is performed daily before treatment, 
to verify the set up as well as to perform the image registration before delivering the 
dose. With the tools made available by the software, automatic as well as a manual 
match is performed to register the current MVCT to the reference CT on which the 
plan was carried out. The resulting shifts generated by the registration are applied 
before beaming on.
8.2.1. Head and Neck
Head & neck cases were chosen because the distance between the tumour site and 
organs at risk is smaller. Also, these patients lose weight over the course of treatment 
which requires setup adjustments to make sure that the tumour receives the planned 
dose.
Head and neck cancers represent a group of different tumours, which are classified by 
their site and sub-site of origin.
The immobilization device used to keep up the position of the head and neck is 
crucial to the accuracy of the treatment delivery. Orfit is the most simple 
immobilization device, which requires immersion in a warm water bath before being 
stretched over the patient to produce a good fit and attached to the bed (BIR, 2003).
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Laryngopharynx
(hypopharynx)
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O eso p h a g u s
(guHet)
Figure 8.2.1 The anatomy o f the head and neck region (Joshi, 2008) (46)
8.2.2. Prostate
The prostate is situated between two organs, the bladder and the rectum, which are 
critical normal organs; the prostate lies directly under the bladder, in front of the 
rectum. Both these organs undergo significant motion (as well as changes in size due 
to varying degree of bladder filling; likewise the rectum if not properly evacuated) 
and this may affect the tumour volume and position. Random changes, such as day to 
day prostate motion, have been quoted for the prostate as 3-4 mm due to setup and 3-4 
mm due to organ motion uncertainty (Yan et al, 2000).
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Figure 8.2.2 The structure of the internal organ in prostate case (Company, 2000) (47)
8.3. Results and discussion
The overall examination of the discrepancies concerning the simulation reference CT 
image and the MVCT permits the assessment of the overall quality of treatment 
delivery: the number of set-up errors for the two sets of patients are signified in 
Figures (8.3.1-2) below. This displays their position on three planes, which are the 
lateral or V-axis, the left-right or 7-axis, and lastly the superior-inferior or Z-axis.
Table 8.3.1.1 shows the head & neck setup- error measurements; it was found an 
average standard deviation displacement between the simulation reference CT image 
and the MVCT of 1.32mm (X), 1.06mm(Y) and 1.08mm (Z) for the head & neck 
selected patients group. In the prostate patient group, an average standard deviation of 
5.06mm (X), 1.64mm(Y) and 2.05mm (Z) was determined. There are differences in 
standard deviations between the two groups. Significant errors (7.08 mm) were 
detected in the prostate case on the Y-axis, and the reason of this high error in prostate 
is due to the internal movement. The graph in the figures represents the standard 
deviation mean of the setup error on a daily basis for the whole treatment 
administered to each patient.
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In the head and neck setup error results we found the variation is approximately 2mm 
laterally on the x-axis, 1mm longitudinally on y-axis, and 1mm vertically on the z- 
axis.
There are factors which may cause uncertainties in the head and neck setup:
• Clinical observations of weight loss or tumour shrinkage/growth
• Observations of volumetric or dosimetric change made, based on repeated 
imaging
• Observations of dosimetric changes, cumulative or daily, that are 
facilitated by Deformable Image Registration (DIR)
The measurements for prostate are illustrated in Table 7.3.1.2 below. Figure 7.3.2 
shows there are 5mm laterally on the x-axis and 1.6 mm longitudinally on the y-axis 
and 2mm vertically on the z- axis; these variations may be due to the size and the 
shape of the bladder which may change significantly during the treatment. Possible 
factors are:
• Variation in bladder filling due to changes in oral fluid intake.
• Variation in bladder emptying due to the tumour.
• Influence of other organs such as changes in rectal filling (BIR, 2003).
The rectum can introduce a systematic positioning error that may increase the 
probability of missing the CTV.
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Table 8.3.1.1 Head and neck setup error measurements (24)
Patient X Shift (mm) 
(Lat)
Y Shift(mm) 
(Long)
Z Shift (mm) 
(Vert)
1 1.15 1.08 0.94
2 0.98 1.16 1.019
3 1.42 1.05 0.81
4 0.72 1.06 0.95
5 1.03 0^8 0# 2
6 ft86 1.13 1.39
7 1.08 0.96 1.13
8 1.56 128 1.28
9 1.22 1.08 0#5
10 2 6 4 1.56 1.67
11 12# 0J3 1.11
12 1.14 0.76 1.05
13 1.19 1.34 0.95
14 1.60 1.07 ft96
15 1.78 028 1.24
Uncertainty% 0.34 0.27 0.28
Combined
uncertainties 0.89
Head & Neck Patients X Shift (Lat) 
Y Shi ft (Long) 
ZShift(Vert)
3.00
2.50
2.00
1.50
1.00
0.50
0.00
Patients
Figure 8.3.1 Head & neck patients’ setup errors measurement for whole course of treatment for each
patient chosen in this study (48)
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Table 8.3.1.2 Prostate setup error measurements (25)
Patient XSWA
(mm) (Lat)
Y Shift(mm) 
(Long)
Z Shift (mm) 
(Vert)
1 4.20 1.65 2 2 7
2 2.60 128 3.16
3 6.47 1.73 1.27
4 4.40 1.38 1.67
5 4.64 1.66 1.47
6 5.76 1.21 2.06
7 5.69 2.61 2.11
8 4.71 1.41 2.26
9 4.71 1.51 1.95
10 520 1.66 2.11
11 7.08 2.11 2.25
12 526 1.32 1.69
Uncertainty % 1.46 0.47 0.59
Combined
uncertainties 2.52
Prostate X Shift (Lat)
Y Shi ft (Long)
1.00  n
Z Shift (Vert)
7.00 -
1.00 -
5.00 -
4.00 -
3.00 -
2.00  -
1 .00  -
0.00
patients
Figure 8.3.2 Prostate patients setup errors measurement for whole course of treatment for each patient
chosen in this study (49)
8. 4 Uncertainty estimated from the patient’s setup:
8,4.1. Systematic errors
A systematic error for each particular patient is represented by the average value of 
the displacements along the X, Y and Z-axis. The systematic deviations distribution is 
given by the standard deviation of the mean shifts values along a given axis for the 
entire group. The systematic errors affect every treatment set-up, arising to a great 
extent from inconsistent file handover from treatment room simulations or treatment
1 2 7
establishment errors (Carine Mitinel, 1999). These need to be amended to stop error 
repetition in any subsequent treatments.
8.4.2. Random errors
Random displacements are related to everyday variations
8.5. Conclusion:
The head and neck mean setup error was less than that of the prostate. Significant 
errors (7.08 mm) were identified in the prostate case on the X-axis; these are due to 
internal movement. The head and neck setup error was generally of around 2mm, a 
good result based on IGRT. The pre-treatment MVCT can be used in order to enhance 
patient positioning accuracy or reduce tumour margin. The combined uncertainty for 
head and neck cases was found to be 0.89 %, while the combined uncertainty for 
prostate cases was of 2.52 %.
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CHAPTER 9: Summary
The aim of this project was to determine the currently achievable accuracy and 
reproducibility of radiotherapy, with particular reference to tomotherapy.
An initial experimental comparison of dosimetry codes of practice between the IAEA 
CoP and the IPEM (1990) and AAPM TG-51 Co? revealed the maximum difference 
between measurements in the absorbed dose for photon beams of 6MV/600C in solid 
water phantom of 1.0%. The values measured in the solid water phantom with 
6MV/2100c with the use of IPEM protocol revealed dose differences from 100 cGy 
with a - 0.73% margin, which is higher than the one obtained using the IAEA protocol 
(-0.4%). Similarly, TG-51 expressed the exact value of lOOcGy. The uncertainties 
evaluated are consistent within the photon energies, demonstrated by the comparison 
of quality index TPR2o,io, using the IAEA TRS-398 and IPEM 1990 protocols. Some 
of the factors influencing the measured values were taken into consideration, such as 
the measurement depth Zref and the position of the reference point of the chamber 
between the three protocols, all using a virtual phantom. Furthermore, the measured 
and tabulated %DD (10cm) values for photon beams, used in the TG-51 protocol, 
revealed a close agreement close to 0.3% for the 6MV beam, and close to 1.11% at 18 
MV, demonstrating high accuracy in dose delivery. Moreover, we studied the 
absorbed dose for 6 and 18 MV photon beams over a period of 12 months. The 
outputs are in the range 99.059 to 100.66, with standard deviations of 0.4 %.
By employing the IAEA-TRS-398 CoP in electron beam calibration, we obtained 
good agreement of 0.5% between theoretical values and experimental ones. On the 
other hand, the use of AAPM TG-51, revealed significant differences of up to 2.0%, 
due to the factors of electron quality conversion factor k rso, Pgr the gradient at point of 
measurement. By using AAPM TG-51 protocol in tomotherapy, we found a 
difference of 0.5 between the energy (actual energy (nC)) and the expected energy. 
The outputs were found to be 858.24 cGy/ min, while the difference in the output was 
0.97.
The series of study in the clinical evaluation of the assessment of the target volume 
delineation. Within the Tawam Radiotherapy Department, a team of Radiation
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Oncologists, Dosimetrists & RT Technologists worked together to establish and 
implement protocols from sources such as RTOG atlas. These protocols give clear 
directions on the type of imaging to be used, on how to interpret the imaging, the 
target volume delineation and on how to deal with uncertainties in imaging and 
prescription.
The greatest contribution on uncertainties was brought by the target volume 
delineation. Delineation is currently performed by the radiation oncologists. However, 
they may have a limited background and experience in radiology, making it difficult 
to precisely identify the detailed anatomical structures on computed tomography 
images (CT). The combined uncertainties for head & neck cases were found at 1.67%, 
which is due to the changes in the size of tumour and loss of weight; the uncertainties 
for the prostate study were found to be 5.57%, which are due to target motion and 
internal motion arising from the internal organs (bladder, reetum and seminal vessel).
The series of investigations on the validation of the treatment plan and delivery QA 
(Delivery Quality Assurance: DQA study) focused on the evaluation of dose 
distribution using two different phantoms in tomotherapy. The purpose of this 
experiment was to test the two different phantom MapCheck2 and Cheese phantom 
systems to ensure the adequate functionality and to compare the results with film and 
ionization chamber measurements. The tests were performed on 15 head and neck 
patients and 12 prostate patients. The results indicate that the Cheese phantom 
technique provides a superior gamma factor relative to that of the MapCheck2 
technique because of the improved resolution of the film. The combined uncertainties 
coming from this investigation were found to be 1.11% for the head & neck study and 
1.16% for the prostate study.
Each treatment fraction needs to ensure that it accurately represents the patient’s 
position in the reference image series. We studied the Daily patient treatment - 
(patient setup) and found that the mean setup error for head and neck was smaller than 
the prostate position analyzed. An average standard deviation of 1.32 (mmX), 1.06 
(mmY) and 1.08(mmZ) was calculated for the head and neck patients group. In the 
prostate patients group we found an average standard deviation of 5.06 (mmX), 
1.64(mmY) and 2.05(mmZ). Significant errors (7.08 mm) were detected in the
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prostate case on the X-axis, which were due to internal motion. The combined 
uncertainty for the head & neck case was found to be 0.89 %, while the combined 
uncertainty for prostate was 2.52 %.
In order to achieve the required quality and guarantee standards are maintained, a 
number of programmes are essential. A previous method to determine the accuracy 
reached in practice consists of measurement-based studies, including dose inter­
comparisons, which can be carried out at various levels of the technical radiotherapy 
process to define errors and uncertainties at each of those stages. In this manner, 
uncertainties at various stages in radiotherapy can be analysed and quantified.
The study carried out in this thesis covered two different cases head & neck and 
prostate. The accuracy of the absorbed dose delivered to a patient depends on several 
factors, namely output, target volume delineation, DQA and daily setup uncertainties. 
The overall uncertainty in this thesis for head & neck was 2.7% on the other hand the 
overall uncertainty for prostate is 6.4%. The uncertainty related to these factors has a 
direct effect on the accuracy of the dose received by all patients. Several methods, 
suggestions and criteria were proposed to improve dose accuracy and to verify that 
the uncertainty related to the investigated factors is not too high compared with the 
uncertainty of other factors currently achievable. The overall uncertainty of the dose 
and the combined effects of the proposed factors aimed to improve it were also 
estimated.
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Appendices
Appendix A: Lists of symbols and abbreviation
List of symbols
D dose
D dose rate
absorbed dose to air
dose to water 
E  effective dose
Eq rest energy
Ee release energy
Eb orbital electron binding energy
Eq mean electron energy on phantom surface
Ey is the incident photon energy
fmsr machine-specific reference field
fpcsr plan-class specific reference field
I  current; measured ionization
correction factor for photon attenuation and scatter in the 
chamber wall 
k^ i^i correction factor for central electrode
k  ^ humidity correction factor
k^ correction factor for non-air equivalence of the chamber wall
kp i^ polarity correction factor
kq ionization chamber correction factor
k^ ^^  saturation correction factor
kj p temperature and pressure correction factor
K  kerma
i^aiXir kerma in air
Q^msr beam quality of machine specific reference field
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Q^pcsr beam quality of plan-class machine specific reference field
j^ LsrJrrf is the correction factor for the differences between the conditions
Hmsr,Q
of field size, geometry, phantom material and beam quality of the 
convention reference field fref and the machine-specific reference 
field fmsr* Jeraj et al. (2005) determined this value as being equal to 
0.997 for most ion chambers commonly used, 
mass of air 
M  ionization chamber reading
M q ionization chamber reading at beam quality Q
MU monitor unit
is the corrected reading of the dosimeter in the field fmsr; 
^D,air cavity air calibration coefficient
dose in water calibration coefficient 
Np- air kerma in air calibration coefficient
air kerma in air calibration coefficient obtained in a ”^Co beam 
exposure calibration coefficient 
p  perturbation correction factor
p^ ^  ^ cavity perturbation factor
p^ j^ central electrode perturbation factor
Pj^  ^ replacement correction factor
Pji electron fluence correction factor
Pq overall perturbation correction factor for an ionization chamber
p^^ii chamber wall perturbation factor
Q charge; beam quality
Qmsr is the beam quality (%dd(10)%) of the machine-specific reference
field fmsr (10x5 cm^  field at 85 cm SSD);
Rp practical range
^ 5 0  depth in water of the 50% percentage depth dose of an electron
beam
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w^,air ratio of restricted mass collision stopping power water to air
T temperature
standard uncertainty of type A 
Up standard uncertainty of type B
effective volume
(j^ air ! average energy required to produce an ion pair in air
z depth in phantom
z ^  depth of dose maximum
z^  ^ reference depth
Z atomic number
Z^ effective atomic nimber
Zref reference depth
0^ Incident spectrum electron energy
Rso represents the depth at which the maximum value of the dose of
the electron beams is halved
is the mean energy at depth z in a phantom 
Rp represents the functional range of the electron beam
Cpi represents a material defined by the scaling parameter stipulated
in the IAEA TRS 381 protocol 
Rpi ranges in water
(y) Gamma
Abbreviations
AAPM American Association of Physicists in Medicine
BIPM Bureau International des Poids et Measures
CoP Codes of Practice
CTV Clinical T arget V olume
CCRI Consultative Committee for Ionizing Radiation
CPE charged particle equilibrium
CRT Conformai Radiotherapy
DTA distance -to- agreement
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DQA Delivery Quality Assurance
ENEA Ente per le Nuove tecnologie,l’Energia e I ’Ambiente
FWHM full width at half maximum
GTV Gross Target Volume
Gy/MU Gray/Monitor Unit
HP A Hospital Physicists’ Association
HVL Half -Value Layer
IAEA International Atomic Energy Agency
ICRU International Commission of Radiological Units and
Measurements
IPEM Institute of Physics and Engineering in Medicine
IPEMB Institute of Physics and Engineering in Medicine and Biology
LPRI Laboratorie Primaire de Métrologie des Rayonnements Ionisants
IM Internai Margins
IGRT Image Guided Radiotherapy
MRI Magnetic resonance imaging
MU Monitor Unit
MeV MegaElectron volts
MLC multi leaf collimator
MV Mega Volts
MVCT megavoltage computer tomography
NPL National Physical Laboratory
NTCP normal tissue complication probability
NAP Nominal Accelerating Potential
NIST National Institute of Standards and Technology
NPL National Physical Laboratory
RSH Royal Surrey Hospital
PDD Percentage Depth Dose
PET Positron emission tomography
PET-CT Positron emission tomography-computed tomography
PTB Physikalisch-Technische Bundesanstalt
PTV Planning Target Volume
PSDL Primary Standards Dosimetry Laboratory
QC quality control
150
TCP tumour control probability
TMR tissue-maximum ratio
TPR Tissue Phantom Ratio
TPS treatment planning system
SAD Source to Axis Distance
SSD Source to Surface Distance
SSDL Secondary Standards Dosimetry Laboratory
SM Setup Margins
SD standard deviations
WHO World Health Organization
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Appendix B: 
QA protocols that are recommended for daily, monthly and annual 
testing used in tomotherapy
Table 1 Recom m endations and  tolerance limits fo r daily assurance procedures.
Daily test Purpose Tolerance limit
Output-Rotational or static Consistency 3%
Image/laser coordinate coincidence Accuracy 2-1 mm
Image registration /alignment Accuracy 1mm
Red laser initialization Red= green laser 1.5-1 mm
Table 2 Recom m endation and tolerance limits for m onthly quality assurance procedures.
Monthly test Purpose Tolerance limit
Beam  param eters
Output-static Consistency : 2% "
Output-Rotational Consistency with TPS 2% .........
Rotation output variation Amplitude o f variation ,2 %
Beam quality Consistency with baseline l% PDDioor T M R Iq
Transverse profile Consistency with baseline 1% average difference in field 
core
Longitudinal profile Consistency with baseline 1% o f slice width at FWHM
Alignm ent and Misc.
Interrupted procedure Agreement with uninterrupted 
Proc.
:'3%
Red laser movement Correct movement 1 mm
Treatment couch Digital readout versus actual 
movement
1mm
Treatment couch Level 6.5%
Treatment couch Longitudinal motion alignment 1mm
Treatment couch Sag 5mm
■ M V C T ..................................................
Geometric distortion Dim ension, orientation 2-1 mm
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Noise Monitor image quality Consistency with baseline
Uniformity Monitor image quality Consistency with baseline
Spatial resolution Monitor image quality 1.6mm
Contrast Monitor image quality Consistency with baseline
I f  M V CT is used for dose calc.
Uniformity : Monitor image quality 25 HU
HU (water test plug) Monitor HU accuracy : Within ±HU 30 o f baseline
HU( lung/bone test plug) : Monitor HU accuracy Within ±HU 50 o f baseline
Table 3 Recom m endations and  tolerance limits for annual quality assurance procedures.
Annual test Purpose Tolerance limit
M echanical alignments
y-j aw centering Source to y-j aw alignment : 0.3mm at source
x-alignment o f source Source to MLC alignment : 0.34mm at source
y-j am divergence/beam centering Source alignment with axis o f 
rotation
; 0.5mm at iso
y-jaw/gantry rotation plane alignment y-jaw alignment with axis o f 
rotation
..... ...................
Treatment beam field centering Common center 0.5 mm at iso
MLC lateral offset MLC alignment with center o f 
rotation
1.5 mm at iso
MLC twist Alignment with beam plane 0.5°
Beam param eters
Beam quality (each slice width) Agreement with model l% PD D ioor T M R Iq
Transverse profile (each slice width) Agreement with model 1% average difference in 
field core
Longitudinal profiles (each slice width) Agreement with model 1% o f slice width at 
FWHM
TG-51 calibration Calibration 1%
M VCT
Imaging /treatment/laser coordinate Accurate location o f dose 2-1mm
coincidence
T reatm ent planning system
CT data import
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Dimension o f object in TPS ; Agreement with physical 
dimension
1 kVCT voxel
CT voxel dimensions Correct transfer Pass/fail
CT orientation Correct transfer Pass/fail
CT gray scale values Correct transfer Pass/fail
Associated text info Correct transfer Pass/fail
Structure set import
' Dimension o f structure ! Agreement with contouring 
; software
1 kVCT voxel
Location o f structure ! Agreement with contouring 
! software
P ass/fa il
i Orientation of structure i  Agreement with contouring 
; software
Pass / fail
; Dosimetric verification
Point dose in low gradient area Agreement with TPS Within 3%
Point dose in high gradient Agreement with TPS 3%/3 mm
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A number of codes of pra c t ice  (CoP) for electron and photon radiotherapy beam dosimetry are currently 
in use. Comparison is made of the more widely used of these, specifically those of the International 
Atomic Energy Agency (IAEA TRS-398), the American Association of Physicists in Medicine (AAPM TG-51) 
and the Institute of Physics and Engineering in Medicine (IPEM 2003). All are based on calibration of 
ionization chambers in terms of absorbed dose to water, each seeking to reduce uncertainty in delivered 
dose, providing an even stronger system of primary standards than previous air-kerma based approaches. 
They also provide a firm, traceable and straight-forward formalism (Radiology, 1996). Included in making 
dose assessments for the three CoP are calibration coefficients for a range of beam quality indices. 
Measurements have been performed using clinical photon and electron beams, the absorbed dose to water 
being obtained following the recommendations given by each code. Electron beam comparisons have been 
carried out using measurements for electron beams of nominal energies 6, 9, 12, 16 and 20 MeV. 
Comparisons were also carried out for photon beams of nominal energies 6 and 18 MV. For photon beams 
use was made of NE2571 cylindrical graphite walled ionization chambers, cross-calibrated against an 
NE2611 Secondary Standard; for electron beams, PTW Markus and NACP-02 plane-parallel chambers were 
used. Irradiations were made using Varian 6Ü0C/2100C linacs, supported by water tanks and Virtual 
Water™ phantoms. The absorbed doses for photon and electron beams obtained following these CoP are all 
in good agreement, with deviations of less than 2%.
A number of studies have been carried out by different groups in different countries to examine the 
consistency of dosimetry codes of practice or protocols. The aim of these studies is to confirm that the goal 
of those codes is met, namely uniformity in establishment of dosimetry of all radiation beam types used in 
cancer therapy in the world, and this is one of the studies.
© 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Over the last two decades a number of national and interna­
tional organizations have published codes of practice (CoP) for the 
calibration of clinical radiotherapy beams. Recent CoP include 
those of the International Atomic Energy Agency (IAEA TRS-398; 
IAEA, 2000), the American Association of Physicists in Medicine 
(AAPM TG-51; AAPM, 1999) and the Institute of Physical Engi­
neering in Medicine (IPEM 2003; IPEM Working Party et al., 2003) 
for electron beams only and Institute of Physical Science in 
Medicine (IPSM; NPL, 2006) for photon beams only. In these, 
calibration has changed from air kerma based calibration to 
absorbed dose to water calibration. Since the absorbed dose to
* Corresponding author at: D epartm en t o f  Physics, U niversity o f  Surrey, 
Guildford GU2 7XH, UK.
E-mail address: ss_alahbabi@ hotm ail.com  (S. Saeed Al-Ahbabi).
0 9 6 9 -8 0 4 3 /$ - s e e  front m atter © 2011 Elsevier Ltd. All rights reserved, 
doi: 10 .1 0 1 6/j.ap rad iso .2011.11.065
water relates to the biological effects of radiation, it is the main 
quantity of interest in radiation therapy. The new standards of 
absorbed dose to water reduce uncertainty in the dosimetry of 
radiotherapy beams. These new standards also provide a more 
robust system of primary standard than air kerma based stan­
dards. In addition, it allows use of a simple formalism. In regard to 
general or particular features of the protocols, (Huq et al., 2001) 
have suggested that IAEA TRS-398 offers the most general and 
flexible structure for calibration, allowing four very detailed 
possibilities tbat consist of the use of theoretical or experimental 
beam quality conversion factors. These are the absorbed dose to 
water calibration of an ionization chamber at ™Co,
IAEA TRS-398 recommends the use of basic experimental 
beam quality conversions factors restrictively determined in a 
standards laboratory, such as that at the National Physical 
Laboratory (NPL). /lAPM TG-51 is based on use of ion chambers 
with absorbed dose to water calibration coefficients for *^ °Co 
quality Qo, and beam quality conversion factors.
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Comparisons between the IPEM CoP and the TRS-398 and 
TG-51 CoP can be made only with regard to the chamber 
calibrations N .^w in a ®°Co beam (the subscripts indicating dose 
measurements, D, in water, w) and theoretically determined kq 
factors. Huq et al. (2001 )observes that this is not the preferred 
recommendation in international protocols.
According to IAEA TRS-398, for chambers using in a beam of 
quality Q, different from that used in its calibration Qo, the 
absorbed dose to water at the reference depth Zref in water is 
given by [3]
(1)
where M q  is the chamber charge or current corrected for influ­
ence factors and determined at beam quality Q. There are 
differences between the reference beam quality Qo and the actual 
user quality Q, which is why the beam quality factor is 
employed to correct for this effect. From the standards users can 
be provided with different types of Nd.w.Qo calibration.
In TG-51, the formula provided for the absorbed dose to water 
is similar to that embodied in the IAEA TRS-398 protocol. In 
regard to the recommended calibration for the chamber at the 
quality of ®°Co gamma-rays, the absorbed dose to water at the 
reference depth in water in a beam of quality Q, is given by [3]
D  ^= MkqN^-^° (2)
where the absorbed dose to water calibration factor for
®°Co beams, is corrected by k q  for an arbitrary beam of quality Q, 
For the electron energies, k q  is given as a product of three 
factors [3]:
k q  =  F ^ r^ J? 5o ^ecal ( 3 )
where P^, is the gradient correction factor, is the component of kQ 
in an electron beam that is dependent on the ionization gradient 
at the point of measurement, k'^ ^^  is the electron quality conver­
sion factor, which is a function of the electron beam quality 
specified by R50 and kgcau the Photon-electron conversion factor.
2. Materials and methods
For photons beam measurements the IPEM (1990) and IAEA 
TRS-398 protocols recommend use of the tissue-phantom ratio 
(TPR20.10) 3S a beam quality specifier (IAEA, 2 0 0 0 ; Lilicrap et a!., 
1990). The factor TPR20,10 is described as the ratio of doses on the 
beam central axis at the depths 2 0  cm and 10  cm in water, 
obtained with a field size of 1 0 x 10  cm  ^ and a constant source 
to detector distance of 100 cm. This quality index allows the 
choice of beam quality conversion factors or appropriate calibra­
tion coefficients. AAPM TG-51 (AAPM, 1999) recommends that 
the quality specifier be the percent depth dose obtained at 10  cm 
depth, PDD (lO)x: electron contamination is excluded using a 
1 mm lead foil.
For electron beam measurements, the IAEA TRS-398 (IAEA, 
2000), IPEM 2003 (IPEM Working Party et al., 2003) and AAPM 
TG-51 (AAPM, 1999) protocols specify the beam quality in terms 
of the depth in water at which the absorbed dose falls to 50% of 
the maximum ( R 5 0 ) .  In the electron beam reference dosimetry 
measurements that follow the protocols IAEA TRS-398 and AAPM 
TG-51, use has been made of the plane-parallel PTW Markus 
chamber. In measurements made following the IPEM 2003 CoP, 
use has been made of an NACP chamber.
In all of the protocols, the setup for the energy determination 
is done with a 1 0 x 1 0  cm^ field size at 100 cm SSD, the gantry 
and the collimator being at 0 °. In determination of absorbed doses 
to water, obtained using IAEA TRS-398 and AAPM TG-51, use has 
been made of the most appropriate type of ionization chamber.
For photon beams the cylindrical ionization chamber has been 
used, while for electron beams the plane-parallel ionization 
chamber is used, both with a direct calibration in a ®°Co 
gamma-ray beam.
For nominal photon energies of 6  and 18 MV and electron 
energies of 6 , 9, 12, 16 and 20 MeV, respectively, measurements 
have been obtained using a 0.6 cm^ Farmer ionization chamber 
and a plane-parallel ionization chamber. The Farmer-type cham­
bers used in this study were NE2571 graphite walled ionization 
chambers (s/n 237 and 2433), cross-calibrated against an NE2611 
Secondary Standard, the latter being calibrated at the NPL This 
was carried out using the IPEM protocol, for photon energies only, 
readout being obtained through use of two different electro­
meters, namely a Keithley (Cardinal Health Therapy Dosimeter, 
USA, s/n 64106) and a Dosemaster (NE Technology LTD, UK, 
lONEX Dosemaster 2590, s/n 416). For the reference standard, 
use has been made of the NPL NE2611 primary standard in 
graphite (NE Technology Ltd, Reading, UK). For electron beams, 
the plane-parallel chamber used was a PTW Markus chamber.
Measurement of absolute dose, obtained in the reference 
setting, was achieved using each of the three protocols, including 
the beam quality indices. Protocol recommendations have been 
strictly followed.
The measurements were performed using a brown solid 
phantom™ (Virtual Water™, Density BWP=1.03 g/m^; water 
equivalent materials, Med-Cal, USA) and a water tank phantom 
(Scanditronix Medical AB, Sweden, RFA water tank). In the 
protocols there are both differences and similarities relating to 
the calibration setup, choice of quality index and standards for 
ionization chamber calibration.
For photons beams, measurements were taken at a source- 
surface distance (SSD) of 100 cm, at a depth of 10 cm and with a 
field size 10 x 10 cm  ^ at the phantom surface. Conversely, for 
electron beams, measurements were taken with two different 
electron applicators, depending on the electron energy using 
IAEA TRS-398 and AAPM TG-51 protocols. For example, at 6 , 9 
and 12 MeV, use was made of a 10 x 10 cm^ applicator, while a 
2 0  X 20  cm^ applicator was used for the higher electron energies, 
16 and 20 MeV. Electron beam measurements using the IPEM 
2003 CoP were performed using one electron applicator for all 
electrons beams, namely an 10 x 10 cm^ applicator. An SSD of 
100 cm was used for both applicators. The positions of ionization 
chambers were also verified directly; the uncertainty of align­
ment of the scanner central axis with the beam central axis was 
estimated to be ~  1 mm.
Both protocols for photon beams, IAEA TRS-398 and AAPM 
TG-51, recommend a reference depth in a water phantom of 
10 cm, as well as the IPSM reference depth: for E< 10 MV, 5 cm 
and for £ > 11 MV, 7 cm. Further, for electron beams, both of these 
protocols recommend the reference point Zre/ for all measure­
ments obtained using plane-parallel chambers; the reference 
depth in water is near the depth of dose maximum Zmax- The 
measurements are obtained from the inner surface of the entrance 
window at the center of the window, moreover; the reference depth 
using the IPEM is at the depth of O.6 R50—0.1 g/cm^.
3. Results and discussion
3.1. Photon energies
Comparison of the three protocols includes dose, beam quality 
PDD (1 0 );; and TPR20.10. as detailed in the various tables below. 
Table 1 shows measured values of absorbed dose, measured in 
Virtual Water™ using the three protocols. Table 2 details the mea­
sured TPR20.10 for the two protocols IAEA TRS-398 and IPEM 1990.
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Table 3 provides the PDD (10)x, measured using the AAPM TG-51 
protocol for the three specified photon beams. The three sets of 
tabulated measurements were obtained using a Farmer ion cham­
ber NE2571/237 and a Dosemaster electrometer. The tabulations 
also include the absorbed dose to water, D ,^ and the beam quality 
factors, kq. The beam quality is the quality index and in the IPEM 
CoP is the tissue-phantom ratio (TPR) of a radiation beam (Lilicrap 
et al., 1990).
Measurements on the 6MV/60GC linear accelerator were per­
formed with two protocols, those due to IPEM and the AAPM and, 
as shown in Table 1, the maximum uncertainty in absorbed dose
Tab le 1
Absorbed d ose  for photon  beam s obtain ed  in the so lid  w ater phantom  for a 
nom in al 100 cGy delivered.
IAEA TR S-398 IPEM 1 9 9 0 AAPM TG-51
D o se  (cGy) D o se  (cGy) (%) D ose  (cGy) (%)
6M V/600C N ot p er fo rm ed 1 0 0 .6 4  ± 0 .0 4 9 9 .5 8  ±  0 .2 0
6M V/2100C 9 9 .6 0  ±0 .1 9 % 9 9 .2 7  ± 0 .1 2 10 0 .0 0  ±  0 .1 3
18M V /2100C 1 0 0 .0 6 +  0.19% 9 9 .0 0  ±  0 .0 5 10 0 .7 0  +  0.11
T ab le 2
TPR20, 10 resu lts u sing  tw o  protocols IAEA TRS-398 and IPEM 199 0  (th e  uncer­
ta in ties are % uncertainties).
IAEA TR S-398 IPEM 1 9 9 0
TPR20.10 (%) TPR20.10 (%)
6M V/600C 0.6 6  ± 0 .1 5 0 .6 6  ± 0 .1 5
6M V/2100C 0.6 8  ± 0 .1 5 0 .6 7  ±  0 .1 5
18M V /2100C 0.7 8  ±  0 .1 3 0 .7 8  ±  0 .1 3
T ab le 3
M easured and tabulated valu es for PDD(IO) for photon  beam s o f  nom in al energies  
in the range 6 - 1 8  MV using th e TG-51 protocol.
PDD(IO)
T ab u lated  v a lu e M easu red  v a lu e
6M V/600C 6 6 .3 6 66 .0 8
6M V/2100C 67 .2 0 66 .9 7
18M V /2100C 78 .9 0 77 .9 3
for the photon beam 6MV/60ÜC in the solid water phantom was 
found to be 0.04% and 0.20%, respectively. Measurements of 
absorbed dose made at 6 MV, produced by the 2100C linear 
accelerator, yield a maximum uncertainty using the TRS-398, IPEM 
1990 and TG-51 protocols of 0.19%, 0.12% and 0.13%, respectively. 
The evaluation of uncertainty in this work follows IAEA TRS-398.
For measurements obtained in the solid water phantom with 
6MV/2100C, and using the IPEM protocol, the absorbed dose 
discrepancy from 100 cGy is 0.73%, being larger than that obtained 
with the IAEA protocol (0.4%) while TG-51 gives us the exact value 
of 100 cGy. The chi-square test applied to the photon beam data 
provides a value of 0.028, showing the null hypothesis to hold, with 
insignificant difference between the measured and expected doses.
With IAEA TRS-398 and IPEM 1990  the comparison quality 
index TPRzo.io values shown in Table 2 are in agreement across 
the photon energies to within the evaluated uncertainties. In 
addition, using the TG-51 protocol, measured and tabulated (PDD 
values that come from planning software) PDD(IO) values for 
photon beams have also been found to be in close agreement, 
to within 0.3% for the 6 MV beam and to within 1.11% at 18 MV, 
as shown in Table 3. As mentioned previously, PDD(IO) for the 
18 MV beam has been obtained using Eq. 4  in TG-51. The result, 
77.93%, is close to the tabulated value, the difference being within 
1.3%. In addition, the PDD using the 1 mm lead foil, i.e. PDD(10)pb, 
was found to be 74% while the beam quality k(j= 0 .985 . The ratios 
of absorbed dose obtained were found to be approximately 
0 .9 9 4 -1 .0 0 4 :
PDD(10)^ =  [0.8116 +  0 .00 2 6 4  PDD(10)pb] PDD(10)pb
[foil at 30cm, PDD(10)py > 71%]. (4)
In Fig. 1 a comparison is made using 6 MV photon for two 
different protocols AAPM TG-51 and IAEA TRS-398. It is apparent 
that there is a difference of within 1%, with the use of PDD 
producing the largest values and the differences of Sw.air are due 
to the method type they used to calculate them. Both TRS-398 
and IPSM take Sw.atr from Ding et al. (1995), which used Monte 
Carlo simulation, while in IPSM, they used basic input data from 
ICRU 37 (Measurements, 1984b). In AAPM TG-51, it is calculated 
using a Monte Carlo method, calculated according to Nahum 
(1978) and ICRU (1984) (Measurements, 1984a).
3.2. E lectron en erg ies
The IAEA TRS-398 and AAPM TG-51 fluence ratios of the 
absorbed dose measured in a water phantom (Scanditronix 
Medical AB, Sweden, REA water tank) and the absorbed dose 
measured in a brown solid phantom™ (Virtual Water ™, Density
6MV-2100C
Absorbed dose (cGy)
Fig. 1. Com parison o f 6 MV photon  for tw o  protocols.
T 0.(0.585 -1
■  %DD (10) 
TPR20.10 -- 0.6750.58-
-- 0.67
0.575 - y = -0.0052x+ 1.0963 
= 0.9999
-- 0.665 %
Q 0.57 -s
0.565 -
-- 0.655
y = -0.0066% -t 1.3285
r 2 = 0.99990.56- -- 0.65
0.6450.555
100 100.5 102 10398.5 99 99.5 101 101.5 102.598
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BWP=1,03 g/m^: water equivalent materials. Med-Cal, USA) were 
obtained using a Markus chamber. For all electron beams the ratio 
of the measurements performed in the water phantom to those in 
the solid water equivalent phantom for the three CoP results for 
fluence was found to be close to 1.0, except for the 16 MeV, for 
which it is 0.974. Specifically, the IAEA fluence ratios were found 
to be 1.008, 0.995, 0.997, 0.998 and 0.993 for the nominal 6  MeV, 
9 MeV, 12 MeV, 16 MeV and 20 MeV electron beams, respectively, 
while the corresponding AAPM TG-51 values were found to be
1.002, 0.996,1.007, 0.974 and 0.998.
In addition, the IPEM 2003 protocol values are 1.002, 0.999,
0.992, 0.994 and 1.021, and these measurements were carried out 
using an NACP chamber (Nordic Association of Clinical Physics- 
designed Scanditronix NACP PP chamber), the measurements being 
done using two phantoms. Water phantom (QADOS, UK) and a 
brown solid phantom™ (Virtual Water™, Density BWP=1.03 g/m^: 
water equivalent materials, Med-Cal, USA), using a 10 cm x 10 cm 
electron applicator for all electron energies. The fluence ratios are 
provided in Table 6 . The output measurements obtained using the 
water tank improve upon the output value obtained using the solid 
water phantom. Table 6  below shows the measured values of 
absorbed dose, together with values for Rsq, the reference point 
and The measurements were made using two phantoms: solid 
water™ (Virtual Water™, Density BWP=1.03 g/m^: water equiva­
lent materials, Med-Cal, USA) and a water tank (Scanditronix Medical 
AB, Sweden, RFA water tank). The measurements were performed 
with a plane-parallel PTW Markus chamber; a Varian 2100C linear 
accelerator provided the five clinical electron beams. The depth 
ionization curves were measured with a source-surface distance 
(SSD) of 100 cm and use was made of a 10 cm x 10 cm electron 
applicator for the electron energies 6 ,9  and 12 MeV, while for 16 and 
20 MeV electrons a 20 cm x 20 cm electron applicator was used. The 
ionization chamber readings were corrected to standard atmospheric 
pressure and also for polarity and recombination effects. The 
reference point in the plane-parallel chamber was at the center of 
the window. For electrons energies the differences between the 
absorbed doses measured in solid water phantom were smaller than 
that obtained in the water tank by 0.1%. From the result shown in 
Table 4, it can be concluded that on average the measurements, 
achieved using the IAEA TRS-398 protocol with the solid water
phantom, gives a relative absorbed dose of 99.67 with a standard 
deviation of 0.2, closer to the expected dose by 4% than the 
measurements obtained using a water tanlc, which is 99.50 with 
standard deviation of 0 .2. In contrast, the measurements of absorbed 
dose obtained using the AAPM TG-51 protocol and made using a 
water tank are closer to the reference value of 100 cGy than the 
measurements with a solid phantom, the standard deviations for 
these being 0.5 and 0.9, respectively. It can be concluded that the 
dose in water at the reference point, measured using the solid water 
phantom, is practically identical with the measured dose in the 
water phantom.
For the IAEA TRS-398 and AAPM TG-51 CoP, R50 and Zref fo r  all 
electrons energies agree with each other with insignificant 
difference. Nevertheless, there are differences between iîso and 
Zref in IPEM 2003 compared with the two protocols mentioned 
above. It is clear from the table that the absorbed dose measured 
using IAEA TRS-398 is lower than that obtained using AAPM TG-51, 
by on average 0.13% and 0.2%.
Thus said, in general the average of absorbed dose is closer 
than that obtained using TG-51. It is found that the chi-square 
test value for electrons beams in solid phantom is 0.045. In the 
water tank the chi-square test value for electrons beams is 0.036, 
the null hypothesis being satisfied in both cases. The clinical 
electron beam of a linear accelerator provides an initial surface 
dose, which progressively increases to its peak, after which it rapidly 
decreases.
4. Comparison of three protocols in the beam quality 
correction factors fcq values
In order to validate the calculated values of for high 
energy photon and electron beams, a comparison with experi­
mental values derived in clinical beams was carried out in this 
work. All the beam quality correction factors referred to as Uq  are 
based on the use of ^ °Co as the reference beam quality Qo. There is 
good agreement, to within 0.5%, between theoretical and experi­
mental values in using the IAEA TRS-398 CoP for the electron 
beams. This can be compared with the situation in using AAPM 
TG-51, in which there are clear differences, to within 2.0% (Fig. 2).
T a b l e  4
The IAEA uncerta inty  param eters.
Energy ^ref R so (th ) Sw,air(Zref) PQ Kq(exp) Unc.(JC,)% D ose U n certainty
b udgets
U n certa inty
p ercen tage
6 1.25 2 .5 0 1.07 0.98 0.92 0.51 9 9 .6 0 0 .5 4 0.03
9 1 .99 3 .8 0 1.06 0.99 0.91 0 .4 4 99 .8 3 0.47 0.03
12 2 .83 5.10 1.04 0.99 0.91 0 .4 4 9 9 .3 9 0.47 0.03
16 3 .8 2 6.80 1.03 0.99 0 .9 0 0.37 9 9 .8 7 0 .4 0 0.03
2 0 4 .7 4 8 .60 1.02 1.00 0.89 0.39 9 9 .6 8 0.42 0.03
0 .9 4
0.93 • 
0 .9 2  
g  0 .91-  
0 .9 0
0.89
0.88
0.87 •
0.00 2.00
y  = -0.0053X + 0.93 
r 2 = 0 .992 ■ Water-Phantom- 
IAEA-398
Solid-phanotm-
IAEA-398
Water phantom
TG-51
Solid-phantom-
TG-5I
• Linear(SoIid- 
phantom-TG-5I)
4 .0 0  6.00
R (5 0 )
8.00 10.00
Fig. 2 . Com parison b e tw een  TG-51 and IAEA-398 u sin g  so lid  and w a ter  phan tom s.
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5. Uncertainties
In order to reduce uncertainties five readings were taken at 
each depth for all of the ionization chambers used in determining 
the absorbed dose using each code. Given that the same set of 
readings have been used to determine the beam calibration 
regardless of the CoP applied, experimental uncertainties, includ­
ing chamber position, accuracy of barometer and thermometer 
readings, machine output, setup of field size and SSD/SAD, are the 
same. The TRS-398 and IPEM CoP provide a detailed uncertainty 
estimate for the different steps used while TG-51 and IPSM CoP 
do not provide an estimation of the uncertainties involved in the 
determination of absorbed dose in reference conditions.
In regard to TRS-398 estimates for high energy photon beams, 
the combined standard uncertainty in is ±0.5% and the 
combined standard uncertainty in Dw  is estimated to be around 
±1.5% with standard deviation 0.3. For high energy electron 
beams, the CoP TRS-398 estimates the combined standard uncer­
tainty in k(2 to be ±1% for a Markus chamber plane-parallel 
calibrated against ^°Co beam energy, the standard deviation 
using the solid water phantom to be 0.2  and for the water 
phantom, 0.5. The corresponding estimates for Dw  are ±  2% for 
a plane-parallel chamber, based on calibration against ®°Co beam 
quality.
In regard to TG-51 code estimate for high energy photon 
beams, the combined standard uncertainty in k d  is ± 2 % and
T a b l e  5
The TG-51 uncerta inty  param eters.
Energy 2,^/ 
(M eV)
R so(th ) P Q Kg (exp ) Une. (K q ) D ose U n certa inty  U n certa inty  
bu d gets percen tage
6  1.25 2 .5 0 1.07 0.98 0 .9 4  2 .2 6 100 .38 2 .2 9  0.03
9  1.99 3 .8 0 1.06 0 .9 9 0.93  2.31 100 .2 9 2 .3 4  0.03
1 2  2 .83 5.10 1.04 0.99 0 .9 2  1.99 9 9 .3 3 2 .0 2  0.03
16  3 .8 2 6.80 1.03 0 .9 9 0.91 1.83 9 8 .8 8 1.8 6  0.03
2 0  4 .7 4 8 .6 0 1.02 1.00 0 .9 0  1.74 100.01 1 .77  0.03
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Absorbed d ose , beam  quality. R^o and Zref for tw o  protocols IAEA TRS-398 and AAPM TG-51.
6  MeV lAEA-Tawam TG -51-Tawam IPEM 2003-RSH
Solid w a ter  p han tom « 5 0 = 2 .2 5 5  cm « 5 0 = 2 .2 5 5  cm « s o = « g = 2 .5  cm
Z re/= 1 .2 5 cm Z re/=1.25 cm Z re /= 1 .4 cm
R q = 0.9 2 3  cm «q,R5Q =  0-939
D ose ( c G y ) = 9 9 .6 0 ± 0 .1 5 D o se (c G y ) = 1 0 0 .3 8  ± 0 .2 1 D ose ( c G y ) = 9 9 .7 7 ± 0 .2 3
W ater tank « 5 0 = 2 .3  cm « 5 0 = 2 .2 5 5  cm «50=1^5=2-5 cm
Zrg/= 1.28 cm Zre/= 1 .253 cm Z re f= 1 .4 c m
« 0 = 0 .9 2 3  cm K j,r50 = 0 -9 3 9  cm
D o se (c G y )= 100.41  ± 0 .1 8 D o s e (c G y )= 1 0 0 .5 8 ±  0.21 D ose(cG y)= 1 0 0 .0 0  ±  0 .0
R atio= dosCw/doseeq.w 1.008 1.002 1.002
9  MeV
Solid w ater  p han tom « 5 0 = 3 .4 9 0  cm « 5 0 = 3 .4 9 0  cm « 50= « 5 = 3 .6 7  cm
Zre/= 1 .99  cm «re/=  1.99  cm Zref = 2 .1  cm
« 0 = 0 .9 2 5  cm «q.R so=0'930 cm
D ose ( c G y ) = 9 9 .8 3 ± 0 .1 3 D ose (cG y )=  100 .2 9  ± 0 .1 9 D ose ( c G y ) = 9 9 .0 4 ± 0 .9 6
W ater tank « 5 0 = 3 .4 9  cm « 50=  3 .3 4  cm «5o= « 5 = 3 .7 1  cm
Z re/= 1 .9 9 cm «re/= 1 .90  cm Zre/=2.1 cm
« 0 = 0 .9 9 4  cm fQ.R5o = 9 .9 3 0  cm
D ose ( c G y ) = 9 9 .3 5 ± 0 .1 6 D ose ( c G y ) = 9 9 .9 2 ± 0 .2 0 D ose ( c G y ) = 9 9 .0 0 ± 1 .1 5
R atio= dosew/doseeg,w 0.995 0 .9 9 6 0 .9 9 9
12 MeV
Solid  w a ter  p han tom « 5 0 = 4 .8 7 9  cm « 5 0 = 4 .8 7 9  cm R so = K g = 5 .2 5  cm
Zrc/=2.83 cm Zre/= 2 .8 3  cm Zref= 3  cm
« q = 0 .9 0 6  cm «g.R5o=0 .9 2 0  cm
D ose ( c G y ) = 9 9 .3 9 ± 0 .1 2 D ose ( c G y ) = 9 9 .3 3 ± 0 .1 9 D ose ( c G y )= 100 .8 5  ± 2 .4
W ater tank « 5 0 = 4 .9 8  cm « 5 0 = 4 .8 8  cm « so= « 5 = 5 .2 5  cm
Z ref=2.89 cm Zre/=2.83 cm Zref = 3  cm
« q =  0 .9 0 6  cm K].R5o = 0 .9 2 0  cm
D ose ( c G y ) = 9 9 .0 7 ± 0 .1 2 D ose ( c G y )= 1 0 0 .0 4  ±  0 .19 D ose ( c G y ) = 1 0 0 .0 0 ± 1 .3
R atio= dosCw/dosCeq.w 0.997 1.007 0 .9 9 2
16 MeV IAEA TG-51 IPEM 2003-RSH
Solid w ater  p han tom « 5 0 = 6 .5 2 6  cm « 5 0 = 6 .5 2 6  cm « 50= « 5 = 0 .7 9 7  cm
Zre/=3.82 cm Z re/=3.82 cm Zre/=3.9 cm
« q = 0.8 9 7  cm «q.Rso= 0 .9 1 0  cm
D ose (cG y )= 9 9 .8 7  ± 0 .1 1 D ose (c G y )= 9 8 .8 8  ±  0 .19 D ose  ( c G y )= 100.61 ± 2 .3
W ater Tank «50  =  6 .53  cm « 50=  6 .63  cm « 5 0= « 5 = 0 .7 9 7  cm
Zre/= 3.82  cm « re/= 3 .88  cm Zre/=3.9 cm
« 0 = 0 .8 9 7  cm «^ 3.r5o= 0 .9 1 0  cm
D ose ( c G y ) = 9 9 .6 3 ± 0 .1 2 D ose ( c G y ) = 9 9 .1 8 ± 0 .1 9 D ose ( c G y )= 100 .0 0  ± 1 .2 3
Ratio=dosew /doseeq.w 0.998 1.003 0 .9 9 4
20 MeV
Solid W ater p han tom « 5 0 = 8 .0 6 9  cm « 5 0 = 8 .0 6 9  cm « 5 0= « 5 = 8 .5 4  cm
Z „ /= 4 .7 4  cm Zre/= 4.74  cm Z re /= 4 .9 cm
« g = 0 .8 8 9  cm «5,rso= 0 .901 cm
D ose (c G y )= 9 9 .6 8  ± 0 .1 1 D ose ( c G y )= 100.01 ± 0 .1 9 D ose  ( c G y )= 9 7 .8 9  ± 2 .1 1
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T a b l e  6  (continued )
6  MeV lAEA-Tawam TG -51-T aw am IPEM 2003-RSH
W ater tank « 5 0 = 8 .0 6 9  cm « 5 0  =  8 .1 7 2  cm «5o=K q=8.54 cm
Z re /= 4 .7 4 cm Zre/=4.80 cm Zre/=4.9 cm
K q=0.889 cm «5,rso=0.901 cm
D ose (cG y )= 9 9 .0 3  +  0.12 D ose (cG y )= 9 9 .8 2  +  0 .19 D ose (c G y )1 0 0 .0 0 ± 1 .5
R atio= dosew/doseeq.w 0 .9 9 3 0.998 1.021
the combined standard uncertainty in Dw  is estimated to be 
around ±2% with standard deviation 0.7. The uncertainty for 
high energy electron beams is quoted as a standard deviation 
using the solid water phantom of 0.9 and using the water 
phantom, 0.5. The corresponding estimates for Dw  using different 
phantoms (equivalent to water and water phantoms) are + 1.5%.
The IPEM code estimates an overall uncertainty in Nd.w given by 
NPL to be ±1.5% at 95% confidence level. This gives a combined 
uncertainty of about ± 2 .0% in determination of absorbed dose 
water at the reference depth. IPEM gives additional uncertainties for 
non-water phantom use of better than ±  1.5%.
Tables 4 and 5 give details of uncertainty parameters used in 
IAEA TRS-398 and AAPM TG-51, respectively.
6. Conclusions
This paper presents a detailed comparison of the differences in 
absorbed dose obtained in application of the IAEA TRS-398, AAPM 
TG-51 and IPEM protocols for photon and electron beam energies. 
Absorbed dose to water determinations according to the three 
protocols agree within experimental uncertainty, and this uncer­
tainty is similar to the one reported in IAEA TRS-398.
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• Rotational therapy is an important for treatment delivery.
• The important characteristic of rotational of radiation is its dynamic nature.
• Challenge for clinical physicist is the dosimetric variability in radiation delivery.
• Evaluating H & N cases using two type of phantoms, Cheese phantom and MapCheck.
• Using the Cheese phantom gives us a good results.
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A B S T R A C T
The use of rotational therapy as an important method of treatment delivery is expected to increase due in 
a large part to the development and utilisation of tomotherapy. Rotational therapy minimises the 
occurrence of hotspots and the irradiation of critical organs, providing more uniform dosing while 
sparing critical organs. Two important characteristics of rotational radiation are its dynamic nature and 
dosimetric variability in radiation delivery, both of which present a considerable challenge for clinical 
physicists seeking appropriate tools to meet the demands of quality assurance.
In this paper 15 Delivery Quality Assurance (DQA) plans of head and neck patients were assessed for 
the Hi-Art tomotherapy system using Kodak X-Omat V film and an AISL Ref F92722 ion chamber versus 
MapCheck. Absolute dose measurement showed average differences of 3.42 cGy and 98% Gamma (/) 
factor for the Cheese phantom technique. For the MapCheck technique the average difference and 
Gamma factor were 0.74 cGy and 96%, respectively. Gamma (y) matrix distribution was used to evaluate 
the difference between measured and calculated dose distribution.
© 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Helical tomotherapy (HT) was developed during the search for 
solutions to three major problems in radiation therapy: (1 ) the 
limited dose that can be delivered to a target due to the presence 
of sensitive structures; (2 ) the ability to verify the correct beam 
shape and position while simultaneously ensuring that the patient 
is positioned correctly; and (3) safety concerns during dynamic 
therapy due to the possibility of collision between the patient and 
the treatment unit (Mackie et al., 1993).
* Corresponding author at: University o f  Surrey, D epartm ent o f  Physics, Centre 
for Nuclear and Radiation Physics, Surrey University, Guildford, Surrey, GU2 7XH, 
UK. Tel.: + 4 4  7 50  3 6 8  8997.
E-mail addresses: S.Alahbabi@surrey.ac.uk, 
ss_alahbabi@ hotm ail.com  (S.S. Al-Ahbabi).
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The current standard of practice for HT requires that dosimetric 
verification be performed for each patient by examining patient- 
specific quality assurance (QA) for treatment delivery. This work 
focuses on the patient-specific QA component, and includes DQA 
verification analysis of 15 cases for head and neck patients treated 
using the Hi-Art tomotherapy system.
2. The Hi-Art helical tomotherapy system
The Hi-Art™ HT system has a number of features not found in 
other radiotherapy systems, including a planning system with a built- 
in delivery QA system. A CT scan is carried out for all the different 
phantoms that might be used to check the patient plans and saved in 
the DQA planning system provided by tomotherapy. The aim is then to 
use the original patient plan from the tomotherapy TPS system and 
transfer it to the DQA planning system. The plan is then recalculated
Please cite this article as: Al-Ahbabi, S.S., et al., Tomotherapy evaluation for head and neck cases using two types of phantoms. Radiat.
Phys. Chem. (2013), http://dx.doi.Org/10.1016/j.radphyschem.2013.04.022
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using the same fluence pattern applied to the original plan. When the 
DQA plan is ready and approved by the physicist, it can then be used 
on the tomotherapy unit using the same setup applied to the plan 
based on the appropriate phantom in the DQA plan. When a Cheese 
phantom is used, the radiographic film and/or the ion chambers are 
placed in the phantom, then the phantom is irradiated. The measured 
data using both film and chambers are then collected and evaluated 
using the DQA software. Evaluation tools include a comparison of the 
calculated and measured isodose curves, plots of the dosage compar­
isons along an arbitrary direction, gamma plots and gamma histo­
grams and a comparison of the point-calculated dose versus the ion- 
chamber measurement (Mackie, 2006).
With its excellent spatial resolution, film dosimetry has been 
widely adopted for the above purpose. However, the procedures 
are time consuming and require great care when used for absolute 
dosimetry. Detector arrays with excellent reproducibility and 
independence in the dose-rate response are now replacing films 
for routine QA, simplifying the verification procedures.
The Model 1177 MapCheck 2 system manufactured by Sun 
Nuclear Corporation (Sun nuclear. Model 1177, Melbourne, EL) is a 
2D radiotherapy dosimetry system for Quality assurance (QA).
The MapCheck 2 detector provides a QA test of the ability of the 
linear accelerator to successfully deliver a planned QA dose map 
using a phantom. The DQA plan is not a measurement of the 
planned dose map that would have been delivered during the 
treatment of a patient. Instead, the DAQ plan is a recalculation (on 
a phantom) of the dose (defined by the TPS) that must be 
delivered by the linear accelerator.
The primary points of the DQA comparison were as follows:
•  Comparison of the dose profile between the measured dose 
using the Cheese and MapCheck2 phantoms and the calculated 
dose from the treatment planning system (TPS). The Cheese 
phantom is a cylindrical solid water phantom assembled as two 
hemispheres, each with cavities for ion chambers and plugs for 
CT scans.
•  Gamma factor comparison between the two phantoms.
•  Point dose comparison between the calculated and 
measured doses.
3. Experimental methods
In this study, we analysed DQA verification plans for 15 
patients. Measurements were recorded using a Cheese phantom, 
as shown in Fig. 1. The solid water cylindrical phantom was 30 cm 
in diameter and 15 cm in height with a machined spiral cavity for 
film placement. The phantom was also machined in several 
locations to hold an ionisation chamber to verify the dose 
delivered at these points. The advantage of using this phantom 
is that the radiation beam is always perpendicular to the film.
Kodak XV film was cut to fit and slide into the spiral 
(5.5 cm X 17 cm). These pieces were then taped at the sides of 
the joining ends to avoid slippage in the phantom. The spiral 
phantom was aligned using the DQA module of the TomoTherapy 
planning station software using the patient-positioning red lasers. 
A patient-specific DQA plan was created for each case and 
delivered to the DQA spiral phantom. Point doses were sampled 
from the plan at the location at which the ion chamber measure­
ments were acquired. An Al SL Ref F92722 ion chamber was placed 
in the appropriate hole. The electrometer was then turned on, 
warmed-up, and zeroed. The voltage used with for the chambers 
was +300 V. A treatment was delivered, and the detector response 
was recorded. The percentage dose difference between the calcu­
lated dose, Dc, and the measured dose. Dm, at a specific depth is 
given by (Dc-Dm) x 100%/Dm.
After irradiation, the film was left to stabilise for the same 
period of time as for its corresponding calibration film before 
processing. The films were processed using a Kodak RP X-OMAT 
processor. The treatment film was then scanned at 
0.36 X 0.36 mm^ resolution using a VIDAR VXR-16 Dosimetry Pro 
scanner (VIDAR Systems Corporation, Herndon, VA). The digitised 
optical density map was then converted to a dose map with a 
sensitometry curve using MATLAB. All films were from the same 
film batch and were processed under the same conditions.
As we were interested in the relative dosimetry rather than the 
absolute dosimetry with the film, the change in processor condi­
tions from the time the calibration curve was created to when the 
spiral phantom films were developed was not considered. A 
scaling factor can then be used in the system to correct for the 
difference between both.
The calculated dose distribution corresponding to the plane of 
the measured dose distribution was then determined according to 
the position of the spiral phantom using TomoTherapy, Inc. soft­
ware. The calculated dose distribution was then up-sampled using 
nearest neighbour interpolation such that the dose pixel sizes of 
the measured and calculated dose distributions were both 
0.36 X 0.36 mm .^
The film dose distribution was compared with the calculated 
dose distribution using the DQA Analysis Tools provided on the 
TomoTherapy Planning workstation (DQA Planning). The DQA 
Analysis Tool allows one to register the film data to the calculated 
dose using the reference points selected during the measurements 
and then extract ID dose profiles, as well as to compare the 2D 
distributions using isodose lines and the gamma distribution.
4. Results and discussion
Table 1 provides the results obtained using the Cheese phantom 
compared with the DQA plan for the head and neck cases. 
The data are presented as the point dose measured using the
Fig. 1. (A) ‘C heese phantom  w ith  th e film placed in the centre o f  the phan tom  and the ion cham ber; (B) The setu p  u sing the CHEESE phantom  (G am m ex RMI, M iddelton, W l) 
and th e ion cham ber (Exradin, M odel AISL, S/N XW 102094 , Standard Imaging, M iddleton, W l).
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Table 1
Cheese phan tom  m easurem en ts com p ared w ith  the DQA calculated for the 15 head  
and neck cases.
% of Gamma for Head & Neck patients Using Cheese Phantom
Patient Cheese p h a n to m  
m ea su red  
P o in t d o se  (Gy)
DQA-calculated  
Point dose (Gy)
Difference (%) (r) (%)
1 1.6 1.7 3.1 99.5
2 1.5 1.6 2.0 100.0
3 1.4 1.4 2.1 99.9
4 1.4 1.5 5.0 99 .9
5 2.2 2.2 1.9 99.7
6 1.6 1.7 2.4 100.0
7 1.3 1.3 2.4 94.5
8 1.7 1.7 3 .0 99.7
9 1.5 1.5 0.7 99 .4
10 1.2 1.3 1.6 99 .6
11 1.5 1.6 2.6 91.0
12 1.9 2.1 11.1 99.6
13 1.5 1.6 3.3 99.5
14 1.7 1.8 5.2 98.2
15 1.4 1.5 5.8 99.2
Average d ifferen ce= 3.5
Table 2
Table 1 M apCheck2 phantom  m easu rem en ts com pared w ith  the DQA calculated for 
the 15 head and neck cases.
Patient Map check2-M  
M easu red  
Point d ose (Gy)
DQA-C 
Calculated  
Point d ose (Gy)
Difference (%) (H
1 2.0 2.0 0.5 98.3
2 1.9 1.9 0.9 92.1
3 1.7 1.8 0.6 96.3
4 2.0 2.0 0.9 97.0
5 2.6 2.6 0.4 99.5
6 2.0 2.0 0.6 99.6
7 1.8 1.7 1.4 98.2
8 2.1 2.1 0.2 98.9
9 1.9 1.9 0.7 96.4
10 1.6 1.5 1.0 93.0
11 1.8 1.8 1.2 98.8
12 2.5 2.5 0.5 96.8
13 1.9 1.9 0.8 97.3
14 2.0 2.1 0.9 97.0
15 1.8 1.8 0.3 92.7
Average difference 0.7
cylindrical phantom and the DQA point dose calculated using the 
tomotherapy planning software. The calculated and measured point 
doses were in good agreement with each other, a mean difference 
of 3.5%. Table 2 also provides an equivalent set of measurements 
obtained using MapCheck2 compared with those from the DQA. 
The MapCheck2 and DQA data were again in good agreement with 
each other, a mean difference of 0.7%; Fig. 2 shows a plot of the 
gamma percentage for head and neck cases using the Cheese 
phantom, with a gamma percentage ranging from 100 to 98%. 
Fig. 3 shows a plot of the gamma percentage for head and neck 
cases using the MapCheck2 phantom, in which a fluctuation in the 
gamma percentage is apparent, underlining as expected the super­
ior resolution of film over that of the MapCheck2 detector matrix. 
The difference was calculated using the gamma equation of Low DA 
et al. (1998), and the plans were normalised to a global dose value 
according to Eq. (1):
■ <95% ■ 95%-99% c >99%
Fig. 2. Gamm a percen tages for the head and neck cases u sing  the C heese phantom .
% of Gamma for Head & Neck Patients Using MapCheck2
■ <95%
■ 95%-99%
■ >99%
Fig. 3. Gamm a percen tages for th e head and neck cases u sin g  the M apCheck! 
phantom .
where Dg is the dose value at a point in the calculated or planned 
dose matrix and Dm is the dose value at the corresponding point in 
the measured dose matrix (Myers et al., 2012).
5. Conclusion
The results indicate that the Cheese phantom technique 
provides a superior gamma factor relative to that of the Map- 
Check2 technique because of the improved resolution of the film. 
However, the MapChecl<2 system has other benefits, such as ease 
and speed of use and consumable costs are less than with 
GafChromic film.
References
Low DA. H.W., Mutic. S., Purdy, J A , 1998. A tech n iq u e for th e  evalu ation  o f  d ose  
distributions. Med. Phys. 25. 6 5 6 -6 6 1 .
M ackie, T.H.T., Sw erdloff, S.. Reckwerdt, P., Deasy, J., Yang, J., Paliwal, B., K insella, T., 
1993. Tom otherapy: a n ew  concep t for th e d elivery  o f  d yn am ic conform ai 
radiotherapy. Med. Phys. 2 0  (6), 1709-1719.
M ackie, T.R., 2 0 0 6 . H istory o f  tom otherapy. Phys. M ed. Biol. 51 2 0 0 6 .
M yers, S.S., Esquivel, G., M avoroidis, Papanlkolaou, 2012. Evaluation o f  PTW  
sev en 2 9  for tom otherpay p atient -sp ecific  quality  assurance and com p arison  
w ith  ScandiDos Delta. Med. Phys. 37  (2), 7 2 -8 0 .
D ^ D c D m  ^
( 1)
Please cite this article as: Al-Ahbabi, S.S., et al., Tomotherapy evaluation for head and neck cases using two types of phantoms. Radiat.
Phys. Chem. (2013), http://dx.doi.Org/10.lG16/j.radphyschem.2013.G4.022
Reproduced with permission of copyright owner. Further reproduction prohibited without permission.
